<html lang="en"><head><!-- Shady DOM styles for custom-style --><!-- Shady DOM styles for dom-template --><!-- Shady DOM styles for dom-repeat --><!-- Shady DOM styles for array-selector --><!-- Shady DOM styles for dom-if --><!-- Shady DOM styles for state-modifier --><style scope="state-modifier">a[inherit].state-modifier {
  color: inherit;
}</style><!-- Shady DOM styles for browser-ui --><!-- Shady DOM styles for outlined-text-field --><style scope="outlined-text-field">outlined-text-field {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: column;
}

outlined-text-field span.outlined-text-field {
  display: flex;
  flex-direction: row;
  align-items: center;
}

outlined-text-field input.outlined-text-field {
  height: 40px;
  padding: 0 33px 0 16px;
  
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  flex-grow: 1;
}

outlined-text-field[orig] input.outlined-text-field {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-text-field[dense] input.outlined-text-field {
  height: 32px;
}

outlined-text-field[uppercase] input.outlined-text-field {
  text-transform: uppercase;
}

outlined-text-field:not([wizard-focused]):hover input.outlined-text-field {
  border-color: #737375;
  color: #414447;
}

outlined-text-field:not([wizard-focused]):focus-within input.outlined-text-field,outlined-text-field[wizard-focused] input.outlined-text-field {
  border-color: #3574e0;
  caret-color: #80a5f1;
}

outlined-text-field[wizard-focused] input.outlined-text-field {
  border-width: 2px;
}

outlined-text-field input.outlined-text-field::placeholder {
  color: #65686c;
}

outlined-text-field[uppercase] input.outlined-text-field::placeholder {
  text-transform: none;
}</style><!-- Shady DOM styles for mat-keyword-editor --><!-- Shady DOM styles for mat-chips-input --><!-- Shady DOM styles for mat-input-chip --><!-- Shady DOM styles for pat-dialog --><style scope="pat-dialog">pat-dialog {
  background: white;
  position: absolute;
  border-radius: 8px;
  
  box-shadow: 0 24px 38px 3px rgb(0 0 0 / 14%),
              0 9px 46px 8px rgb(0 0 0 / 12%),
              0 11px 15px -7px rgb(0 0 0 / 20%);
  z-index: 1;
  display: flex;
  flex-direction: column;
}

pat-dialog:not([open]) {
  display: none;
}</style><!-- Shady DOM styles for mat-tabs --><!-- Shady DOM styles for filter-chip --><style scope="filter-chip">filter-chip {
  align-items: center;
  background-color: #fff;
  border-color: #dadce0;
  border-radius: 8px;
  border-style: solid;
  border-width: 1px;
  color: #606368;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 32px;
  letter-spacing: 0.2px;
  padding: 0 16px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

filter-chip[disabled] {
  background-color: #e8e8e8;
  border-color: #e8e8e8;
  color: #a9abad;
  cursor: auto;
}

filter-chip svg.filter-chip {
  visibility: collapse;
  font-size: 18px;
  width: 0;
  height: 18px;
}

filter-chip[selected] svg.filter-chip {
  visibility: visible;
  margin: 0 8px;
  width: 18px;
}

filter-chip[selected] svg.filter-chip path.filter-chip {
  fill: #4577d1;
}

filter-chip:not([disabled]):hover {
  background-color: #f7f8f8;
  border-color: #d7d9dc;
  color: #454649;
}

filter-chip:not([disabled]):hover:active {
  background-color: #eff0f0;
  border-color: #d2d5d8;
  color: #222326;
}

filter-chip:not([disabled]):focus {
  background-color: #e7e8e8;
  border-color: #232528;
  color: #202124;
}

filter-chip:not([disabled])[selected] {
  background-color: #e9f0fd;
  border-color: #e9f0fd;
  color: #4577d1;
  padding-left: 0;
}

filter-chip:not([disabled]):focus[selected] {
  background-color: #d5e1fb;
  border-color: #d5e1fb;
  color: #2550a0;
}

filter-chip:not([disabled]):hover[selected] {
  box-shadow: rgba(0, 0, 0, 0.2) 0px 3px 1px -2px,
    rgba(0, 0, 0, 0.14) 0px 2px 2px 0px, rgba(0, 0, 0, 0.12) 0px 1px 5px 0px;
}

filter-chip:not([disabled]):hover:active[selected] {
  background-color: #abc8f2;
  border-color: #abc8f2;
  color: #2a54a3;
}</style><!-- Shady DOM styles for figure-callout --><!-- Shady DOM styles for mat-button --><style scope="mat-button-0">.mat-button-0 {
  ;
  align-items: center;
  border-radius: 4px;
  color: hsl(217 4% 39%); 
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: 0.2px;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

.mat-button-0[filled] {
  background-color: hsl(217 73% 54%); 
  color: white;
}

.mat-button-0[filled]:hover {
  background-color: hsl(217 60% 47%);
}

.mat-button-0[filled]:focus {
  background-color: hsl(217 59% 44%);
}

.mat-button-0[filled]:active {
  background-color: hsl(217 59% 45%);
}

.mat-button-0[filled][disabled] {
  background-color: hsl(217 2% 90%); 
  color: hsl(217 1% 65%);
}</style><!-- Shady DOM styles for search-term-wizard --><style scope="search-term-wizard">search-term-wizard:not([open]) {
  display: none;
}

search-term-wizard .header.search-term-wizard {
  border-bottom: 1px solid #e5e5e5;
  padding: 24px;
  padding-bottom: 0;
}

search-term-wizard .title.search-term-wizard {
  color: #3c4043;
  font-family: Google Sans,Roboto,Arial,sans-serif;
  font-size: 22px;
  user-select: none;
  margin: 0 48px;
}

search-term-wizard #panels.search-term-wizard > *.search-term-wizard:not([selected]) {
  display: none;
}</style><!-- Shady DOM styles for outlined-textarea --><style scope="outlined-textarea">outlined-textarea {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: row;
  
  position: relative;
}

outlined-textarea span.outlined-textarea {
  display: flex;
  flex-direction: column;
  flex-grow: 1;
  justify-content: center;
}

outlined-textarea span.right-button-container.outlined-textarea {
  position: absolute;
  right: 0;
  height: 100%;
}

outlined-textarea textarea.outlined-textarea {
  padding: 16px 16px 0 16px;
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  resize: none;
}

outlined-textarea[dense] textarea.outlined-textarea {
  padding: 8px;
}

outlined-textarea[has-icon] textarea.outlined-textarea {
  padding-right: 38px;
}

outlined-textarea[orig] textarea.outlined-textarea {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-textarea:not([rows]) textarea.outlined-textarea {
  height: 40px;
}

outlined-textarea textarea.resizable.outlined-textarea {
  resize: vertical;
}

outlined-textarea textarea.outlined-textarea:focus,outlined-textarea[wizard-focused] textarea.outlined-textarea,outlined-textarea textarea.outlined-textarea:focus:hover {
  border-color: #3574e0 !important;
  
  outline: none !important;
}

outlined-textarea textarea.outlined-textarea:hover {
  border-color: #202124;
  color: #414447;
}

outlined-textarea.hasValue textarea.outlined-textarea {
  border-color: #888d91;
  color: #45474a;
}

outlined-textarea #helperText.outlined-textarea {
  color: #6a6c71;
  font-size: 12px;
  letter-spacing: 0.3px;
  margin-left: 17px;
  margin-top: 6px;
  user-select: none;
}

outlined-textarea:not([helper-text]) #helperText.outlined-textarea {
  display: none;
}

outlined-textarea[error] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
  color: #3d4043;
}

outlined-textarea textarea.outlined-textarea::placeholder {
  font-size: 14px;
  font-weight: 400;
}

outlined-textarea:not([error]):not([disabled]) textarea.outlined-textarea::placeholder {
  color: #6a6c71;
}

outlined-textarea[error] textarea.outlined-textarea::placeholder {
  color: #c84132;
}

outlined-textarea[error] #helperText.outlined-textarea {
  color: #cd5648;
}

outlined-textarea[error] textarea.outlined-textarea:focus {
  border-color: #c84031;
  border-width: 2px;
  outline: none !important;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover {
  border-color: #97231b;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover::placeholder,outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover + #helperText.outlined-textarea {
  color: #a94945;
}

outlined-textarea[disabled] textarea.outlined-textarea {
  border-color: #e9e9e9;
  color: #b5b6b8;
}

outlined-textarea[disabled] #helperText.outlined-textarea {
  color: #c4c6c7;
}

outlined-textarea[error][disabled] {
  opacity: 50%;
}

outlined-textarea[error][disabled] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
}

outlined-textarea[error][disabled] #helperText.outlined-textarea,outlined-textarea[error][disabled] textarea.outlined-textarea {
  color: #a94945;
}

outlined-textarea[error][disabled] textarea.outlined-textarea::placeholder {
  color: #c84132;
}</style><!-- Shady DOM styles for chemistry-search-term-wizard --><style scope="chemistry-search-term-wizard">chemistry-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

chemistry-search-term-wizard .suggestions.chemistry-search-term-wizard {
  margin-top: 4px;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard svg.chemistry-search-term-wizard {
  margin-right: 24px;
}

chemistry-search-term-wizard path.chemistry-search-term-wizard {
  fill: #5f6368;
}

chemistry-search-term-wizard .help.chemistry-search-term-wizard {
  margin-left: 12px;
  margin-right: 0;
  cursor: pointer;
}

chemistry-search-term-wizard outlined-text-field.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard mat-button.chemistry-search-term-wizard {
  margin-left: 48px;
}

chemistry-search-term-wizard filter-chip.chemistry-search-term-wizard {
  margin-right: 4px;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard outlined-text-field[batchMode].chemistry-search-term-wizard {
  display: none;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard:not([batchMode]) {
  display: none;
}</style><!-- Shady DOM styles for text-search-term-wizard --><style scope="text-search-term-wizard">text-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

text-search-term-wizard > span.text-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

text-search-term-wizard > span.text-search-term-wizard svg.text-search-term-wizard {
  margin-right: 24px;
}

text-search-term-wizard path.text-search-term-wizard {
  fill: #5f6368;
}

text-search-term-wizard outlined-text-field.text-search-term-wizard {
  flex-grow: 1;
}

text-search-term-wizard mat-button.text-search-term-wizard {
  margin-left: 48px;
}

text-search-term-wizard filter-chip.text-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for classification-wizard --><style scope="classification-wizard">classification-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

classification-wizard > span.classification-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

classification-wizard .suggestions.classification-wizard {
  margin-top: 4px;
}

classification-wizard > span.classification-wizard svg.classification-wizard {
  margin-right: 24px;
}

classification-wizard path.classification-wizard {
  fill: #5f6368;
}

classification-wizard outlined-text-field.classification-wizard {
  flex-grow: 1;
}

classification-wizard mat-button.classification-wizard {
  margin-left: 48px;
}

classification-wizard filter-chip.classification-wizard {
  margin-right: 4px;
}

classification-wizard .no-matches.classification-wizard {
  margin-left: 64px;
}

classification-wizard .table-container.classification-wizard {
  max-height: 300px;
  overflow: scroll;
  margin-top: 8px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar {
  -webkit-appearance: none;
  width: 10px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar-thumb {
  border-radius: 5px;
  background-color: #5f636880;
  -webkit-box-shadow: 0 0 1px rgba(255,255,255,.5);
}

classification-wizard table.classification-wizard {
  margin-left: 51px;
  max-width: 575px;
}

classification-wizard tr.classification-wizard {
  margin-top: 4px;
}

classification-wizard tr.classification-wizard suggestive-chip.classification-wizard {
  margin-right: 8px;
}

classification-wizard #spinner.classification-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}</style><!-- Shady DOM styles for suggestive-chip --><!-- Shady DOM styles for mat-checkbox --><!-- Shady DOM styles for measure-search-term-wizard --><style scope="measure-search-term-wizard">measure-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

measure-search-term-wizard > span.measure-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

measure-search-term-wizard .suggestions.measure-search-term-wizard {
  margin-top: 4px;
}

measure-search-term-wizard > span.measure-search-term-wizard svg.measure-search-term-wizard {
  margin-right: 24px;
}

measure-search-term-wizard path.measure-search-term-wizard {
  fill: #5f6368;
}

measure-search-term-wizard outlined-text-field.measure-search-term-wizard {
  flex-grow: 1;
}

measure-search-term-wizard mat-button.measure-search-term-wizard {
  margin-left: 48px;
}

measure-search-term-wizard filter-chip.measure-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for numerical-search-term-wizard --><style scope="numerical-search-term-wizard">numerical-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

numerical-search-term-wizard .suggestions.numerical-search-term-wizard {
  margin-top: 4px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard svg.numerical-search-term-wizard {
  margin-right: 24px;
}

numerical-search-term-wizard path.numerical-search-term-wizard {
  fill: #5f6368;
}

numerical-search-term-wizard outlined-text-field.numerical-search-term-wizard,numerical-search-term-wizard outlined-textarea.numerical-search-term-wizard {
  flex-grow: 1;
}

numerical-search-term-wizard mat-button.numerical-search-term-wizard {
  margin-left: 48px;
}

numerical-search-term-wizard filter-chip.numerical-search-term-wizard {
  margin-right: 4px;
}

numerical-search-term-wizard #spinner.numerical-search-term-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}

numerical-search-term-wizard #suggestions.numerical-search-term-wizard {
  margin-left: 58px;
  display: flex;
  flex-direction: column;
  align-items: flex-start;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard mat-checkbox.numerical-search-term-wizard {
  margin-right: 8px;
}</style><!-- Shady DOM styles for text-button --><style scope="text-button">text-button {
  align-items: center;
  border-radius: 4px;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: .25px;
  margin: 6px 0;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
  line-height: 36px;
  text-decoration: none;
  text-transform: none;
  color: #5f6368;
}

text-button:hover {
  background-color: #f8f9fa;
}

text-button:active {
  background-color: #d5e2fa;
}

text-button[selected] {
  background-color: #e8f0fe;
  color: #1967d2;
}

text-button[selected]:active {
  background-color: #d2e3fc;
}</style><!-- Shady DOM styles for mat-spinner --><!-- Shady DOM styles for requery-tile --><style scope="requery-tile">requery-tile {
  display: flex;
  justify-content: space-between;
  align-items: center;
  box-sizing: border-box;
  min-height: 40px;
  padding: 8px 12px 8px 8px;
  gap: 8px;

  border-radius: 16px;
  background: #f7f8f9;
  color: #1f1f1f;
}

requery-tile:hover {
  background: #d7d8d9;
}

requery-tile > [slot="image"] {
  flex-shrink: 0;

  border-radius: 8px;

  background: #fff;
}

.label.requery-tile {
  flex-grow: 999;

  font: 16px/20px "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
}

.search-icon.requery-tile {
  flex-shrink: 0;

  width: 24px;
  height: 24px;
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/search/default/24px.svg');
}</style><!-- Shady DOM styles for s-more-inline --><style scope="s-more-inline">s-more-inline {
  display: block;
  margin-top: 24px;
  padding: 16px;
  padding-top: 0;
  position: relative;

  line-height: 18px;
  text-overflow: ellipsis;
  white-space: nowrap;
  cursor: pointer;
}

hr.s-more-inline {
  background-color: #dadce0;
  margin-top: 18px;
  position: absolute;
  border: 0;
  height: 1px;
  left: 0;
  width: 100%;
}

.button.s-more-inline {
  display: flex;
  align-items: center;
  justify-content: center;

  position: relative; 
  margin: 0 auto;

  font: 400 14px Roboto, arial, sans-serif;
  height: 36px;
  width: 300px;
  border-radius: 18px;
  background-color: #f1f3f4;
}

.button.s-more-inline:hover {
  background-color: #d8d7dc;
}

.button.s-more-inline > [slot] {
  padding-right: 8px;
}

.expand.s-more-inline {
  display: inline-block;
  width: 20px;
  height: 20px;
}

.expand.less.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_less/default/20px.svg');
}

.expand.more.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_more/default/20px.svg');
}</style><!-- Shady DOM styles for workspace-ui-search --><!-- Shady DOM styles for keyword-wizard --><style scope="keyword-wizard">keyword-wizard {
  display: inline-block;
}

iron-icon.keyword-wizard {
  height: 20px;
    width: 20px;
    color: #999;
    cursor: pointer;
}

iron-icon[active].keyword-wizard {
  color: #4285f4 !important;
}

iron-icon.keyword-wizard:hover {
  color: #ccc;
}

#wizardIcon.keyword-wizard {
  padding-left: 1px;
    height: 16px;
    width: 16px;
    margin: 4px 1px 1px 1px;
}

#wizard.keyword-wizard {
  padding: 0;
    left: 0;
    top: 37px;
    position: absolute;
    background-color: white;
    z-index: 2;
    overflow: hidden;
}

.wizard-header.keyword-wizard {
  display: block;
    width: 100%;
    color: #737373;
    text-transform: uppercase;
    font-size: 13px;
    margin: 16px 0 6px 12px;
}

.filter-chips.keyword-wizard {
  margin-left: 20px;
}

.chip.keyword-wizard {
  background-color: #ebebeb;
    color: #6a6a6a;
    display: inline-block;
    font-size: 13px;
    font-family: inherit;
    border-radius: 12px;
    padding: 6px 12px;
}

.chip.keyword-wizard:hover {
  cursor: pointer;
}

.chip[selected].keyword-wizard {
  background-color: #4285f4;
    color: white;
}

.input-label.keyword-wizard {
  display: inline-block;
    font-size: 13px;
    font-family: inherit;
}

.keyword-input.keyword-wizard {
  display: inline-block;
    border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    padding: 3px;
}

.keyword-input.keyword-wizard::placeholder {
  font-style: italic;
}

.keyword-input.keyword-wizard:hover,.keyword-input.keyword-wizard:focus {
  border-color: #4284f4;
    border-width: 1px;
    outline: none;
}

.cpc-field.keyword-wizard {
  display: inline-block;
    margin: 6px 0 0 24px;
}

#checkboxCPC.keyword-wizard:hover {
  cursor: pointer;
}

.checkbox-label.keyword-wizard {
  font-size: 13px;
    font-style: italic;
    color: #737373;
}

.chemistry-field.keyword-wizard {
  display: block;
}

#inputChem.input-batch.keyword-wizard {
  height: 150px;
    border: 1px solid #dfe1e5;
    padding: 6px;
}

#inputChem.keyword-wizard {
  resize: none;
    height: 15px;
    vertical-align: text-top;
    font-size: 13px;
    font-family: inherit;
    padding: 2px;
}

.chem-type-label.keyword-wizard {
  display: inline;
    font-size: 13px;
    margin-left: 12px;
    margin-right: 4px;
}

#chemType.keyword-wizard {
  border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    margin: 6px;
    padding: 2px;
    outline: none;
    font-family: inherit;
    font-size: 13px;
}

.import.keyword-wizard {
  font-size: 13px;
    font-family: inherit;
}

.import-text.keyword-wizard {
  vertical-align: middle;
    display: inline-block;
}

.import-button.keyword-wizard {
  margin: 6px 0 0 24px;
}

.import-button.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.import-button.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard {
  float: right;
    padding: 12px;
}

.wizard-buttons.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    margin: 2px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
}

@media screen and (max-width: 700px) {
#wizard.keyword-wizard {
  width: 275px;
}

.chip.keyword-wizard {
  margin: 4px 2px;
}

.keyword-input.keyword-wizard {
  width: 82%;
      margin: 4px 12px 12px 24px;
}

.search-within.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 225px;
      margin: 12px 0 6px 0;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  margin-top: 6px;
}

#inputChem.keyword-wizard {
  width: 82%;
      padding: 2px;
      margin: 8px 12px 12px 24px;
}

#inputChem.input-batch.keyword-wizard {
  width: 220px;
      padding: 4px;
}

#chemType.keyword-wizard {
  width: 150px;
}

.import-text.keyword-wizard {
  margin: 6px 12px 6px 24px;
      width: 220px;
}

iron-icon.help-header.keyword-wizard {
  display: none;
}

}

@media screen and (min-width: 700px) {
#wizard.keyword-wizard {
  width: 540px;
}

.chip.keyword-wizard {
  margin: 0 2px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 240px;
      margin: 12px 16px 6px 6px;
}

.cpc-inputs.keyword-wizard {
  display: inline;
}

.find-patents.keyword-wizard .keyword-input.keyword-wizard {
  width: 53%;
      margin: 4px 10px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard::placeholder,#inputAnd.keyword-wizard::placeholder,#inputExact.keyword-wizard::placeholder,#inputOr.keyword-wizard::placeholder,#inputMinus.keyword-wizard::placeholder {
  color: white;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  width: 35%;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  width: 42%;
      margin: 6px 4px;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

#inputChem.keyword-wizard {
  width: 290px;
      margin: 2px 12px 2px 6px;
}

#inputChem.input-batch.keyword-wizard {
  width: 280px;
      padding: 6px;
}

.import-text.keyword-wizard {
  margin: 6px 12px;
      width: 415px;
}

#chemType.keyword-wizard {
  width: 105px;
}

iron-icon.keyword-wizard:hover.help-header {
  cursor: default;
}

iron-icon.help-header.keyword-wizard {
  height: 16px;
      padding: 0 2px 2px 2px;
      color: #a3a3a3;
}

.help.keyword-wizard p.keyword-wizard {
  margin: 0 0 8px 0
}

.help.keyword-wizard .q.keyword-wizard {
  font-family: monospace;
      color: #0b8043;
      white-space: nowrap;
}

.help.keyword-wizard {
  z-index: 4;
      position: absolute;
      right: 10px;
      padding: 12px;
      border-radius: 2px;
      border: 1px solid #e0e0e0;
      box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.2), 0 6px 10px 0 rgba(0, 0, 0, 0.3);
      background: white;
      font-size: 13px;
      line-height: 20px;
      width: 450px;
      max-height: 400px;
      overflow: auto;
}

#withinHelp.keyword-wizard {
  top: 75px;
}

#chemHelp.keyword-wizard {
  top: 0;
}

#searchBooleanHelp.keyword-wizard {
  top: 140px;
}

}</style><!-- Shady DOM styles for bottom-bar --><style scope="bottom-bar">.fixed.bottom-bar {
  display: block;
  position: fixed;
  height: 46px;
  bottom: 0;
}

.fixed[medium].bottom-bar {
  height: 280px;
}

.fixed[large].bottom-bar {
  height: 480px;
}

.shadow.bottom-bar {
  background: white;
  padding: 16px;
  border-radius: 8px 8px 0px 0px;
  box-shadow: 0px 8px 10px 1px rgba(0,0,0,.14), 0px 3px 14px 2px rgba(0,0,0,.12), 0px 5px 5px -3px rgba(0,0,0,.2);
}

.oneline.bottom-bar {
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  cursor: pointer;
}

.button.bottom-bar {
  cursor: pointer;
}

.buttonAlign.bottom-bar {
  margin-top: -4px;
}

.header.bottom-bar {
  height: 30px;
  font-family: 'Google Sans';
  font-size: 18px;
  padding-bottom: 8px;
}

.list.bottom-bar {
  overflow-y: auto;
  line-height: 20px;
}

.definition.bottom-bar {
  padding: 0px 0px 4px 0px;
  cursor: pointer;
}

[medium].bottom-bar .content.bottom-bar {
  height: 230px;
}

[large].bottom-bar .content.bottom-bar {
  height: 430px;
}

[medium].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 200px;
}

[large].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 400px;
}

[hidden].bottom-bar {
  display: none;
}

.label.bottom-bar {
  font-family: 'Google Sans';
  font-size: 12px;
  line-height: 16px;
  font-weight: 400;
  padding: 6px 0px 4px 0px;
  color: #1f1f1f;
}

[pad].bottom-bar {
  margin-left: 16px;
}

.layout.vertical.bottom-bar {
  display: flex;
  flex-direction: column;
}

.layout.horizontal.bottom-bar {
  display: flex;
  flex-direction: row;
}

.flex.bottom-bar {
  flex: 1;
  flex-basis: 0.000000001px;
}

.layout.start.bottom-bar {
  align-items: flex-start;
}

.layout.center.bottom-bar {
  align-items: center;
}

.layout.end.bottom-bar {
  align-items: flex-end;
}

.flex-2.bottom-bar {
  flex: 2;
}

.flex-3.bottom-bar {
  flex: 3;
}

.flex-4.bottom-bar {
  flex: 4;
}

.flex-5.bottom-bar {
  flex: 5;
}

.flex-6.bottom-bar {
  flex: 6;
}

.flex-7.bottom-bar {
  flex: 7;
}

.flex-8.bottom-bar {
  flex: 8;
}

.flex-9.bottom-bar {
  flex: 9;
}

.flex-10.bottom-bar {
  flex: 10;
}

.flex-11.bottom-bar {
  flex: 11;
}

.flex-12.bottom-bar {
  flex: 12;
}</style><!-- Shady DOM styles for landscape-link --><!-- Shady DOM styles for landscape-summary-box --><!-- Shady DOM styles for search-state --><!-- Shady DOM styles for iron-overlay-backdrop --><!-- Shady DOM styles for opaque-animation --><!-- Shady DOM styles for iron-dropdown --><!-- Shady DOM styles for iron-meta --><!-- Shady DOM styles for iron-icon --><style scope="iron-icon-0">.iron-icon-0 {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;-ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;-ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
        position: relative;

        vertical-align: middle;

        fill: currentcolor;
        stroke: none;

        width: 24px;
        height: 24px;;
}

.iron-icon-0[hidden] {
  display: none;
}</style><!-- Shady DOM styles for iron-iconset-svg --><!-- Shady DOM styles for iron-list --><!-- Shady DOM styles for paper-icon-item --><!-- Shady DOM styles for paper-item-body --><!-- Shady DOM styles for paper-item --><!-- Shady DOM styles for dropdown-menu --><!-- Shady DOM styles for chips-input --><!-- Shady DOM styles for input-chip --><!-- Shady DOM styles for keyword-editor --><!-- Shady DOM styles for paper-ripple --><!-- Shady DOM styles for paper-button --><!-- Shady DOM styles for date-editor --><!-- Shady DOM styles for metadata-editor --><!-- Shady DOM styles for restrict-editor --><!-- Shady DOM styles for overlay-tooltip --><style scope="overlay-tooltip">overlay-tooltip {
  display: none;
        color: #fff;
        background-color: #000;
        padding: 10px 12px;
        border-radius: 3px;
        font-size: 13px;
        font-weight: normal;
        line-height: normal;
        position: fixed;
        z-index: 100;
}

#arrow.overlay-tooltip {
  width: 0;
        height: 0;
        border-style: solid;
        border-width: 0 6px 8px 6px;
        border-color: transparent transparent #000 transparent;
        position: absolute;
        top: -8px;
        left: calc(50% - 6px);
}</style><!-- Shady DOM styles for query-renderer --><!-- Shady DOM styles for result-nav --><style scope="result-nav">result-nav {
  display: block;
        white-space: nowrap;
        padding: 0 30px;
        line-height: 30px;
        height: 30px;
        margin-top: 17px;
        font-weight: 500;
        font-size: 15px;
}

state-modifier.result-nav {
  color: #333;
}

state-modifier[disabled].result-nav {
  pointer-events: none;
        color: #ccc;
}</style><!-- Shady DOM styles for raw-html --><!-- Shady DOM styles for paper-material --><style scope="paper-material-0">.paper-material-0 {
  display: block;
        position: relative;
}

.paper-material-0[elevation="1"] {
  box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14),
                    0 1px 5px 0 rgba(0, 0, 0, 0.12),
                    0 3px 1px -2px rgba(0, 0, 0, 0.2);
}

.paper-material-0[elevation="2"] {
  box-shadow: 0 4px 5px 0 rgba(0, 0, 0, 0.14),
                    0 1px 10px 0 rgba(0, 0, 0, 0.12),
                    0 2px 4px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="3"] {
  box-shadow: 0 6px 10px 0 rgba(0, 0, 0, 0.14),
                    0 1px 18px 0 rgba(0, 0, 0, 0.12),
                    0 3px 5px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="4"] {
  box-shadow: 0 8px 10px 1px rgba(0, 0, 0, 0.14),
                    0 3px 14px 2px rgba(0, 0, 0, 0.12),
                    0 5px 5px -3px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="5"] {
  box-shadow: 0 16px 24px 2px rgba(0, 0, 0, 0.14),
                    0  6px 30px 5px rgba(0, 0, 0, 0.12),
                    0  8px 10px -5px rgba(0, 0, 0, 0.4);
}

.paper-material-0[animated] {
  transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
}

.paper-material-0 {
  ;
}</style><!-- Shady DOM styles for search-box --><style scope="search-box">.layout.horizontal.search-box,.layout.vertical.search-box {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-box {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-box {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-box {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-box {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-box {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-box,.layout.center-center.search-box {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-box,.layout.center-center.search-box {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-box {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-box {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-box {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.inputbox.search-box {
  border: 1px solid #ccc;
        padding: 0 12px;
        background: white;
}

.inputbox[focused].search-box {
  border: 1px solid #4285f4 !important;
}

.inputbox.search-box:hover {
  border: 1px solid #999;
}

#searchInput.search-box {
  font-family: inherit;
        font-size: 16px;
        padding: 8px 0;
        outline: none;
        border-right: none;
        width: 100%;
        margin-right: 0;
        border: 0;
}

#searchButton.search-box {
  cursor: pointer;
        background-color: #4285f4;
        border: none;
        color: #fff;
        vertical-align: top;
        width: 70px;
        height: 37px;
        outline: none;
}

.suggest-bg.search-box {
  display: inline-block;
        min-width: 0;
        white-space: nowrap;
}

#suggestMenu.search-box {
  position: absolute;
        margin-top: 38px;
        width: 100%;
        background: white;
        z-index: 1;
}

#suggestMenu.search-box .row.search-box {
  font-size: 13px;
        line-height: 28px;
        white-space: nowrap;
        overflow: hidden;
        text-overflow: ellipsis;
        padding: 4px 2px;
        cursor: pointer;
}

.row[selected].search-box {
  background: rgba(0, 0, 0, 0.05);
}

.suggest-icon.search-box {
  height: 20px;
        width: 20px;
        padding: 0 12px 0 6px;
        transition: transform .15s linear;
        transform: scale(1);
}

.suggest-icon[hide].search-box {
  transform: scale(0);
}

#corpora.search-box {
  padding: 6px 0;
        user-select: none;
}

#corpora.search-box iron-icon.search-box {
  height: 20px;
        width: 20px;
        color: #ccc;
        cursor: pointer;
}

#corpora.search-box iron-icon[active].search-box {
  color: #4285f4 !important;
}

#corpora.search-box iron-icon.search-box:hover {
  color: #999;
}</style><!-- Shady DOM styles for iron-media-query --><!-- Shady DOM styles for paper-header-panel --><!-- Shady DOM styles for iron-a11y-announcer --><style scope="iron-a11y-announcer">iron-a11y-announcer {
  display: inline-block;
        position: fixed;
        clip: rect(0px,0px,0px,0px);
}</style><!-- Shady DOM styles for iron-autogrow-textarea --><!-- Shady DOM styles for iron-input --><!-- Shady DOM styles for paper-input-char-counter --><!-- Shady DOM styles for paper-input-container --><!-- Shady DOM styles for paper-input-error --><!-- Shady DOM styles for paper-input --><!-- Shady DOM styles for paper-textarea --><!-- Shady DOM styles for paper-toast --><style scope="paper-toast-0">.paper-toast-0 {
  display: block;
        position: fixed;
        background-color: #323232;
        color: #f1f1f1;
        min-height: 48px;
        min-width: 288px;
        padding: 16px 24px;
        box-sizing: border-box;
        box-shadow: 0 2px 5px 0 rgba(0, 0, 0, 0.26);
        border-radius: 2px;
        margin: 12px;
        font-size: 14px;
        cursor: default;
        -webkit-transition: -webkit-transform 0.3s, opacity 0.3s;
        transition: transform 0.3s, opacity 0.3s;
        opacity: 0;
        -webkit-transform: translateY(100px);
        transform: translateY(100px);font-family: 'Roboto', 'Noto', sans-serif;
        -webkit-font-smoothing: antialiased;
}

.paper-toast-0.capsule {
  border-radius: 24px;
}

.paper-toast-0.fit-bottom {
  width: 100%;
        min-width: 0;
        border-radius: 0;
        margin: 0;
}

.paper-toast-0.paper-toast-open {
  opacity: 1;
        -webkit-transform: translateY(0px);
        transform: translateY(0px);
}</style><!-- Shady DOM styles for paper-toolbar --><!-- Shady DOM styles for search-footer --><style scope="search-footer">#footer.search-footer {
  font-size: 13px;
        margin-top: 10px;
        background: #fafafa;
        padding: 20px 10px;
        align-items: center;
        border-top: 1px solid #ebebeb;
}

#footer.search-footer .links.search-footer > *.search-footer {
  display: inline-block;
        margin: 0 12px;
}

.layout.horizontal.search-footer,.layout.vertical.search-footer {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-footer {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-footer {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-footer {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-footer {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-footer {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-footer {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-footer {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-footer {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-footer {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-footer {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-footer {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-footer {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-footer {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-footer {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-footer {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-footer {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-footer {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-footer {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-footer {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-footer {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-footer {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-footer {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-footer {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-footer {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-footer {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-header --><style scope="search-header">search-header {
  display: block;
}

.lockup-logo.search-header,.lockup-text.search-header {
  display: inline-block;
}

.lockup-logo.search-header {
  width: 74px;
        height: 24px;
        background-image: url('https://www.gstatic.com/images/branding/googlelogo/1x/googlelogo_color_74x24dp.png');
        background-size: 74px 24px;
}

.lockup-text.search-header {
  font-family: "Product Sans", Arial, Helvetica, sans-serif;

        
        font-size: 22.1px;

        
        text-rendering: optimizeLegibility;

        
        position: relative;
        top: -6px;
        left: -5px;

        
        -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
}

.lockup-brand.search-header {
  opacity: 0.54;
}

@media (-webkit-min-device-pixel-ratio: 1.5), (min-resolution: 144dpi) {
.lockup-logo.search-header {
  background-image: url('https://www.gstatic.com/images/branding/googlelogo/2x/googlelogo_color_74x24dp.png');
}

.lockup-text.search-header {
  font-size: 21.3px;
          left: -7px;
}

}

header.search-header {
  background-color: #fafafa;
        border-bottom: 1px solid #ebebeb;
        color: #333;
        height: 60px;
        width: 100%;
        z-index: 1;
        display: block;
}

[latestStyle].search-header header.search-header {
  background-color: transparent;
}

.headerpad.search-header {
  margin-left: 16px;
}

[wide].search-header .headerpad.search-header {
  margin-left: 32px;
}

.leftheader.search-header {
  width: 322px;
}

header.search-header h1.search-header {
  display: none;
}

header.search-header h1.search-header state-modifier.search-header {
  color: #777;
        text-decoration: none;
        display: inline-block;
}

[wide].search-header header.search-header h1.search-header {
  box-sizing: border-box;
        margin: 0;
        padding: 20px 0 10px;
        font-size: 20px;
        font-weight: 400;
        white-space: nowrap;
        display: block;
}

search-box.search-header {
  height: 37px;
        padding: 0 16px;
        width: 900px;
        align-self: center;
}

.layout.horizontal.search-header,.layout.vertical.search-header {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-header {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-header {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-header {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-header {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-header {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-header {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-header {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-header {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-header {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-header {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-header {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-header {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-header {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-header {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-header {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-header {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-header {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-header {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-header {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-header {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-header {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-header {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-header {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-header {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-header {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-ui --><style scope="search-ui-0">.search-ui-0 paper-button.search-ui {
  display: inline-block;
        text-align: center;
        font-family: inherit;
}

.search-ui-0 .layout.horizontal.search-ui,.search-ui-0 .layout.vertical.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.search-ui-0 .layout.inline.search-ui {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.search-ui-0 .layout.horizontal.search-ui {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.search-ui-0 .layout.vertical.search-ui {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.search-ui-0 .layout.wrap.search-ui {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.search-ui-0 .layout.no-wrap.search-ui {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .flex.search-ui {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.search-ui-0 .flex-auto.search-ui {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.search-ui-0 .flex-none.search-ui {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.search-ui-0 .layout.start.search-ui {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.end.search-ui {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.search-ui-0 .layout.baseline.search-ui {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.search-ui-0 .layout.start-justified.search-ui {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .layout.end-justified.search-ui {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.search-ui-0 .layout.around-justified.search-ui {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.search-ui-0 .layout.justified.search-ui {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.search-ui-0 .self-start.search-ui {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.search-ui-0 .self-center.search-ui {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.search-ui-0 .self-end.search-ui {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.search-ui-0 .self-stretch.search-ui {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.search-ui-0 .self-baseline.search-ui {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.search-ui-0 .layout.start-aligned.search-ui {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.search-ui-0 .layout.end-aligned.search-ui {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.search-ui-0 .layout.center-aligned.search-ui {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.search-ui-0 .layout.between-aligned.search-ui {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.search-ui-0 .layout.around-aligned.search-ui {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.search-ui-0 {
  display: block;
        min-width: 350px;
        height: 100%;
}

.search-ui-0 #content.search-ui {
  height: 100%;
}

.search-ui-0 #leftBarOverflow.search-ui {
  padding-right: 16px;
}

.search-ui-0 [wide].search-ui #leftBarOverflow.search-ui {
  overflow: auto;
}

.search-ui-0 #leftBar.search-ui {
  box-sizing: border-box;
        color: #666;
        font-size: 13px;
        padding: 16px 0 16px 16px;
        border-bottom: 1px solid #e5e5e5;
}

.search-ui-0 [wide].search-ui #leftBar.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;

        -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
        position: relative;
        width: 350px;
        margin-bottom: 0;
        padding-bottom: 0;
        border-bottom: none;
}

@media print {
.search-ui-0 #leftBar.search-ui {
  display: none !important;
}

}

.search-ui-0 #leftBar.search-ui h3.search-ui {
  text-transform: uppercase;
        font-size: 13px;
        font-weight: normal;
        margin-top: 6px;
        margin-bottom: 6px;
        cursor: default;
        display: inline-block;
        color: #a3a3a3;
}

.search-ui-0 #closeButton.search-ui {
  position: absolute;
        right: 0;
}

.search-ui-0 #searchTermsHeader.search-ui {
  position: relative;
}

.search-ui-0 #searchTermsQ.search-ui iron-icon.search-ui {
  height: 16px;
        padding: 0 2px 2px 2px;
        color: #a3a3a3;
}

.search-ui-0 #searchTermsHeader.search-ui:hover iron-icon.search-ui {
  color: #4285f4;
}

.search-ui-0 #closeLeftBar.search-ui {
  height: 16px;
        width: 16px;
        padding: 0 0 8px 0;
        cursor: pointer;
}

.search-ui-0 #compactQuery.search-ui iron-icon.search-ui {
  height: 20px;
}

.search-ui-0 #backToResultsButton.search-ui {
  color: #fff;
        background: #4285f4;
        margin-top: 20px;
        text-align: center;
}

.search-ui-0 #main.search-ui {
  display: block;
        min-height: calc(100vh - 127px);
}

@media print {
.search-ui-0 [wide].search-ui main.search-ui {
  margin-left: 0;
}

}</style><!-- Shady DOM styles for import-list --><!-- Shady DOM styles for iron-request --><!-- Shady DOM styles for iron-ajax --><!-- Shady DOM styles for paper-dialog --><!-- Shady DOM styles for coverage-stats --><!-- Shady DOM styles for iron-image --><!-- Shady DOM styles for iron-selector --><!-- Shady DOM styles for paper-card --><!-- Shady DOM styles for paper-checkbox --><!-- Shady DOM styles for landing-page --><!-- Shady DOM styles for remote-fetch --><!-- Shady DOM styles for paper-spinner --><style scope="paper-spinner-0">.paper-spinner-0 {
  display: inline-block;
        position: relative;
        width: 28px;
        height: 28px;
}

.paper-spinner-0 #spinnerContainer.paper-spinner {
  width: 100%;
        height: 100%;

        
        direction: ltr;
}

.paper-spinner-0 #spinnerContainer.active.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite;
        animation: container-rotate-paper-spinner-0 1568ms linear infinite;
}

@-webkit-keyframes container-rotate-paper-spinner-0 {
to {
  -webkit-transform: rotate(360deg)
}

}

@keyframes container-rotate-paper-spinner-0 {
to {
  transform: rotate(360deg)
}

}

.paper-spinner-0 .spinner-layer.paper-spinner {
  position: absolute;
        width: 100%;
        height: 100%;
        opacity: 0;
        white-space: nowrap;
        color: #4285f4;
}

.paper-spinner-0 .layer-1.paper-spinner {
  color: #4285f4;
}

.paper-spinner-0 .layer-2.paper-spinner {
  color: #db4437;
}

.paper-spinner-0 .layer-3.paper-spinner {
  color: #f4b400;
}

.paper-spinner-0 .layer-4.paper-spinner {
  color: #0f9d58;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0;
        -webkit-animation-duration: 5332ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-name: fill-unfill-rotate-paper-spinner-0;
        animation-duration: 5332ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
        opacity: 1;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-1.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-2.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-3.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-4.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
}

@-webkit-keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  -webkit-transform: rotate(135deg)
}

25% {
  -webkit-transform: rotate(270deg)
}

37.5% {
  -webkit-transform: rotate(405deg)
}

50% {
  -webkit-transform: rotate(540deg)
}

62.5% {
  -webkit-transform: rotate(675deg)
}

75% {
  -webkit-transform: rotate(810deg)
}

87.5% {
  -webkit-transform: rotate(945deg)
}

to {
  -webkit-transform: rotate(1080deg)
}

}

@keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  transform: rotate(135deg)
}

25% {
  transform: rotate(270deg)
}

37.5% {
  transform: rotate(405deg)
}

50% {
  transform: rotate(540deg)
}

62.5% {
  transform: rotate(675deg)
}

75% {
  transform: rotate(810deg)
}

87.5% {
  transform: rotate(945deg)
}

to {
  transform: rotate(1080deg)
}

}

@-webkit-keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@-webkit-keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

.paper-spinner-0 .circle-clipper.paper-spinner {
  display: inline-block;
        position: relative;
        width: 50%;
        height: 100%;
        overflow: hidden;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after {
  left: 45%;
        width: 10%;
        border-top-style: solid;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after,.paper-spinner-0 .circle-clipper.paper-spinner::after {
  content: '';
        box-sizing: border-box;
        position: absolute;
        top: 0;
        border-width: 3px;
        border-radius: 50%;
}

.paper-spinner-0 .circle-clipper.paper-spinner::after {
  bottom: 0;
        width: 200%;
        border-style: solid;
        border-bottom-color: transparent !important;
}

.paper-spinner-0 .circle-clipper.left.paper-spinner::after {
  left: 0;
        border-right-color: transparent !important;
        -webkit-transform: rotate(129deg);
        transform: rotate(129deg);
}

.paper-spinner-0 .circle-clipper.right.paper-spinner::after {
  left: -100%;
        border-left-color: transparent !important;
        -webkit-transform: rotate(-129deg);
        transform: rotate(-129deg);
}

.paper-spinner-0 .active.paper-spinner .gap-patch.paper-spinner::after,.paper-spinner-0 .active.paper-spinner .circle-clipper.paper-spinner::after {
  -webkit-animation-duration: 1333ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-duration: 1333ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.left.paper-spinner::after {
  -webkit-animation-name: left-spin-paper-spinner-0;
        animation-name: left-spin-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.right.paper-spinner::after {
  -webkit-animation-name: right-spin-paper-spinner-0;
        animation-name: right-spin-paper-spinner-0;
}

@-webkit-keyframes left-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(130deg)
}

50% {
  -webkit-transform: rotate(-5deg)
}

to {
  -webkit-transform: rotate(130deg)
}

}

@keyframes left-spin-paper-spinner-0 {
0% {
  transform: rotate(130deg)
}

50% {
  transform: rotate(-5deg)
}

to {
  transform: rotate(130deg)
}

}

@-webkit-keyframes right-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(-130deg)
}

50% {
  -webkit-transform: rotate(5deg)
}

to {
  -webkit-transform: rotate(-130deg)
}

}

@keyframes right-spin-paper-spinner-0 {
0% {
  transform: rotate(-130deg)
}

50% {
  transform: rotate(5deg)
}

to {
  transform: rotate(-130deg)
}

}

.paper-spinner-0 #spinnerContainer.cooldown.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
        animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
}

@-webkit-keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}</style><!-- Shady DOM styles for paper-spinner-lite --><!-- Shady DOM styles for concept-card --><!-- Shady DOM styles for concept-mention --><!-- Shady DOM styles for fterm-concept-card --><!-- Shady DOM styles for fterm-concept-mention --><!-- Shady DOM styles for paper-fab --><!-- Shady DOM styles for paper-icon-button --><!-- Shady DOM styles for paper-icon-button-light --><!-- Shady DOM styles for classification-tree --><!-- Shady DOM styles for classification-viewer --><style scope="classification-viewer">.table.classification-viewer {
  border: 1px solid #eaeaea;
        display: block;
}

.more.classification-viewer {
  padding: 6px 12px;
        cursor: pointer;
        font-style: italic;
        color: #aaa;
}

.more.classification-viewer:hover {
  background: #fafafa;
}

.chip.classification-viewer {
  display: inline-block;
        padding: 4px 6px;
        border-radius: 2px;
}

.chip[additional].classification-viewer {
  font-style: italic;
}</style><!-- Shady DOM styles for image-carousel --><!-- Shady DOM styles for image-viewer --><!-- Shady DOM styles for patent-result --><style scope="patent-result">#wrapper.patent-result {
  padding: 20px;
        max-width: 1050px;
        outline: 0;
}

.scroll-target.patent-result:before {
  display: block;
        content: '';
        visibility: hidden;
}

h1.patent-result {
  font-weight: 500;
        font-size: 20px;
        margin: 0 0 20px 0;
}

h3.patent-result {
  font-size: 15px;
        font-weight: 500;
        margin: 28px 0 18px 0;
}

dl.patent-result {
  line-height: 1.5;
        font-size: 0;
}

dt.patent-result,dd.patent-result {
  display: inline;
        font-size: 13px;
        margin: 0;
}

dt.patent-result {
  font-weight: 500;
        color: #000;
}

dt.patent-result::after {
  content: ': ';
}

dd.patent-result {
  color: #aaa;
}

dd.patent-result ~ dd.patent-result::before {
  content: ', ';
}

dt.patent-result + dd.patent-result::before {
  content: '';
}

dd.patent-result ~ dt.patent-result::before {
  display: block;
        content: '';
        margin-top: 8px;
}

dd.patent-result core-icon.patent-result {
  width: 14px;
        height: 14px;
        vertical-align: top;
        color: inherit;
}

.table.patent-result {
  display: table;
        border-collapse: collapse;
        border-spacing: 0;
        border: 1px solid #eaeaea;
        width: 100%;
        box-sizing: border-box;
}

.tr.patent-result {
  display: table-row;
        border-bottom: 1px solid #eaeaea;
}

.th.patent-result,.td.patent-result {
  display: table-cell;
        padding: 10px 12px;
}

.thead.patent-result {
  display: table-header-group;
}

.tbody.patent-result {
  display: table-row-group;
}

.th.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.td.patent-result {
  vertical-align: top;
}

.td.patent-result > p.patent-result {
  margin-top: 0;
}

.nowrap.patent-result {
  white-space: nowrap;
}

.knowledge-card.patent-result {
  border: 1px solid #e5e5e5;
        border-radius: 2px;
}

.knowledge-card.patent-result > header.patent-result {
  -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
        background: #4285f4;
        color: #fff;
        padding: 20px 12px;
}

.knowledge-card.patent-result > header.patent-result state-modifier.patent-result,.knowledge-card.patent-result > header.patent-result a.patent-result {
  color: inherit;
        margin: 0 12px 0 0;
        display: inline-block;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result,.knowledge-card.patent-result > header.patent-result .tagline.patent-result {
  margin: 0;
        font-weight: normal;
        padding-top: 4px;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result {
  font-size: 20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result {
  background: #3367d6;
        padding: 10px 12px;
        margin: 20px -12px -20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result core-icon.patent-result {
  margin-right: 12px;
        width: 24px;
        height: 24px;
}

.knowledge-card.patent-result dl.patent-result {
  padding: 16px 12px;
}

.knowledge-card.patent-result hr.patent-result {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 0;
}

.main-link.patent-result {
  margin: 14px;
        font-weight: 500;
}

.footer.patent-result h3.patent-result state-modifier.patent-result,.footer.patent-result h3.patent-result a.patent-result {
  float: right;
        font-weight: 400;
        font-size: 13px;
        line-height: 24px;
}

.footer.patent-result dl.patent-result {
  margin-left: 30px;
}

.footer.patent-result > ul.patent-result > li.patent-result {
  margin-bottom: 8px;
}

h3.patent-result .righthead.patent-result {
  color: #aaa;
        font-weight: 400;
        font-size: 13px;
        cursor: help;
}

.tooltip-hint.patent-result {
  border-bottom: 1px dotted #ccc;
}

[marginRight].patent-result {
  margin-right: 60px;
}

.flex-width.patent-result {
  min-width: 0;
        word-break: break-word;
}

.responsive-table.patent-result {
  width: 100%;
        overflow-x: auto;
        overflow-y: hidden;
}

.layout.horizontal.patent-result,.layout.vertical.patent-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.flex.patent-result,.flex-1.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-2.patent-result {
  -ms-flex: 2;
        -webkit-flex: 2;
        flex: 2;
}

.flex-3.patent-result {
  -ms-flex: 3;
        -webkit-flex: 3;
        flex: 3;
}

.flex-4.patent-result {
  -ms-flex: 4;
        -webkit-flex: 4;
        flex: 4;
}

.flex-5.patent-result {
  -ms-flex: 5;
        -webkit-flex: 5;
        flex: 5;
}

.flex-6.patent-result {
  -ms-flex: 6;
        -webkit-flex: 6;
        flex: 6;
}

.flex-7.patent-result {
  -ms-flex: 7;
        -webkit-flex: 7;
        flex: 7;
}

.flex-8.patent-result {
  -ms-flex: 8;
        -webkit-flex: 8;
        flex: 8;
}

.flex-9.patent-result {
  -ms-flex: 9;
        -webkit-flex: 9;
        flex: 9;
}

.flex-10.patent-result {
  -ms-flex: 10;
        -webkit-flex: 10;
        flex: 10;
}

.flex-11.patent-result {
  -ms-flex: 11;
        -webkit-flex: 11;
        flex: 11;
}

.flex-12.patent-result {
  -ms-flex: 12;
        -webkit-flex: 12;
        flex: 12;
}

@media print {
#text.patent-result {
  flex-direction: column-reverse !important;
}

}

patent-result-ref-list.patent-result {
  width: 100%;
}

patent-result-ref-list.patent-result + patent-result-ref-list.patent-result {
  margin-left: 10px;
}

[narrow].patent-result {
  flex-direction: column-reverse !important;
}

.famheader.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.collapse.patent-result {
  color: #616161;
        font-size: 13px;
        cursor: pointer;
}

#imageDrag.patent-result {
  position: fixed;
        cursor: col-resize;
}

#imageDrag.patent-result div.patent-result {
  width: 4px;
        height: 100%;
        margin: 0 4px;
        background: #eee;
}

#imageDrag.patent-result:hover {
  background: #eee;
}

#imageDrag.patent-result:hover div.patent-result {
  background: #ccc;
}

.imageWrapper.patent-result {
  position: fixed;
        top: 60px;
        background: white;
        margin-left: 12px;
}

#notices.patent-result {
  padding: 20px;
}

#figures.patent-result {
  background: #efefef;
}

.headerButton.patent-result {
  color: #3c80f6;
        cursor: pointer;
        display: inline-block;
        padding: 0 14px;
        line-height: 27px;
}

.headerButton.patent-result iron-icon.patent-result {
  width: 16px;
        height: 16px;
}

.tr.conceptDomain.patent-result {
  display: table-row;
}

.responsive-grid.patent-result {
  display: grid;
        gap: 8px;
        grid-template-columns: none;
}</style><!-- Shady DOM styles for family-viewer --><!-- Shady DOM styles for app-row --><!-- Shady DOM styles for application-timeline --><style scope="application-timeline">.layout.horizontal.application-timeline,.layout.vertical.application-timeline {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.application-timeline {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.application-timeline {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.application-timeline {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.application-timeline {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.application-timeline {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.application-timeline {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.application-timeline {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.application-timeline {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.wrap.application-timeline {
  padding: 16px 12px;
}

.event.application-timeline {
  padding: 3px 0;
}

[date].application-timeline {
  color: #5f6368;
        font-size: 13px;
        padding: 3px 0;
        width: 70px;
        line-height: 16px;
}

[critical].application-timeline [date].application-timeline {
  color: #202124;
        font-weight: 500;
        line-height: 18px;
}

.line.application-timeline {
  margin: 9px 6px;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
}

.dot.application-timeline {
  margin: 3px 0;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
        display: inline-block;
}

[critical].application-timeline .line.application-timeline {
  background: #4285f4;
}

[current].application-timeline .line.application-timeline {
  background: #81c995;
}

[current][critical].application-timeline .line.application-timeline {
  background: #81c995;
}

.title.application-timeline {
  font-size: 13px;
        padding: 3px 0;
        line-height: 16px;
}

.title-text.application-timeline {
  color: #5f6368;
}

.description-item.application-timeline {
  font-size: 12px;
        padding: 6px 0;
        max-width: 300px;
}

#legal.application-timeline {
  height: 14px;
        width: 14px;
        padding: 0 3px 1px 3px;
        vertical-align: text-bottom;
}

#icon.application-timeline {
  height: 12px;
        width: 12px;
        padding: 0 3px 3px 3px;
        vertical-align: text-bottom;
}

.unknown.application-timeline {
  font-style: italic;
}

.not_active.application-timeline {
  text-decoration: line-through;
}

.active.application-timeline {
  font-weight: 500;
}

#cc[this].application-timeline {
  color: #202124 !important;
        text-decoration: underline;
}

#cc[this].not_active.application-timeline {
  text-decoration: line-through underline;
}

hr.application-timeline {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 10px 0 16px 0;
}

.header.application-timeline {
  font-size: 13px;
        line-height: 20px;
        font-weight: 500;
        color: #202124;
        padding-bottom: 8px;
}

.block.application-timeline {
  padding: 0 6px 0 0;
}

.year.application-timeline {
  color: #5f6368;
        font-size: 13px;
        font-weight: 500;
        padding: 3px 1px;
        width: 70px;
}

.expand.application-timeline {
  cursor: pointer;
        padding: 6px 0 3px 0;
}</style><!-- Shady DOM styles for patent-text --><style scope="patent-text">.layout.horizontal.patent-text,.layout.vertical.patent-text {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-text {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-text {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-text {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-text {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-text {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-text {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-text {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-text {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-text {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-text {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-text {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-text {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-text {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-text {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-text {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-text {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-text {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-text {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-text {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-text {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-text {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-text {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-text {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-text {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-text {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

patent-text {
  display: block;
}

#text.patent-text {
  line-height: 20px;
        min-width: 0;
}

#margin.patent-text {
  width: 16px;
}

#createHighlight.patent-text {
  position: relative;
        width: 16px;
        height: 16px;
        cursor: pointer;
}

.notranslate.patent-text > .google-src-text.patent-text {
  display: none;
}

.notranslate.patent-text:hover,mark.patent-text {
  background-color: #fbfcae;
}

.description-paragraph.patent-text {
  margin-block-start: 1em;
        margin-block-end: 1em;
}

.claim-text.patent-text {
  margin: 14px 0 0 20px;
}

.claim-dependent.patent-text {
  margin-left: 40px;
        color: #888;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim-text.patent-text {
  height: 0;
        width: 0;
        visibility: hidden;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim.patent-text:after {
  content: ""
}

.patent-full-image.patent-text {
  max-width: 100%;
        height: auto;
}

.small-patent-image.patent-text {
  display: inline;
}

ul.patent-text {
  padding: 0 0 0 50px;
}

li.patent-text {
  list-style-type: none;
        position: relative;
}

ol.claims.patent-text li.patent-text {
  list-style-type: decimal;
        font-weight: bold;
}

ol.claims.patent-text li.patent-text > *.patent-text {
  font-weight: normal;
}

li.patent-text > para-num.patent-text {
  position: absolute;
        left: -45px;
        color: #888;
}

mark.patent-text {
  background: #fff59d;
}

mark.searchText.patent-text {
  background: #80deea;
}

.searchTextHeader.patent-text {
  font-weight: 500;
}

pre.patent-text {
  white-space: pre-wrap;
}

heading.patent-text {
  display: block;
        font-weight: 500;
        font-size: 13px;
}

#comment.patent-text {
  width: 16px;
        height: 16px;
}

[has-search][no-results].patent-text {
  display: none;
}

.highlight.patent-text {
  background-color: #fef7e0;
}</style><!-- Shady DOM styles for para-num --><!-- Shady DOM styles for result-container --><style scope="result-container">paper-spinner.result-container {
  position: absolute;
        
        top: calc(50%  + 56px - 16px);
        left: calc(50% + 175px - 16px);
}</style><!-- Shady DOM styles for scholar-result --><!-- Shady DOM styles for search-result --><style scope="search-result">.layout.horizontal.search-result,.layout.vertical.search-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

search-result {
  display: block;
        font-size: 13px;
}

#mainContainer.search-result {
  min-height: calc(100vh - 127px);
        color: #333;
}

#compactQuery.search-result {
  padding: 18px 20px 10px 20px;
        cursor: pointer;
}

#compactQuery.search-result > span.search-result {
  padding: 0 14px 0 0;
}

#compactQuery.search-result iron-icon.search-result {
  padding-right: 6px;
        height: 16px;
        width: 16px;
}</style><!-- Shady DOM styles for webdoc-result --><!-- Shady DOM styles for iron-pages --><!-- Shady DOM styles for paper-tab --><!-- Shady DOM styles for paper-tabs --><!-- Shady DOM styles for debug-info --><!-- Shady DOM styles for search-paging --><!-- Shady DOM styles for search-result-item --><!-- Shady DOM styles for search-result-image --><!-- Shady DOM styles for search-result-entities --><!-- Shady DOM styles for search-result-measures --><!-- Shady DOM styles for search-results --><!-- Shady DOM styles for summary-box --><!-- Shady DOM styles for timeline-page --><!-- Shady DOM styles for iron-localstorage --><!-- Shady DOM styles for search-app --><style scope="search-app">search-app {
  display: block;
        height: 100%;
}

#toast.search-app {
  min-height: 64px;
        min-width: 742px;
}</style><style>body {transition: opacity ease-in 0.2s; } 
body[unresolved] {opacity: 0; display: block; overflow: hidden; position: relative; } 
</style>
    <title>CA2497031A1 - Farnesyl dibenzodiazepinones, processes for their production and their use as pharmaceuticals 
        - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/CA2497031A1/en">
    <meta name="description" content="
      The present invention relates to dibenzodiazepinones of Formula I, their pharmaceutically acceptable salts and prodrugs, to methods for obtaining such compounds, to pharmaceutical compositions comprising them, and to their use as pharmaceuticals, in particular as inhibitors of cancer, and mammalian lipoxygenase, or as a PBR binding agent.       
   
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="Farnesyl dibenzodiazepinones, processes for their production and their use as pharmaceuticals 
       ">
    <meta name="DC.date" content="2005-02-11" scheme="dateSubmitted">
    <meta name="DC.description" content="
      The present invention relates to dibenzodiazepinones of Formula I, their pharmaceutically acceptable salts and prodrugs, to methods for obtaining such compounds, to pharmaceutical compositions comprising them, and to their use as pharmaceuticals, in particular as inhibitors of cancer, and mammalian lipoxygenase, or as a PBR binding agent.       
   
   ">
    <meta name="citation_patent_application_number" content="CA: 2497031">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/cf/26/bd/dea761c9294b13/CA2497031A1.pdf">
    <meta name="citation_patent_publication_number" content="CA:2497031:A1">
    <meta name="DC.date" content="2006-05-08">
    <meta name="DC.contributor" content="James B. Mcalpine" scheme="inventor">
    <meta name="DC.contributor" content="Ecopia Biosciences Inc" scheme="assignee">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      body { transition: none; }
    </style>

    <script src="https://apis.google.com/_/scs/abc-static/_/js/k=gapi.lb.en.IKZeRvoAYNY.O/m=client/rt=j/sv=1/d=1/ed=1/am=AAAQ/rs=AHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw/cb=gapi.loaded_0?le=scs" async=""></script><script>
      window.version = 'patent-search.search_20240531_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <style>[hidden]:not([style-scope]):not(.style-scope) {
  display: none !important;
}

</style><style></style><style></style><style></style><style></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,300,300italic,400italic,500,500italic,700,700italic"><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Mono:400,700"><style></style><style></style><style>
  html, body {
    min-width: 100%;
    width: 100%;
    min-height: 100%;
    height: 100%;
  }

  body {
    background-color: #fff;
    font-family: 'Roboto', sans-serif;
    color: #333;
    margin: 0;
    padding: 0;
    /*
     * Turn off https://github.com/WICG/ScrollAnchoring/blob/master/explainer.md
     * https://memegen.googleplex.com/5230756293246976
     */
    overflow-anchor: none;
  }

  body h1, body h2, body h3 {
    -webkit-font-smoothing: antialiased;
    -moz-osx-font-smoothing: grayscale;
  }

  body a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  body a:visited {
    color: #3c80f6;
  }

  body a[open-result]:visited {
    color: #7e57c2;
  }

  /* For Firefox */
  a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  a:visited {
    color: #3c80f6;
  }

  a[open-result]:visited {
    color: #7e57c2;
  }

  ::selection , body ::selection {
    background-color: #c6dafc;
    color: #333;
  }
</style><link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.html">
  <style>[hidden] { display: none !important; }</style><script type="text/javascript" charset="UTF-8" src="https://apis.google.com/js/client.js" gapi_processed="true"></script></head>
  <body>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.js"></script><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span>
    <search-app>
    
    <remote-fetch class="style-scope search-app"></remote-fetch>
    <search-state class="style-scope search-app"></search-state>
    <browser-ui class="style-scope search-app"></browser-ui>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    
      <search-result id="result" class="style-scope search-app">
    
    
    <search-ui mode="result" class="style-scope search-result x-scope search-ui-0">
    
    
    
    <div id="content" class="style-scope search-ui" wide="">
      <search-header show-search="" class="style-scope search-ui">
    
    
    <div class="style-scope search-header" wide="">
      <header class="style-scope search-header">
        <div class="layout horizontal headerpad style-scope search-header">
          <div class="layout horizontal leftheader style-scope search-header">
            <h1 class="style-scope search-header">
              <state-modifier inherit="" act="{&quot;type&quot;: &quot;HOME&quot;}" class="style-scope search-header"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                <div class="lockup style-scope search-header">
                  <span class="lockup-logo style-scope search-header"></span>
                  <span class="lockup-text style-scope search-header">
                    <span class="lockup-brand style-scope search-header">&nbsp;Patents</span>
                  </span>
                </div>
              </a></state-modifier>
            </h1>
          </div>
          
            <search-box class="style-scope search-header">
    
    <div class="layout horizontal style-scope search-box" style="position: relative;">
      <div class="inputbox flex layout horizontal style-scope search-box">
        <div class="suggest-bg flex style-scope search-box">
          <input name="q" id="searchInput" data-proto="SEARCH_INPUT" autocomplete="off" class="style-scope search-box">
        </div>
        <div id="corpora" class="style-scope search-box">
          <iron-icon icon="icons:lightbulb-outline" id="patentIcon" class="style-scope search-box x-scope iron-icon-0" active=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M9 21c0 .55.45 1 1 1h4c.55 0 1-.45 1-1v-1H9v1zm3-19C8.14 2 5 5.14 5 9c0 2.38 1.19 4.47 3 5.74V17c0 .55.45 1 1 1h6c.55 0 1-.45 1-1v-2.26c1.81-1.27 3-3.36 3-5.74 0-3.86-3.14-7-7-7zm2.85 11.1l-.85.6V16h-4v-2.3l-.85-.6C7.8 12.16 7 10.63 7 9c0-2.76 2.24-5 5-5s5 2.24 5 5c0 1.63-.8 3.16-2.15 4.1z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#patentIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include patents
    </div>
  </overlay-tooltip>
          <iron-icon icon="social:school" id="nplIcon" class="style-scope search-box x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M5 13.18v4L12 21l7-3.82v-4L12 17l-7-3.82zM12 3L1 9l11 6 9-4.91V17h2V9L12 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#nplIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include non-patent literature
    </div>
  </overlay-tooltip>
          <keyword-wizard id="wizardIcon" class="style-scope search-box">


<div id="wizardContainer" class="style-scope keyword-wizard">
  <iron-icon icon="image:tune" id="wizardIcon" class="style-scope keyword-wizard x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M3 17v2h6v-2H3zM3 5v2h10V5H3zm10 16v-2h8v-2h-8v-2h-2v6h2zM7 9v2H3v2h4v2h2V9H7zm14 4v-2H11v2h10zm-6-4h2V7h4V5h-4V3h-2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
  <paper-material elevation="2" id="wizard" class="style-scope keyword-wizard x-scope paper-material-0" hidden="">
    
    

    
    
    <div class="search-within style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Search within
        <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="within"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="withinHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search within the title, abstract, claims, or full patent document</b>: You can
          restrict your search to a specific field using field names.</p>
        <p class="style-scope keyword-wizard">Use <span class="q style-scope keyword-wizard">TI=</span> to search in the title, <span class="q style-scope keyword-wizard">AB=</span> for the
          abstract, <span class="q style-scope keyword-wizard">CL=</span> for the claims, or <span class="q style-scope keyword-wizard">TAC=</span> for
          all three. For example, <span class="q style-scope keyword-wizard">TI=(safety belt)</span>.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search by Cooperative Patent Classifications (CPCs)</b>: These are commonly used to
          represent ideas in place of keywords, and can also be entered in a search term box. If
          you're searching for<span class="q style-scope keyword-wizard">seat belts</span>, you could also search for
          <span class="q style-scope keyword-wizard">B60R22/00</span> to retrieve documents that mention safety belts or body
          harnesses. <span class="q style-scope keyword-wizard">CPC=B60R22</span> will match documents with exactly this CPC,
          <span class="q style-scope keyword-wizard">CPC=B60R22/low</span> matches documents with this CPC or a child
          classification of this CPC.
        </p>
          <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="filter-chips style-scope keyword-wizard">
        <span class="chip style-scope keyword-wizard" id="title" selected="">Title</span>
        <span class="chip style-scope keyword-wizard" id="abstract" selected="">Abstract</span>
        <span class="chip style-scope keyword-wizard" id="claims" selected="">Claims</span>
        <span class="chip style-scope keyword-wizard" id="fullDoc" selected="">Full Document</span>
      </div>
      
      <div class="cpc-field style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputCPC" class="style-scope keyword-wizard">or CPC</label></span>
        <div class="cpc-inputs style-scope keyword-wizard">
          <input class="keyword-input style-scope keyword-wizard" id="inputCPC" placeholder="Or search with CPC">
          <input type="checkbox" id="childCPC" checked="" class="style-scope keyword-wizard">
          <label class="checkbox-label style-scope keyword-wizard" for="childCPC">
            Include child classifications
          </label>
        </div>
      </div>
    </div>
    
    <div class="find-patents style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Find patents
        <iron-icon class="help-header style-scope keyword-wizard x-scope iron-icon-0" icon="icons:help-outline" id="searchBoolean"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="searchBooleanHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Keywords and boolean syntax (USPTO or EPO format)</b>:
          <span class="q style-scope keyword-wizard">seat belt</span> searches these two words, or their plurals and close
          synonyms. <span class="q style-scope keyword-wizard">"seat belt"</span> searches this exact phrase, in order.
          <span class="q style-scope keyword-wizard">-seat -belt</span> searches for documents not containing either word.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">For searches using boolean logic</b>, the default operator is
          <span class="q style-scope keyword-wizard">AND</span> with left associativity. <i class="style-scope keyword-wizard">Note:</i> this means
          <span class="q style-scope keyword-wizard">safety OR seat belt</span> is searched as <span class="q style-scope keyword-wizard">(safety OR seat)
          AND belt</span>. Each word automatically includes plurals and close synonyms. Adjacent
          words that are implicitly ANDed together, such as <span class="q style-scope keyword-wizard">(safety belt)</span>,
          are treated as a phrase when generating synonyms.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputAnd" class="style-scope keyword-wizard">with ALL of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputAnd" placeholder="with ALL of the words">
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputExact" class="style-scope keyword-wizard">with the EXACT PHRASE</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputExact" placeholder="with the EXACT PHRASE"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputOr" class="style-scope keyword-wizard">with AT LEAST ONE of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputOr" placeholder="with AT LEAST ONE of the words"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputMinus" class="style-scope keyword-wizard">WITHOUT the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputMinus" placeholder="WITHOUT the words"></div>
    </div>
    <div class="search-by style-scope keyword-wizard">
      <div class="wizard-header style-scope keyword-wizard">
          Search by
          <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="chem"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </div>
      
      <div class="help style-scope keyword-wizard" id="chemHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Chemistry searches</b> match terms (trade names, IUPAC names, etc.
          extracted from the entire document, and processed from .MOL files.)
        </p>
        <p class="style-scope keyword-wizard">Substructure (use <span class="q style-scope keyword-wizard">SSS=</span>) and similarity (use
          <span class="q style-scope keyword-wizard">~</span>) searches are limited to one per search at the top-level
          <span class="q style-scope keyword-wizard">AND</span> condition. Exact searches can be used multiple times throughout
          the search query.
        </p>
        <p class="style-scope keyword-wizard">Searching by SMILES or InChi key requires no special syntax. To search by SMARTS, use
          <span class="q style-scope keyword-wizard">SMARTS=</span>.
        </p>
        <p class="style-scope keyword-wizard">To search for multiple molecules, select "Batch" in the "Type" menu. Enter multiple
          molecules separated by whitespace or by comma.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      
      <div class="chemistry-field style-scope keyword-wizard">
          <span class="input-label style-scope keyword-wizard"><label for="inputChem" class="style-scope keyword-wizard">Chemistry</label></span>
          <span class="chem-type-label style-scope keyword-wizard"><label for="chemType" hidden="" class="style-scope keyword-wizard">Type</label></span>
          <select id="chemType" class="style-scope keyword-wizard">
            <option value="identical" class="style-scope keyword-wizard">Identical</option>
            <option value="substructure" class="style-scope keyword-wizard">Substructure</option>
            <option value="smarts" class="style-scope keyword-wizard">SMARTS</option>
            <option value="similarity" class="style-scope keyword-wizard">Similarity</option>
            <option value="batch" class="style-scope keyword-wizard">Batch</option>
          </select>
          <textarea class="keyword-input style-scope keyword-wizard" id="inputChem" placeholder="Trade name, SMILES, InChiKey"></textarea>
      </div>
      <div class="import style-scope keyword-wizard">
        <div class="wizard-header style-scope keyword-wizard">
          Patent numbers
        </div>
        <span class="import-button style-scope keyword-wizard">
          <a href="https://patents.google.com/import" class="style-scope keyword-wizard"><button class="style-scope keyword-wizard">Import</button></a>
        </span>
        <p class="import-text style-scope keyword-wizard">
          Search specific patents by importing a CSV or list of patent publication or application numbers.
        </p>
      </div>
    </div>
    
    <div class="wizard-buttons style-scope keyword-wizard">
      <button type="reset" class="style-scope keyword-wizard">Close</button>
      <button type="button" autofocus="" class="style-scope keyword-wizard">Add</button>
    </div>
  
  </paper-material>
</div>
</keyword-wizard>
          <overlay-tooltip positioning-target="#wizardIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Display advanced search options
    </div>
  </overlay-tooltip>
        </div>
      </div>
      <paper-material id="suggestMenu" class="style-scope search-box x-scope paper-material-0" elevation="1" hidden="">
    
    

    
        <template is="dom-repeat" class="style-scope search-box"></template>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Sorry, we couldn't find this patent number.
        </div>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> 
        </div>
      
  </paper-material>
      <button id="searchButton" class="style-scope search-box"><iron-icon class="style-scope search-box x-scope iron-icon-0" icon="search"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></button>
    </div>
  </search-box>
          <template is="dom-if" class="style-scope search-header"></template>
          <div class="flex style-scope search-header"></div>
          
            <div id="header-container" class="style-scope search-header">
              <result-nav class="style-scope search-header">
    
    <div class="style-scope result-nav" hidden="">
      <state-modifier id="current" act="{&quot;type&quot;: &quot;BACK_TO_RESULTS&quot;}" inherit="" class="style-scope result-nav"><a id="link" href="#" class="style-scope state-modifier" inherit=""><span class="style-scope result-nav"></span> of
      <template is="dom-if" class="style-scope result-nav"></template>
      0<template is="dom-if" class="style-scope result-nav"></template></a></state-modifier>
      <state-modifier id="prevResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-left" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.41 7.41L14 6l-6 6 6 6 1.41-1.41L10.83 12z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier><state-modifier id="nextResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-right" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M10 6L8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier>
      <overlay-tooltip positioning-target="#prevResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Previous result
    </div>
  </overlay-tooltip>
      <overlay-tooltip positioning-target="#nextResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Next result
    </div>
  </overlay-tooltip>
    </div>
  </result-nav>
            </div>
          <template is="dom-if" class="style-scope search-header"></template>
        </div>
      </header>
    </div>
  </search-header>

      <div class="layout horizontal style-scope search-ui">
        <template is="dom-if" class="style-scope search-ui"></template>

        <div id="main" class="style-scope search-ui">
          <search-term-wizard class="style-scope search-ui"><pat-dialog open="" class="style-scope search-term-wizard">
  <span class="header style-scope search-term-wizard">
    <span class="title style-scope search-term-wizard">Search tools</span>
    <span id="language" class="style-scope search-term-wizard">
      <text-button id="textButton" selected="" class="style-scope search-term-wizard">Text
</text-button>
      <text-button id="classificationButton" class="style-scope search-term-wizard">Classification
</text-button>
      <text-button id="chemistryButton" class="style-scope search-term-wizard">Chemistry
</text-button>
      <text-button id="measureButton" class="style-scope search-term-wizard">Measure
</text-button>
      <text-button id="numbersButton" class="style-scope search-term-wizard">Numbers
</text-button>
    </span>
  </span>
  <span id="panels" class="style-scope search-term-wizard">
    <text-search-term-wizard id="textPanel" class="style-scope search-term-wizard" selected=""><span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Type a concept you want to search for here" class="style-scope text-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Type a concept you want to search for here">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="title" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Title</filter-chip>
  <filter-chip id="abstract" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Abstract</filter-chip>
  <filter-chip id="claims" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="all" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
All</filter-chip>
  <filter-chip id="any" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Any</filter-chip>
  <filter-chip id="exact" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="not" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Not</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope text-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope text-search-term-wizard">Add AND condition</span></mat-button></span></text-search-term-wizard>
    <classification-wizard id="classificationPanel" class="style-scope search-term-wizard"><span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope classification-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Enter a CPC here" uppercase="" class="style-scope classification-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Enter a CPC here">
  
</span>
</outlined-text-field>
</span>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope classification-wizard"></path>
  </svg>
  <filter-chip id="notExact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These CPCs and their children
  </filter-chip>
  <filter-chip selected="" id="exact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These exact CPCs
  </filter-chip>
</span>
<span class="style-scope classification-wizard">
  <mat-button id="button" filled="" class="style-scope classification-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope classification-wizard">Add AND condition</span></mat-button>
</span></classification-wizard>
    <chemistry-search-term-wizard id="chemistryPanel" class="style-scope search-term-wizard"><span class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Trade name, SMILES, InChI Key" class="style-scope chemistry-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Trade name, SMILES, InChI Key">
  
</span>
</outlined-text-field>
  <outlined-textarea id="textArea" placeholder="Enter multiple SMILES or InChI Keys, one per line" rows="4" class="style-scope chemistry-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple SMILES or InChI Keys, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
  <a href="https://support.google.com/faqs/answer/7049475#zippy=%2Csearching-by-chemistry" target="_blank" class="style-scope chemistry-search-term-wizard">
    <svg class="help style-scope chemistry-search-term-wizard" xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49">
      <path d="M11.95 18q.525 0 .888-.363.362-.362.362-.887t-.362-.887q-.363-.363-.888-.363t-.888.363q-.362.362-.362.887t.362.887q.363.363.888.363Zm-.9-3.85h1.85q0-.825.188-1.3.187-.475 1.062-1.3.65-.65 1.025-1.238.375-.587.375-1.412 0-1.4-1.025-2.15T12.1 6q-1.425 0-2.312.75-.888.75-1.238 1.8l1.65.65q.125-.45.563-.975Q11.2 7.7 12.1 7.7q.8 0 1.2.437.4.438.4.963 0 .5-.3.937-.3.438-.75.813-1.1.975-1.35 1.475-.25.5-.25 1.825ZM12 22q-2.075 0-3.9-.788-1.825-.787-3.175-2.137-1.35-1.35-2.137-3.175Q2 14.075 2 12t.788-3.9q.787-1.825 2.137-3.175 1.35-1.35 3.175-2.138Q9.925 2 12 2t3.9.787q1.825.788 3.175 2.138 1.35 1.35 2.137 3.175Q22 9.925 22 12t-.788 3.9q-.787 1.825-2.137 3.175-1.35 1.35-3.175 2.137Q14.075 22 12 22Zm0-2q3.35 0 5.675-2.325Q20 15.35 20 12q0-3.35-2.325-5.675Q15.35 4 12 4 8.65 4 6.325 6.325 4 8.65 4 12q0 3.35 2.325 5.675Q8.65 20 12 20Zm0-8Z" class="style-scope chemistry-search-term-wizard"></path>
    </svg>
  </a>
</span>
<span id="chemQuantifiers" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M5 21.2q-1.4 0-2-1.25-.6-1.25.3-2.325l5.5-6.7V5.15h-.825q-.475 0-.8-.338Q6.85 4.475 6.85 4q0-.475.325-.813.325-.337.8-.337h8.05q.475 0 .8.337.325.338.325.813 0 .475-.325.812-.325.338-.8.338H15.2v5.775l5.5 6.7q.9 1.075.3 2.325-.6 1.25-2 1.25Zm2.15-3.275h9.7l-3.275-3.85h-3.15Zm-2 1h13.7l-5.925-7.2V5.15h-1.85v6.575Zm6.85-6.9Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="exact" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="exactBatch" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact Batch</filter-chip>
  <filter-chip id="similar" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Similar</filter-chip>
  <filter-chip id="substructure" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure</filter-chip>
  <filter-chip id="smarts" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure (SMARTS)</filter-chip>
</span>
<span id="location" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="claims" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims only</filter-chip>
</span>
<span class="style-scope chemistry-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope chemistry-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope chemistry-search-term-wizard">Add AND condition</span></mat-button>
</span>
</chemistry-search-term-wizard>
    <measure-search-term-wizard id="measurePanel" class="style-scope search-term-wizard"><span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M4.1 18.15q-.95 0-1.612-.663-.663-.662-.663-1.612v-7.75q0-.95.663-1.613Q3.15 5.85 4.1 5.85h15.8q.95 0 1.613.662.662.663.662 1.613v7.75q0 .95-.662 1.612-.663.663-1.613.663Zm0-2.275h15.8v-7.75H17V12h-2V8.125h-2V12h-2V8.125H9V12H7V8.125H4.1v7.75ZM7 12h2Zm4 0h2Zm4 0h2Zm-3 0Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="measureExpression" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M3.875 20.15V8.85h4.25v11.3Zm6 0V3.85h4.25v16.3Zm6 0v-7.3h4.25v7.3Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="context" placeholder="activity, wavelength, embossing depth, absorption" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="activity, wavelength, embossing depth, absorption">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope measure-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope measure-search-term-wizard">Add AND condition</span></mat-button>
</span>
</measure-search-term-wizard>
    <numerical-search-term-wizard id="numericalPanel" class="style-scope search-term-wizard"><span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-textarea id="batch" placeholder="Enter multiple Patent Application and Publication Numbers, one per line" rows="4" class="style-scope numerical-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple Patent Application and Publication Numbers, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
</span>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="m10.825 23.45-1.6-1.625L10.9 20.15H8q-.35.9-1.162 1.488-.813.587-1.838.587-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.025.588-1.837Q2.95 16.35 3.85 16V8q-.9-.35-1.487-1.163Q1.775 6.025 1.775 5q0-1.35.938-2.288Q3.65 1.775 5 1.775q1.025 0 1.838.587Q7.65 2.95 8 3.85h2.9L9.225 2.175l1.6-1.625L15.275 5l-4.45 4.45-1.6-1.625L10.9 6.15H8q-.25.65-.725 1.125T6.15 8v8q.65.25 1.125.725T8 17.85h2.9l-1.675-1.675 1.6-1.625 4.45 4.45ZM19 22.225q-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.05.588-1.863.587-.812 1.487-1.137V8q-.9-.325-1.487-1.137-.588-.813-.588-1.863 0-1.35.938-2.288.937-.937 2.287-.937 1.35 0 2.288.937.937.938.937 2.288 0 1.05-.587 1.863Q21.05 7.675 20.15 8v8q.9.35 1.488 1.163.587.812.587 1.837 0 1.35-.937 2.288-.938.937-2.288.937ZM5 19.95q.4 0 .675-.275T5.95 19q0-.4-.275-.675T5 18.05q-.4 0-.675.275T4.05 19q0 .4.275.675T5 19.95Zm14 0q.4 0 .675-.275T19.95 19q0-.4-.275-.675T19 18.05q-.4 0-.675.275T18.05 19q0 .4.275.675t.675.275Zm-14-14q.4 0 .675-.275T5.95 5q0-.4-.275-.675T5 4.05q-.4 0-.675.275T4.05 5q0 .4.275.675T5 5.95Zm14 0q.4 0 .675-.275T19.95 5q0-.4-.275-.675T19 4.05q-.4 0-.675.275T18.05 5q0 .4.275.675T19 5.95ZM5 19Zm14 0ZM5 5Zm14 0Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <filter-chip id="applicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Application Numbers</filter-chip>
  <filter-chip id="publicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Publication Numbers</filter-chip>
  <filter-chip id="either" selected="" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Either</filter-chip>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M12 22.2q-2.1 0-3.962-.8-1.863-.8-3.25-2.175Q3.4 17.85 2.6 15.988 1.8 14.125 1.8 12t.8-3.988q.8-1.862 2.188-3.237Q6.175 3.4 8.038 2.6 9.9 1.8 12 1.8q2.125 0 3.988.8 1.862.8 3.237 2.175Q20.6 6.15 21.4 8.012q.8 1.863.8 3.988t-.8 3.988q-.8 1.862-2.175 3.237Q17.85 20.6 15.988 21.4q-1.863.8-3.988.8Zm-1-2.325v-1.95q-.8 0-1.387-.575-.588-.575-.588-1.4v-.975L4.275 10.2q-.075.45-.137.9-.063.45-.063.9 0 3 1.975 5.25T11 19.875Zm6.85-2.525q.5-.55.888-1.175.387-.625.65-1.313.262-.687.4-1.412.137-.725.137-1.45 0-2.425-1.338-4.438-1.337-2.012-3.612-2.887v.375q0 .825-.587 1.4-.588.575-1.388.575h-2v2q0 .4-.287.687-.288.288-.688.288h-2v2h5.95q.425 0 .713.287.287.288.287.688v2.975h1q.65 0 1.163.387.512.388.712 1.013Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryFilter" placeholder="Restrict search to these countries" class="style-scope numerical-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Restrict search to these countries">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M2.85 18.225V15.95h6.3v2.275Zm0-5.075v-2.3h12.3v2.3Zm0-5.1V5.775h18.3V8.05Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryOrder" placeholder="Prefer results from these countries in this order" class="style-scope numerical-search-term-wizard" value="US, EP, WO, JP, CN"><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Prefer results from these countries in this order">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope numerical-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope numerical-search-term-wizard">Add AND condition</span></mat-button>
</span>
</numerical-search-term-wizard>
  </span>

</pat-dialog>
</search-term-wizard>
          
      <div content="" class="style-scope search-result">
        <div id="mainContainer" class="vertical layout style-scope search-result">
          <template is="dom-if" class="style-scope search-result"></template>
          <result-container class="style-scope search-result">
    

    <paper-spinner class="style-scope result-container x-scope paper-spinner-0" aria-hidden="true" hidden=""><div id="spinnerContainer" class="  style-scope paper-spinner"><div class="spinner-layer layer-1 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-2 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-3 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-4 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div></div></paper-spinner>
    
      <patent-result class="style-scope result-container">
    
    
    <div class="layout horizontal style-scope patent-result">
      <div style="width: 1200px; height: auto; overflow: auto;" class="style-scope patent-result">
        <div id="wrapper" tabindex="0" class="style-scope patent-result">
          <result-tags class="style-scope patent-result"></result-tags>
          <h1 id="title" class="scroll-target style-scope patent-result">
            Farnesyl dibenzodiazepinones, processes for their production and their use as pharmaceuticals 
       </h1>
          <div class="horizontal layout style-scope patent-result">
            
            <div class="flex-3 style-scope patent-result" style="margin-top:-20px;overflow:hidden;" marginright="">
              <section id="abstract" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Abstract</div>
                  <div class="righthead style-scope patent-result" hidden="">translated from </div>
                </h3>
                <patent-text name="abstract" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><abstract mxw-id="PA76197307" lang="EN" load-source="patent-office" class="style-scope patent-text">
    <div class="abstract style-scope patent-text"> The present invention relates to dibenzodiazepinones of Formula I, their pharmaceutically acceptable salts and prodrugs, to methods for obtaining such compounds, to pharmaceutical compositions comprising them, and to their use as pharmaceuticals, in particular as inhibitors of cancer, and mammalian lipoxygenase, or as a PBR binding agent. </div>
  </abstract>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <section id="classifications" class="style-scope patent-result" hidden="">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Classifications</div>
                  <div id="machineClassifiedWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">machine-classified</div>
                  <div id="machineClassifiedCPCWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">cpc-machine-classified</div>
                  <div id="machineClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-machine-classified</div>
                  <div class="style-scope patent-result" hidden="">&nbsp;</div>
                  <div id="familyClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-family-classified</div>
                </h3>
                <overlay-tooltip positioning-target="#machineClassifiedWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedCPCWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The CPC classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#familyClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned based on a patent family member containing these classification codes.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <classification-viewer class="style-scope patent-result">
    
    <div class="table style-scope classification-viewer">
      <template is="dom-repeat" class="style-scope classification-viewer"></template>
      <template is="dom-if" class="style-scope classification-viewer"></template>
    </div>
  </classification-viewer>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              
                <section class="style-scope patent-result">
                  <h3 class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Landscapes</div>
                  </h3>
                  <div class="responsive-grid style-scope patent-result">
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Pharmaceuticals Containing Other Organic And Inorganic Compounds"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Pharmaceuticals Containing Other Organic And Inorganic Compounds
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    <template is="dom-repeat" class="style-scope patent-result"></template>
                  </div>
                  <s-more-inline class="style-scope patent-result"><hr aria-hidden="true" class="style-scope s-more-inline">

<div class="button style-scope s-more-inline" style="" hidden="">
  <span slot="expand_text" class="style-scope patent-result">Show more</span>
  <span class="expand more style-scope s-more-inline"></span>
</div>
<div class="button style-scope s-more-inline">
  <span slot="collapse_text" class="style-scope patent-result">Show less</span>
  <span class="expand less style-scope s-more-inline"></span>
</div>
</s-more-inline>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
            <div class="flex-2 style-scope patent-result">
              <section class="knowledge-card style-scope patent-result">
                <header class="style-scope patent-result">
                  <h2 id="pubnum" class="style-scope patent-result">CA2497031A1</h2>
                  <p class="tagline style-scope patent-result">Canada</p>
                  <overlay-tooltip positioning-target="#pubnum" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                    <div style="max-width: 300px;" class="style-scope patent-result">Laid-open patent application</div>
                  
    </div>
  </overlay-tooltip>

                  <div class="knowledge-card-action-bar style-scope patent-result">
                    <a target="_blank" class="style-scope patent-result" href="https://patentimages.storage.googleapis.com/cf/26/bd/dea761c9294b13/CA2497031A1.pdf"><iron-icon icon="description" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download PDF</a>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_FIND_PRIOR_ART&quot;, &quot;keywords&quot;: $keywords, &quot;before&quot;: &quot;$before&quot;}" class="style-scope patent-result" data-keywords="[&quot;compound&quot;,&quot;pharmaceutically acceptable&quot;,&quot;compounds&quot;,&quot;prodrug&quot;,&quot;acceptable salt&quot;]" data-before="20041108"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="find-in-page" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 19.59V8l-6-6H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c.45 0 .85-.15 1.19-.4l-4.43-4.43c-.8.52-1.74.83-2.76.83-2.76 0-5-2.24-5-5s2.24-5 5-5 5 2.24 5 5c0 1.02-.31 1.96-.83 2.75L20 19.59zM9 13c0 1.66 1.34 3 3 3s3-1.34 3-3-1.34-3-3-3-3 1.34-3 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Find Prior Art
                    </a></state-modifier>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_SIMILAR_DOCUMENTS&quot;, &quot;id&quot;: &quot;$id&quot;}" class="style-scope patent-result" data-id="patent/CA2497031A1"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="editor:functions" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M18 4H6v2l6.5 6L6 18v2h12v-3h-7l5-5-5-5h7z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Similar
                    </a></state-modifier>
                  </div>
                </header>

                <dl class="important-people style-scope patent-result">
                  
                    <dt class="style-scope patent-result">Other languages</dt>
                    <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2497031A1/fr"><a id="link" href="#" class="style-scope state-modifier">French</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                  
                  <dt class="style-scope patent-result">Inventor</dt>
                  <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="James B. Mcalpine"><a id="link" href="#" class="style-scope state-modifier">James B. Mcalpine</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>

                  
                  <dt class="style-scope patent-result">
                    <span class="tooltip-hint style-scope patent-result" id="assigneeWarning">Current Assignee</span>
                    <overlay-tooltip positioning-target="#assigneeWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                      The listed assignees may be inaccurate.<br class="style-scope patent-result">
                      Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.
                    
    </div>
  </overlay-tooltip>
                  </dt>
                  <dd class="style-scope patent-result">
                    
    Thallion Pharmaceuticals Inc
  
                  </dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                </dl>

                <hr class="style-scope patent-result">

                <application-timeline class="style-scope patent-result">
    
    
    <div class="wrap style-scope application-timeline">
      <div class="header style-scope application-timeline">Worldwide applications</div>
      <div class="event style-scope application-timeline">
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2005</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA2497031A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline" this="">CA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CA 2497031</div>
                <div class="style-scope application-timeline">Filing date: 2005-02-11</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        <template is="dom-repeat" class="style-scope application-timeline"></template>
      </div>
      <hr class="style-scope application-timeline">
      <div class="header style-scope application-timeline">Application CA 2497031 events <iron-icon id="legal" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        <overlay-tooltip positioning-target="#legal" direction="right" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
          <div style="max-width: 300px;" class="style-scope application-timeline">
            A timeline of key events for this patent application, including priority claims, publications, legal status, reassignments, and litigation.<br class="style-scope application-timeline"><br class="style-scope application-timeline">
            Google has not performed a legal analysis and makes no representation as to the accuracy or completeness of the events listed.
          </div>
        
    </div>
  </overlay-tooltip>
      </div>
      <div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="filed style-scope application-timeline">2005-02-11</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee="Ecopia Biosciences Inc"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Application filed by Ecopia Biosciences Inc</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="priority style-scope application-timeline">2005-07-21</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA2511750C/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Priority to CA002511750A</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2006-05-08</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA2497031A1/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of CA2497031A1</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" current="" critical=""><div date="" class="legal-status style-scope application-timeline">Status</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Abandoned</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><template is="dom-repeat" strip-whitespace="" class="style-scope application-timeline"></template>
      
        <div class="event layout horizontal expand style-scope application-timeline">
          Show all events <iron-icon style="height: 15px; width: 15px;" icon="expand-more" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M16.59 8.59L12 13.17 7.41 8.59 6 10l6 6 6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope application-timeline"></template>
          <template is="dom-if" class="style-scope application-timeline"></template>
        </div>
      <template is="dom-if" class="style-scope application-timeline"></template>
    </div>
  </application-timeline>
                <hr class="style-scope patent-result">

                <dl class="links style-scope patent-result">
                  <dt class="style-scope patent-result">Info</dt>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#legalEvents" class="style-scope patent-result">Legal events</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#similarDocuments" class="style-scope patent-result">Similar documents</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#relatedApplications" class="style-scope patent-result">Priority and Related Applications</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <dt class="style-scope patent-result">External links</dt>

                  <dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=CA&amp;NR=2497031A1&amp;KC=A1&amp;FT=D">Espacenet</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://globaldossier.uspto.gov/#/result/publication/CA/2497031/1">Global Dossier</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/patent/2497031/summary.html">CIPO</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patents.stackexchange.com/questions/tagged/CA2497031A1">Discuss</a></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                </dl>
              </section>
            </div>
          </div>

          <div id="text" class="horizontal layout style-scope patent-result">
            <div class="flex flex-width style-scope patent-result" marginright="">
              <section id="description" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Description</div>
                  <div class="righthead style-scope patent-result" hidden="">translated from </div>
                </h3>
                <patent-text name="description" id="descriptionText" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><div mxw-id="PDES62427618" lang="EN" load-source="patent-office" class="description style-scope patent-text">
    <disclosure class="style-scope patent-text">
      <div class="description-paragraph style-scope patent-text"> FARNESYL DIBENZODIAZEPINONES, PROCESSES FOR THEIR PRODUCTION<br class="style-scope patent-text">     AND THEIR USE AS PHARMACEUTICALS<br class="style-scope patent-text">     FIELD OF THE INVENTION<br class="style-scope patent-text">    This invention relates to derivatives of a naturally produced farnesylated dibenzodiazepinone, referred to as Compound 1, their pharmaceutically acceptable salts and prodrugs, and to methods for obtaining the compounds. One method of obtaining Compound 1 is by cultivation of a strain of Micromonospora sp., i.e., 046-EC011 or [S01 ]046. One method of obtaining the derivatives involves post-biosynthesis chemical modification of Compound 1. The present invention further relates to the use of Compound 1 derivatives, and their pharmaceutically acceptable salts and prodrugs as pharmaceuticals, in particular to their use as inhibitors of cancer cell growth, mammalian lipoxygenase, and for treating acute and chronic inflammation, and to pharmaceutical compositions comprising Compound 1 derivatives, or pharmaceutically acceptable salts or prodrugs thereof.<br class="style-scope patent-text">     BACKGROUND OF THE INVENTION<br class="style-scope patent-text">     The euactinomycetes are a subset of a large and complex group of Gram-positive bacteria known as actinomycetes. Over the past few decades these organisms, which are abundant in soil, have generated significant commercial and scientific interest as a result of the large number of therapeutically useful compounds, particularly antibiotics, produced as secondary metabolites. The intensive search for strains able to produce new antibiotics has led to the identification of hundreds of new species.<br class="style-scope patent-text">Many of the euactinomycetes, particularly Streptomyces and the closely related Saccharopolyspora genera, have been extensively studied. Both of these genera produce a notable diversity of biologically active metabolites. Because of the commercial significance of these compounds, much is known about the genetics and physiology of these organisms. <br class="style-scope patent-text"> <br class="style-scope patent-text"> Another representative genus of euactinomycetes, Micromonospora, has also generated commercial interest. For example, U.S. Patent No. 5,541,181 (Ohkuma et al.) discloses a dibenzodiazepinone compound, specifically 5-farnesyl-4,7,9-trihydroxy-dibenzodiazepin-11-one (named "BU-4664L"), produced by a known euactinomycetes strain, Micromonospora sp. M990-6 (ATCC 55378). ECO-4601 (herein referred to as Compound 1 ) and novel Micromonospora sp. strains 046-EC011 and [S01 ]046 are disclosed in CA 2,466,340. ECO-4601 was also disclosed as Diazepinomicin in Charan et al (2004), J. Nat. Prod., vol 67, 1431-1433.<br class="style-scope patent-text">     Compound 1 Although many biologically active compounds have been identified from bacteria, there remains the need to obtain novel compounds with enhanced properties. <br class="style-scope patent-text">Thus, there exists a considerable need to obtain pharmaceutically active compounds in a cost-effective manner and with high yield. The present invention solves these problems by providing new therapeutic compounds and to methods to generate these novel compounds by post-biosynthesis chemical modifications.<br class="style-scope patent-text">     SUMMARY OF THE INVENTION<br class="style-scope patent-text">  In another aspect, the invention relates to derivatives of Compound 1 and to pharmaceutical compositions comprising a derivative of Compound 1 or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.<br class="style-scope patent-text">     In a further aspect, the invention relates to a derivatve of Compound 1 represented by Formula I: </div>
      <div class="description-paragraph style-scope patent-text"> Formula 1 wherein, W', W2 and W3 are each independently selected from H ~ H3 ~ H3 H i Hs -~- ; Or R5 R6 ~ O<br class="style-scope patent-text">the chain from the tricycle terminates at W3, W2 or W' with W3, W2 or W' respectively being either -CH=O or -CH20H;<br class="style-scope patent-text"> R' is selected from H, C1_,oalkyl, C2_~oalkenyl, C2_~oalkynyl, C6_,oarYl, C5_ ,oheteroaryl, C3_~ocycloalkyl, C3_loheterocycloalkyl, C(O)Ci_~oalkyl, C(O)C2_loalkenyl, C(O)C2_,oalkynyl, C(O)Cs_ioaryl, C(O)C5_,oheteroaryl, C(O)C3_locycloalkyl; <br class="style-scope patent-text">C(O)C3_ ,oheterocycloalkyl or a C-coupled amino acid;<br class="style-scope patent-text">R2, R3, and R4 are each independently selected from H, C,_loalkyl, C2_ioalkenyl, C2-loalkynyl, C6_,oaryl, C5_~oheteroaryl, C3_locYcloalkyl, C3_~oheterocycloalkyl, C(O)H, C(O)C,_~oalkyl, C(O)C2_,oalkenyl, C(O)C2_~oalkynyl, C(O)Cs_,oaryl, C(O)C5_,oheteroaryl, C(O)C3_,ocycloalkyl; C(O)C3_,oheterocycloalkyl or a C-coupled amino acid;<br class="style-scope patent-text">     R5 and R6 are each independently selected from H, OH and OC1_salkyl;<br class="style-scope patent-text">wherein, when any of R', R2, R3, R4, R5 and R6 comprises an alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group, then the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group is optionally substituted with substituents selected from acyl, amino, acylamino, acyloxy, carboalkoxy, carboxy, carboxyamido, cyano, halo, hydroxyl, nitro, thio, C1_salkyl, C2_~alkenyl, C2_~alkynyl, C3_ iocycloalkyl, C3_~oheterocycloalkyl, C6_~oaryl, C5_loheteroaryl, alkoxy, aryloxy, sulfinyl, sulfonyl, oxo, guanidino and formyl; and with the proviso that when W', W2 and W3 are all -CH=C(CH3)-, and R2, R3 and R4 are all H, then R' is not H; <br class="style-scope patent-text"> <br class="style-scope patent-text"> or a pharmaceutically acceptable salt or prodrug thereof.<br class="style-scope patent-text">In one embodiment, R' is H, and all other groups are as previously disclosed. <br class="style-scope patent-text">In another embodiment, R' is -CH3, and all other groups are as previously disclosed. In another embodiment, R' is C,_~oalkyl, and all other groups are as previously disclosed.<br class="style-scope patent-text">In a subclass of this embodiment, the alkyl group is optionally substituted with a substituent selected from halo, fluoro, C6_~oaryl, and C5_~oheteroaryl. In another embodiment, R' is -C(O)Ci.~oalkyl, and all other groups are as previously disclosed. In another embodiment, R2 is H, and all other groups are as previously disclosed. <br class="style-scope patent-text">In another embodiment, R3 is H, and all other groups are as previously disclosed. <br class="style-scope patent-text">In another embodiment, R4 is H, and all other groups are as previously disclosed. <br class="style-scope patent-text">In another embodiment, R2, R3 and R4 are each H, and all other groups are as previously disclosed. In another embodiment, one of R2, R3 and R4 is CH3, the others being each H, and all other groups are as previously disclosed. In another embodiment, two of R2, R3 and R4 are CH3, the other being H, and all other groups are as previously disclosed.<br class="style-scope patent-text">In another embodiment, R2, R3 and R4 are each CH3, and all other groups are as previously disclosed. In another embodiment, R2, R3 and R4 are each H, and W' is -CH=C(CH3)-, and all other groups are as previously disclosed. In another embodiment, R2, R3 and R4 are each H, and W2 is -CH=C(CH3)-, and all other groups are as previously disclosed. In another embodiment, R2, R3 and R4 are each H, and W3 is -CH=C(CH3)-, and all other groups are as previously disclosed. In another embodiment, R' is H and R2, R3 and R4 are each H, and all other groups are as previously disclosed.<br class="style-scope patent-text">In another embodiment, R' is H, each of W', W2, and W3 is -CH=C(CH3)-, and all other groups are as previously disclosed. In another embodiment, R' is H, each of W', W2, and W3 is -CH2CH(CH3)-, and all other groups are as previously disclosed. In another embodiment, if each of W', W2 and W3 are -CH=C(CH3)-, and each of R2, R3, and are H, then R' is not H. In further embodiment, if each of W', W2 and W3 are -CH=C(CH3)-, and each of R2, R3, and R4 are H, then R' is not CH3. In further embodiment, if each of W', W2 and W3 are -CH=C(CH3)-, and each of R2, R3, and are H, then R' is neither H nor CH3. The invention encompasses all pharmaceutically acceptable salts and prodrugs of the foregoing compounds. </div>
      <div class="description-paragraph style-scope patent-text"> The following are exemplary compounds of the invention:<br class="style-scope patent-text"> <br class="style-scope patent-text">     N / / /<br class="style-scope patent-text">/ ~ ~ OH<br class="style-scope patent-text">     OH H<br class="style-scope patent-text">     HO<br class="style-scope patent-text">    Compound 1; Compound 2;<br class="style-scope patent-text"> <br class="style-scope patent-text">     N / / /<br class="style-scope patent-text">     O<br class="style-scope patent-text">/ N ~ ~ OH \ N /<br class="style-scope patent-text">     OH<br class="style-scope patent-text">H / N ~ ~ OH<br class="style-scope patent-text">     OMe HO<br class="style-scope patent-text">     Compound 3; Compound 4;<br class="style-scope patent-text">/ / / /<br class="style-scope patent-text">     Compound 5; Compound 6;<br class="style-scope patent-text">     Compound 7; Compound 8; <br class="style-scope patent-text"> <br class="style-scope patent-text"> Compound 9; Compound 10;<br class="style-scope patent-text">i I i Compound 11; Compound 12;<br class="style-scope patent-text">  Compound 13; Compound 14;<br class="style-scope patent-text">     Compound 15; Compound 16;<br class="style-scope patent-text">i i Compound 17; Compound 18; <br class="style-scope patent-text"> <br class="style-scope patent-text"> o / / o Compound 19; Compound 20;<br class="style-scope patent-text">     Compound 21; Compound 22;<br class="style-scope patent-text">     Compound 23; Compound 24;<br class="style-scope patent-text">     Compound 25; Compound 26;<br class="style-scope patent-text"> <br class="style-scope patent-text">     Compound 27; Compound 28; <br class="style-scope patent-text"> <br class="style-scope patent-text"> o N<br class="style-scope patent-text">     OH H<br class="style-scope patent-text">     Compound 29; Compound 30;<br class="style-scope patent-text">     Compound 31; Compound 32;<br class="style-scope patent-text"> <br class="style-scope patent-text">     Compound 33; Compound 34;<br class="style-scope patent-text">Compound 35; Compound 36;<br class="style-scope patent-text">~i i Compound 37; Compound 38; <br class="style-scope patent-text"> <br class="style-scope patent-text"> Compound 39; Compound 40;<br class="style-scope patent-text">/ /<br class="style-scope patent-text">     Compound 41; Compound 42;<br class="style-scope patent-text"> <br class="style-scope patent-text">     N I / N<br class="style-scope patent-text">     OH ~ OH<br class="style-scope patent-text">     Compound 43; Compound 44;<br class="style-scope patent-text"> Compound 45; Compound 46;<br class="style-scope patent-text">/ ,o / off Compound 47; Compound 48; <br class="style-scope patent-text"> <br class="style-scope patent-text"> ~o Compound 49; Compound 50;<br class="style-scope patent-text">     Compound 51; Compound 52;<br class="style-scope patent-text">     O OH O<br class="style-scope patent-text">     N / / ~ N ~ /<br class="style-scope patent-text">     OH OH<br class="style-scope patent-text">     OH<br class="style-scope patent-text">     N ~ OH ~ / N ~ ~ OH<br class="style-scope patent-text">     OH H OH<br class="style-scope patent-text">     HO HO<br class="style-scope patent-text">     Compound 53; Compound 54;<br class="style-scope patent-text">     Compound 55; Compound 56;<br class="style-scope patent-text">     Compound 57; Compound 58; <br class="style-scope patent-text"> <br class="style-scope patent-text"> off OH ~ OH ~ OH<br class="style-scope patent-text">     OH OH<br class="style-scope patent-text">     Compound 59; Compound 60;<br class="style-scope patent-text">     Compound 61; Compound 62;<br class="style-scope patent-text">     Compound 63; Compound 64;<br class="style-scope patent-text">i i i Compound 65; Compound 66; <br class="style-scope patent-text"> <br class="style-scope patent-text"> Compound 67; Compound 68;<br class="style-scope patent-text">     Compound 69; Compound 70;<br class="style-scope patent-text">     Compound 71; Compound 72;<br class="style-scope patent-text">i i i i Compound 73; Compound 74; <br class="style-scope patent-text"> <br class="style-scope patent-text"> Compound 75; and Compound 76;<br class="style-scope patent-text">or a pharmaceutically acceptable salt or prodrug of any one of Compounds 1 to 76.<br class="style-scope patent-text">     In one embodiment, the compounds comprise a pharmaceutically acceptable carrier.<br class="style-scope patent-text"> The invention further encompasses a farnesyl dibenzodiazepinone obtained by a method comprising: a) cultivating Micromonospora sp. strain [S01 ]046, wherein the cultivation is performed under aerobic conditions in a nutrient medium comprising at least one source of carbon atoms and at least one source of nitrogen atoms; <br class="style-scope patent-text">and b) isolating a farnesyl dibenzodiazepinone from the bacteria cultivated in step (a).<br class="style-scope patent-text"> The invention further encompasses a farnesyl dibenzodiazepinone obtained by a method comprising: a) cultivating Micromonospora sp. strain selected from strains [S01 ]046 and 046-EC011, wherein the cultivation is performed under aerobic conditions in a riutrient medium comprising at least one source of carbon atoms and at least one source of nitrogen atoms; b) isolating a farnesyl dibenzodiazepinone from the bacteria cultivated in step (a) and c) chemically modifying the compound isolated in (b).<br class="style-scope patent-text">In one embodiment the farnesyl dibenzodiazapinone is selected from Compounds 2 to 76. In another embodiment the farnesyl dibenzodiazapinone is selected from Compounds 2 to 12, 17, 18 and 46.<br class="style-scope patent-text">     The invention further encompasses a process for making a farnesyl dibenzodiazapinone compound, comprising cultivation of Micromonospora sp. <br class="style-scope patent-text">strain 046-EC011, in a nutrient medium comprising at least one source of carbon atoms and at least one source of nitrogen atoms, isolation and purification of the compound, and optional chemical modification of the isolated compound..<br class="style-scope patent-text">     The invention further encompasses a process for making a farnesyl dibenzodiazepinone compound comprising cultivation of Micromonospora sp. <br class="style-scope patent-text">strain [S01 ]046, in a nutrient medium comprising at least one source of carbon atoms and at least one source of nitrogen atoms, isolation and purification of the compound, and optional chemical modification of the isolated compound.<br class="style-scope patent-text">     In one embodiment, the cultivation occurs under aerobic conditions.<br class="style-scope patent-text">   In another embodiment, the carbon atom and nitrogen atom sources are chosen from the components shown in Table 1.<br class="style-scope patent-text">In another embodiment, the cultivation is carried out at a temperature ranging from 18C to 40C. In a further embodiment, the temperature range is 18C to 29C.<br class="style-scope patent-text">In another embodiment, the cultivation is carried out at a pH ranging from 6 to 9.<br class="style-scope patent-text">     The invention further encompasses the Micromonospora sp. having IDAC<br class="style-scope patent-text">     Accession No. 231203-01.<br class="style-scope patent-text">  The invention further encompasses a method of treating a diseases selected from pre-cancerous or cancerous conditions, inflammation, autoimmune diseases, infections, neurodegenerative diseases and stress, the method comprising administering a compound of Formula I to a mammal in need of such treatment. <br class="style-scope patent-text">In one embodiment, the compound is a compound selected from Compounds 2 to 76. In another embodiment, the invention provides a method for treating a diseases selected from pre-cancerous or cancerous conditions, inflammation, autoimmune diseases, infections, neurodegenerative diseases and stress, the method comprising administering a compound of Formula I to a mammal in need of such treatment, with the proviso that the compound of Formula I is not Compound 1, or alternatively is not Compound 2, or alternatively is neither Compound 1 nor 2.<br class="style-scope patent-text">The invention further encompasses a method of inhibiting the growth of a cancer cell, the method comprising contacting the cancer cell with a compound of Formula I, such that growth of the cancer cell is inhibited. In one embodiment, the compound is a compound selected from Compounds 2 to 76. In another embodiment, the invention provides a method of inhibiting the growth of a cancer cell, the method comprising contacting the cancer cell with a compound of Formula I such that growth of the cancer cell is inhibited, with the proviso that the compound of Formula I is not Compound 1, or alternatively is not Compound 2, or alternatively is neither Compound 1 nor 2.<br class="style-scope patent-text">The invention further encompasses a method of inhibiting the growth of a cancer cell in a mammal, the method comprising administering a compound of Formula I <br class="style-scope patent-text">to a mammal comprising a cancer cell, such that growth of the cancer cell is inhibited in the mammal. In one embodiment, the compound is a compound selected from Compounds 2 to 76. In another embodiment, the invention provides a method of inhibiting the growth of a cancer cell in a mammal, the method comprising administering a compound of Formula I to the mammal comprising a cancer cell such that growth of the cancer cell is inhibited, with the proviso that the compound of Formula I is not Compound 1, or alternatively is not Compound 2, or alternatively is neither Compound 1 nor 2.<br class="style-scope patent-text">     The invention further encompasses a method of treating a pre-cancerous or cancerous condition in a mammal, comprising the step of administering to the mammal a therapeutically effective amount of a compound of Formula I, such that a pre-cancerous or cancerous condition is treated. In one embodiment, the compound is a compound selected from Compounds 2 to 76. In another embodiment, the invention provides a method of treating a pre-cancerous or cancerous condition in a mammal, the method comprising the step of administering to the mammal a therapeutically effctive amount of a compound of Formula I such that a pre-cancerous or cancerous condition is treated, with the proviso that the compound of Formula I is not Compound 1, or alternatively is not Compound 2, or alternatively is neither Compound 1 nor 2.<br class="style-scope patent-text">    The invention further encompasses the use of a compound of Formula I, or a pharmaceutically acceptable salt or prodrug thereof as an antitumor agent for the treatment of a pre-cancerous or cancerous condition in a mammal. In one embodiment, the compound is a compound selected from Compounds 2 to 76. In another embodiment, the invention provides use of a compound of Formula I, or a pharmaceutically acceptable salt or prodrug thereof as an antitumor agent for the treatment of a pre-cancerous or cancerous condition in a mammal, with the proviso that the compound of Formula I is not Compound 1, or alternatively is not Compound 2, or alternatively is neither Compound 1 nor 2. <br class="style-scope patent-text"> <br class="style-scope patent-text"> The invention further encompasses the use of a compound of Formula I, or a pharmaceutically acceptable salt or prodrug thereof in the preparation of a medicament for the treatment of a pre-cancerous or cancerous condition in a mammal. In one embodiment, the compound is a compound selected from Compounds 2 to 76. In another embodiment, the invention provides use of a compound of Formula I, or a pharmaceutically acceptable salt or prodrug thereof in the preparation of a medicament for the treatment of a pre-cancerous or cancerous condition in a mammal, with the proviso that the compound of Formula I is not Compound 1, or alternatively is not Compound 2, or alternatively is neither Compound 1 nor 2.<br class="style-scope patent-text">    The invention further encompasses the use of a compound of Formula I, or a pharmaceutically acceptable salt or prodrug thereof as a peripheral benzodiazepine receptor (PBR) binding agent for the treatment of a condition involving PBR. <br class="style-scope patent-text">The peripheral benzodiazepine receptor (PBR) is a well-characterized receptor known to be directly involved in diseases states. PBR is involved in the regulation of immune responses. These diseases states include tumors, inflammatory diseases (such as rheumatoid arthritis and lupus), parasitic infections and neurodegenerative diseases (such as Alzheimer, Huntington and Multiple Sclerosis). See, for example, Casellas et al (2003), Current Med. Chem., vol 10, 1563-1572; Miettinen et al (1995), Cancer Res., vol 55, 2691; Junck et al (1989), J. Ann. Neurol., vol 26, 752; Gavish et al (1993), Clin.<br class="style-scope patent-text">Neuropharm., vol 16, no 5, 401-417; Papadopoulos et al (2003), Ann. Pharm. <br class="style-scope patent-text">Fr., vol 61, 30-50; Vowinckel et al (1997), J. Neurosci. Res., vol 50, 345; Gelhert et al (1997), Neurochem. Int., vol 31, 705; Lacor et al (1999), Brain Res., vol 815, 70). In one embodiment, the compound for use in the treatment of a condition involving PBR <br class="style-scope patent-text">is a compound selected from Compounds 2 to 76. In another embodiment, the compound for use in the treatment of a condition involving PBR is a compound of Formula I with the proviso that the compound of Formula I is not Compound 1, or alternatively is not Compound 2, or alternatively is neither Compound 1 nor 2.<br class="style-scope patent-text">     The invention further encompasses a method of reducing inflammation in a mammal, comprising administering to a mammal having inflammation a therapeutically effective amount of a compound of Formula I, such that the inflammation is reduced. In one embodiment, the compound is a compound selected from Compounds 2 to 76. In another embodiment, the compound for use as an anti-inflamatory is a compound of Formula I with the proviso that the compound of Formula I is not Compound 1, or alternatively is not Compound 2, or alternatively is neither Compound 1 nor 2.<br class="style-scope patent-text">    The invention further encompasses the use of a compound of Formula I, or a pharmaceutically acceptable salt or prodrug thereof as a 5-Lipooxygenase (5-LO) inhibitor for the treatment of a condition involving the 5-LO enzyme. 5-Lipoxygenase (5-LO) catalyzes the oxidative metabolism of arachidonic acid to 5-hydroxyeicosatetraenoic acid (5-HETE), the initial reaction leading to formation of leukotrienes. Eicosanoids derived from arachidonic acid by the action of lipoxygenases or cycloxygenases have been found to be involved in acute and chronic inflammatory diseases (i.e. asthma, multiple sclerosis, rheumatoid arthritis, ischemia, edema) as well in neurodegeneration (Alzheimer disease), aging and various steps of carcinogenesis, including tumor promotion, progression and metastasis. Soberman et al (2003), J. Clin.<br class="style-scope patent-text">Invest, vol 111, no 8, 1107-1113. In one embodiment, the compound for use in the treatment of a condition involving the 5-LO enzyme is a compound selected from Compounds 2 to 76. In another embodiment, the compound for use as in the treatment of a condition involving the 5-LO enzyme is a compound of Formula I with the proviso that the compound of Formula i is not Compound 1, or alternatively is not Compound 2, or alternatively is neither Compound 1 nor 2.<br class="style-scope patent-text">Leukotriene, Cysteinyl (CysLT1) receptor is involved in inflammation and CysLT~-selective antagonists are used as treatment for bronchial asthma. CysLT~ and 5-LO<br class="style-scope patent-text">were known to be upreguiated in colon cancer. See, for example, Lynch et al (1999), Nature, 399(67387), 789; Nielsen et al (2003), Adv. Exp. Med. Biol., vol 525, 201-4. In one embodiment, the invention provides a compound of Formula I for treatment of a condition involving the Leukotriene, Cysteinyl (CysLT~) receptor. In one embodiment, the compound is a compound selected from Compounds 2 to 76. In another embodiment, the compound for use in the treatment of a condition involving CysLT1 receptor is a compound of Formula I with the proviso that the compound of Formula I is not Compound 1, or alternatively is not Compound 2, or alternatively is neither Compound 1 nor 2.<br class="style-scope patent-text">  Cyclooxygenase (COX-2) enzyme is known to be produced only in response to injury or infection. It produces prostaglandins involved in inflammation and the immune response. Elevated levels of COX-2 in the body have been linked to cancer. <br class="style-scope patent-text">See, for example, W ikstrom et al (2003), Biochem. Biophys. Res. Commun, vol 302, no 2, 335. In one embodiment, the invention provides a compound of Formula I for treatment of a condition involving the COX-2 enzyme. In one embodiment, the compound is a compound selected from Compounds 2 to 76. In another embodiment, the compound for use as in the treatment of a condition involving the COX-2 enzyme is a compound of Formula I with the proviso that the compound of Formula I is not Compound 1, or alternatively is not Compound 2, or alternatively is neither Compound 1 nor 2.<br class="style-scope patent-text">    AcyICoA-Cholesterol Acyltransferase, Hepatic (AcoA-AT) is known to convert cholesterol to colesteryl esters and is involved in the development of artherioscerosis.<br class="style-scope patent-text">See, for example, Kusunoki et al (2001 ), Circulation, 2604-2609. In one embodiment, the invention provides a compound of Formula I for treatment of a condition involving AcyICoA-Cholesterol Acyltransferase. In one embodiment, the compound is a compound selected from Compounds 2 to 76. In another embodiment, the compound for use as in the treatment of a condition involving AcyICoA-Cholesterol Acyltransferase is a compound of Formula I with the proviso that the compound of Formula I is not Compound 1, or alternatively is not Compound 2, or alternatively is neither Compound 1 nor 2.<br class="style-scope patent-text">BRIEF DESCRIPTION OF THE FIGURES<br class="style-scope patent-text">     FIGURE 1 shows'H NMR data for Compound 1 dissolved in MeOH-d4.<br class="style-scope patent-text">FIGURE 2 shows the in vitro anti-inflammatory activity of ECO-4601. Graph shows percent inhibition of 5-lipoxygenase activity plotted against the Log NM<br class="style-scope patent-text">concentration of ECO-4601 and NDGA. Graph shows the ECSO of ECO-4601 to be 0.93NM.<br class="style-scope patent-text">FIGURE 3 shows inhibition of tumor growth resulting from administration of 10 to 30 mg/kg of ECO-4601 to glioblastoma-bearing mice one day after tumor cell inoculation.<br class="style-scope patent-text">FIGURE 4 shows inhibition of tumor growth resulting from administration of 20-mg/kg of ECO-4601 to glioblastoma-bearing mice ten days after tumor cell inoculation.<br class="style-scope patent-text">   FIGURE 5 shows micrographs of tumor sections from mice bearing glioblastoma tumors and treated with saline or ECO-4601. The cell density of tumor treated with ECO-4601 appears decreased and nuclei from tumor cells are larger and pynotic suggesting a cytotoxic effect.<br class="style-scope patent-text">     DETAILED DESCRIPTION OF THE INVENTION<br class="style-scope patent-text">     The present invention relates to novel farnesyl dibenzodiazepinone herein referred as the compounds of Formula I, which are derivatives of "ECO-4601"<br class="style-scope patent-text">(Compound 1 ) isolated from strains of actinomycetes, Micromonospora sp. 046-and strain [S01 ]046. These organisms were deposited on March 7, 2003, and December 23, 2003, respectively, with the International Depository Authority of Canada (IDAC), Bureau of Microbiology, Health Canada, 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3R2, under Accession Nos. IDAC 070303-01 and IDAC<br class="style-scope patent-text">231203-01, respectively.<br class="style-scope patent-text">The invention further relates to pharmaceutically acceptable salts and derivatives of ECO-4601, and to methods for obtaining such compounds. One method of obtaining the compound is by cultivating Micromonospora sp. strain 046-EC011, or a mutant or a variarot thereof, under suitable Micromonospora culture conditions, preferably using the fermentation protocol described hereinbelow, and by optional chemical modification of the compound obtained by isolation from the fermentation procedure.<br class="style-scope patent-text">     The invention also relates to a method for producing novel farnesyl dibenzodiazepinone compounds, by chemical modification of the farnesyl dibenzodiazepinone obtained from fermentation and isolation.<br class="style-scope patent-text">The present invention also relates to pharmaceutical compositions comprising a compound of Formula I and its pharmaceutically acceptable salts and derivatives.<br class="style-scope patent-text">Compounds of Formula I are useful as a pharmaceutical, in particular for use as an inhibitor of cancer cell growth, and mammalian lipoxygenase.<br class="style-scope patent-text">     The following detailed description discloses how to make and use the compounds of Formula I and compositions containing these compound to inhibit microbial growth and/or cancer and/or specific disease pathways.<br class="style-scope patent-text">Accordingly, certain aspects of the present invention relate to pharmaceutical compositions comprising the farnesylated dibenzodiazepinone compounds of the present invention together with a pharmaceutically acceptable carrier, and methods of using the pharmaceutical compositions to treat diseases, including cancer, and chronic and acute inflammation, autoimmune diseases, and neurodegenerative diseases.<br class="style-scope patent-text">     Definitions For convenience, the meaning of certain terms and phrases used in the specification, examples, and appended claims, are provided below.<br class="style-scope patent-text">   As used herein, the term "farnesyl dibenzodiazepinone" refers to a class of dibenzodiazepinone compounds containing a farnesyl moiety or being derived from a farnesyl moiety. The term includes, but is not limited to, a compound of Formula I, a compound selected from Compounds 2 to 76, or the exemplified compounds of the present invention, Compounds 2 to 12, 17, 18 and Compound 46. As used herein, the term "farnesyl dibenzodiazepinone" includes compounds of this class that can be used as intermediates in chemical syntheses.<br class="style-scope patent-text">  As used herein, the term "compound(s) of the invention" refers to a farnesyl dibenzodiazepinone as defined above and to pharmaceutically acceptable salts or prodrugs thereof.<br class="style-scope patent-text">The term "receptor" refers to a protein located on the surface or inside a cell that may interact with a different molecule, known as a ligand, to initiate or inhibit a biological response.<br class="style-scope patent-text">As used herein, the term "ligand" refers to a molecule or compound that has the capacity to bind to a receptor and modulate its activity. <br class="style-scope patent-text"> <br class="style-scope patent-text"> As used herein, the terms "binder", "receptor binder" or "binding agent" <br class="style-scope patent-text">refers to a compound of the invention acting as a ligand. The binding agent can act as an agonist, or an antagonist of the receptor. An agonist is a drug which binds to a receptor and activates it, producing a pharmacological response (e.g. contraction, relaxation, secretion, enzyme activation, etc.). An antagonist is a drug which attenuates the effects of an agonist, or a natural ligand. Antagonism can be competitive and reversible (i.e. it binds reversibly to a region of the receptor in common with the agonist.) or competitive and irreversible (i.e. antagonist binds covalently to the agonist binding site, and no amount of agonist can overcome the inhibition). Other types of antagonism are non-competitive antagonism where the antagonist binds to an allosteric site on the receptor or an associated ion channel.<br class="style-scope patent-text">As used herein, the term "enzyme inhibitor" or "inhibitor" refers to a chemical that disables an enzyme and prevents it from performing its normal function.<br class="style-scope patent-text">     As used herein, abbreviations have their common meaning. Unless otherwise noted, the abbreviations "Ac", "Me", "Et", "Pr", "i-Pr", "Bu", and "Ph", respectively refer to acetyl, methyl, ethyl, propyl (n- or iso-propyl), iso-propyl, butyl (n-, iso-or tert-butyl) and phenyl.<br class="style-scope patent-text">The term "alkyl" refers to linear, branched or cyclic, saturated or unsaturated hydrocarbon groups. Examples of saturated alkyl groups include, without limitation, methyl, ethyl, n-propyl, isopropyl, n-butyl, pentyl, hexyl, heptyl, cyclopentyl, cyclohexyl, cyclohexymethyl, 1-propane-2-yl, 1-butane-4-yl, 1-propyne-3-yl, 1-butyne-4-yl, cyclopent-2-yl, and the like. Alkyl groups may optionally be substituted with substituents selected from acyl, amino, acylamino, acyloxy, carboalkoxy, carboxy, carboxyamido, cyano, halo, hydroxyl, nitro, thio, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, sulfinyl, sulfonyl, oxo, guanidino and formyl.<br class="style-scope patent-text">The term "C,."alkyl", wherein n is an integer from 2 to 12, refers to an alkyl group having from 1 to the indicated "n" number of carbons. The C,_"alkyl can be cyclic or a straight or branched chain.<br class="style-scope patent-text">The term "alkenyi" refers to an alkyl group, as defined above, having from one to six carbon-carbon double bonds. Examples of alkenyl groups include, without limitation, vinyl, 1-propene-2-yl, 1-butene-4-yl, 2-butene-4-yl, 1-pentene-5-yl and the like. Alkenyl groups may optionally be substituted with substituents selected from acyl, amino, acylamino, acyloxy, carboalkoxy, carboxy, carboxyamido, cyano, halo, hydroxyl, nitro, thio, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, sulfinyl, sulfonyl, formyl, oxo and guanidino. The double bond portions) of the unsaturated hydrocarbon chain may be either in the cis or trans configuration.<br class="style-scope patent-text">The term "C2_~alkenyl", wherein n is an integer from 3 to 12, refers to an alkenyl group having from 2 to the indicated "n" number of carbons. The C2_"alkenyl can be cyclic or a straight or branched chain.<br class="style-scope patent-text">The term "alkynyl" refers to an alkyl group, as defined above, having at least one carbon-carbon triple bond. Examples of alkynyl groups include, without limitation, ethynyl, 1-propyne-3-yl, 1-butyne-4-yl, 2-butyne-4-yl, 1-pentyne-5-yl and the like.<br class="style-scope patent-text">Alkynyl groups may optionally be substituted with substituents selected from acyl, amino, acylamino, acyloxy, carboalkoxy, carboxy, carboxyamido, cyano, halo, hydroxyl, nitro, thio, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, sulfinyl, sulfonyl, formyl, oxo and guanidine.<br class="style-scope patent-text">The term "C2_~alkynyl", wherein n is an integer from 3 to 12, refers to an alkynyl group having from 2 to the indicated "n" number of carbons. The C2_"alkynyl can be a straight or branched chain.<br class="style-scope patent-text">The term "cycloalkyl" or "cycloalkyl ring" refers to an alkyl group, as defined above, comprising a saturated or partially unsaturated carbocyclic ring in a single or fused carbocyclic ring system having from three to fifteen ring members. A <br class="style-scope patent-text">cycloalkyl ring may include from 1 to 4 heteroatoms or groups selected from: O, N, NH, NRx, P02, S, SO or S02. Examples of cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, oxiranyl, morpholinyl, tetrahydropyranyl and tetrahydrofuranyl. Cycloalkyl groups may optionally be substituted with substituents selected from acyl, amino, acylamino, acyloxy, carboalkoxy, carboxy, carboxyamido, cyano, halo, hydroxyl, vitro, thio, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, sulfinyl, sulfonyl and formyl. <br class="style-scope patent-text"> <br class="style-scope patent-text"> The term "C3.ncycloalkyl", wherein n is an integer from 4 to 15, refers to a cycloalkyl group having from 3 to the indicated "n" number of carbons.<br class="style-scope patent-text">The term "heterocycloalkyl", "heterocyclic" or "heterocycloalkyl ring" refers to a cycloalkyl group, as defined above, containing one to four hetero atoms or hetero groups selected from O, N, NH, NRX, P02, S, SO or S02 in a single or fused heterocyclic ring system having from three to fifteen ring members. Examples of a heterocycloalkyl, heterocyclic or heterocycloalkyl ring include, without limitation, morpholinyl, piperidinyl, and pyrrolidinyl. Heterocycloalkyl, heterocyclic or heterocycloaikyl ring may optionally be substituted with substituents selected from acyl, amino, acylamino, acyloxy, oxo, thiocarbonyl, imino, carboalkoxy, carboxy, carboxyamido, cyano, halo, hydroxyl, nitro, thio, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, sulfinyl, sulfonyl and formyl.<br class="style-scope patent-text">The term "C3."heterocycloalkyl", wherein n is an integer from 4 to 15, refers to an heterocycloaikyl group having from 3 to the indicated "n" number of atoms in the cycle and at least one hetero group as defined above.<br class="style-scope patent-text"> The term "halo" refers to bromine, chlorine, fluorine or iodine substituents.<br class="style-scope patent-text"> The term "aryl" or "aryl ring" refers to common aromatic groups having "4n+2"<br class="style-scope patent-text">electrons, wherein n is an integer from 1 to 3, in a conjugated monocyclic or polycyclic system and having from five to fourteen ring atoms. Aryl ring may include from 1 to 4 heteroatoms such as nitrogen, oxygen and sulphur atoms. Examples of aryl include, without limitation, phenyl, naphthyl, biphenyl, terphenyl, furyl, pyrrollyl, thienyl, pyridyl, oxazolyl, imidazolyl, pyrazolyl and indolyl groups. Aryl may optionally be substituted with one or more substituent group selected from acyl, amino, acylamino, acyloxy, azido, alkythio, carboalkoxy, carboxy, carboxyamido, cyano, halo, hydroxyl, nitro, thin, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, aryloxy, sulfinyl, sulfonyl and formyl.<br class="style-scope patent-text">The term "C5_~aryl", wherein n is an integer from 5 to 14, refers to an aryl group having from 5 to the indicated "n" number of atoms, including carbon, nitrogen, oxygen and sulfur. The C5_~aryl can be mono or polycyclic. <br class="style-scope patent-text"> <br class="style-scope patent-text"> The term "heteroaryl" or "heteroaryl ring" refers to an aryl ring, as defined above, containing one to tour heteroatoms such as nitrogen, oxygen and sulphur atoms.<br class="style-scope patent-text">Examples of heteroaryl include, without limitation, furyl, pyrrollyl, thienyl, pyridyl, oxazolyl, imidazolyl, pyrazolyl and indolyl groups. Heteroaryl may optionally be substituted with one or more substituent group selected from acyl, amino, acylamino, acyloxy, azido, alkythio, carboalkoxy, carboxy, carboxyamido, cyano, halo, hydroxyl, vitro, thio, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, aryloxy, sulfinyl, sulfonyl and formyl.<br class="style-scope patent-text"> The term "C5_nheteroaryl", wherein n is an integer from 5 to 14, refers to an heteroaryl group having from 5 to the indicated "n" number of atoms, including carbon, nitrogen, oxygen and sulphur atoms. The C5_naryl can be mono or polycyclic.<br class="style-scope patent-text">The term "amino acid" refers to an organic acid containing an amino group. The term includes both naturally occurring and synthetic amino acids; therefore, the amino group can be but is not required to be, attached to the carbon next to the acid. A C-coupled amino acid substituent is attached to the heteroatom (nitrogen or oxygen) of the parent molecule via its carboxylic acid function. C-coupled amino acid forms an ester with the parent molecule when the heteroatom is oxygen, and an amide when the heteroatom is nitrogen. Examples of amino acids include, without limitation, alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophane, methionine, glycine, serine, threonine, cysteine, asparagines, glutamine, tyrosine, histidine, lysine, arginine, aspartic acid, glutamic acid, desmosine, ornithine, 2-aminobutyric acid, cyclohexylalanine, dimethylglycine, phenylglycine, norvaline, norleucine, hydroxylysine, alto-hydroxylysine, hydroxyproline, isodesmosine, alto-isoleucine, ethylglycine, beta-alanine, aminoadipic acid, aminobutyric acid, ethyl asparagine, and N-methyl amino acids. Amino acids can be pure L or D isomers or mixtures of L and D isomers.<br class="style-scope patent-text">     The compounds of the present invention can possess one or more asymmetric carbon atoms and can exist as optics! isomers forming mixtures of racemic or non-racemic compounds. The compounds of the present invention are useful as single isomers or as a mixture of stereochemical isomeric forms. Diastereoisomers, i.e., nonsuperimposable stereochemical isomers, can be separated by conventional means such as chromatography, distillation, crystallization or sublimation. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes.<br class="style-scope patent-text">    The invention encompasses isolated or purified compounds. An "isolated" or "purified" compound refers to a compound which represents at least 10%, 20%, 50%, 80% or 90% of the compound of the present invention present in a mixture, provided that the mixture comprising the compound of the invention has demonstrable (i.e.<br class="style-scope patent-text">statistically significant) biological activity including cytostatic, cytotoxic, enzyme inhibitory or receptor binding action when tested in conventional biological assays known to a person skilled in the art.<br class="style-scope patent-text">     The terms "farnesyl dibenzodiazepinone-producing microorganism" and "producer of farnesyl dibenzodiazepinone," as used herein, refer to a microorganism that carries genetic information necessary to produce a farnesyl dibenzodiazepinone compound, whether or not the organism naturally produces the compound. The terms apply equally to organisms in which the genetic information to produce the farnesyl dibenzodiazepinone compound is found in the organism as it exists in its natural environment, and to organisms in which the genetic information is introduced by recombinant techniques.<br class="style-scope patent-text">Specific organisms contemplated herein include, without limitation, organisms of the family Micromonosporaceae, of which preferred genera include Micromonospora, Actinoplanes and Dactylosporangium; the family Streptomycetaceae, of which preferred genera include Streptomyces and Kitasatospora; the family Pseudonocardiaceae, of which preferred genera are Amycolatopsis and Saccharopolyspora; and the family Actinosynnemataceae, of which preferred genera include Saccharothrix and Actinosynnema; however the terms are intended to encompass all organisms containing genetic information necessary to produce a farnesyl dibenzodiazepinone compound. A preferred producer of a farnesyl dibenzodiazepinone compound includes microbial strain 046-EC011, a deposit of which was made on March 7, 2003, with the International Depository Authority of Canada (IDAC), Bureau of Microbiology, Health Canada, 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3R2, under Accession No. IDAC 070303-01.<br class="style-scope patent-text">As used herein, the term "treatment" refers to the application or administration of a therapeutic agent to a patient, or application or administration of a therapeutic agent to an isolated tissue or cell line from a patient, who has a disorder, e.g., a disease or condition, a symptom of disease, or a predisposition toward a disease, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect the disease, the symptoms of disease, or the predisposition toward disease.<br class="style-scope patent-text">  As used herein, a "pharmaceutical composition" comprises a pharmacologically effective amount of a farnesyl dibenzodiazepinone and a pharmaceutically acceptable carrier. As used herein, "pharmacologically effective amount," <br class="style-scope patent-text">"therapeutically effective amount" or simply "effective amount" refers to that amount of a farnesyl dibenzodiazepinone effective to produce the intended pharmacological, therapeutic or preventive result. For example, if a given clinical treatment is considered effective when there is at least a 25% reduction in a measurable parameter associated with a disease or disorder, a therapeutically effective amount of a drug for the treatment of that disease or disorder is the amount necessary to effect at least a 25% <br class="style-scope patent-text">reduction in that parameter.<br class="style-scope patent-text">     The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof.<br class="style-scope patent-text">The term specifically excludes cell culture medium. For drugs administered orally, pharmaceutically acceptable carriers include, but are not limited to pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc.<br class="style-scope patent-text">If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract. <br class="style-scope patent-text"> <br class="style-scope patent-text"> The term "pharmaceutically acceptable salt" refers to both acid addition salts and base addition salts. The nature of the salt is not critical, provided that it is pharmaceutically acceptable. Exemplary acid addition salts include, without limitation, hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulphuric, phosphoric, formic, acetic, citric, tartaric, succinic, oxalic, malic, glutamic, propionic, glycolic, gluconic, malefic, embonic (pamoic), methanesulfonic, ethanesulfonic, 2-hydroxyethanesulfonic, pantothenic, benzenesulfonic, toluenesulfonic, sulfanilic, mesylic, cyclohexylaminosulfonic, stearic, algenic, ~i-hydroxybutyric, malonic, galactaric, galacturonic acid and the like. Suitable pharmaceutically acceptable base addition salts include, without limitation, metallic salts made from aluminium, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine, lysine, procaine and the like. Additional examples of pharmaceutically acceptable salts are listed in Berge et al., Journal of Pharmaceutical Sciences (1977) 66:2, 1-19. All of these salts may be prepared by conventional means from a farnesyl dibenzodiazepinone by treating the compound with the appropriate acid or base.<br class="style-scope patent-text">     The term "pharmaceutically acceptable salt or prodrug" means any pharmaceutically acceptable salt, ester, salt of an ester or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an biologically active metabolite or residue thereof. Particularly favored salts or prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species. Pharmaceutically acceptable prodrugs of the compounds of this invention include, without limitation, esters, amino acid esters, phosphate esters, metal salts and sulfonate esters.<br class="style-scope patent-text">Unless otherwise indicated, all numbers expressing quantities of ingredients and properties such as molecular weight, reaction conditions, MIC and Gl~o values, and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about". Accordingly, unless indicated to the contrary, the numerical parameters set forth in the present specification and attached claims are approximations. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of significant figures and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the examples, tables and figures are reported as precisely as possible. Any numerical values may inherently contain certain errors resulting from variations in experiments, testing measurements, statistical analysis and such.<br class="style-scope patent-text">     II. Compounds of the invention In one aspect, the invention relates to novel farnesyl dibenzodiazepinones, referred to herein as Compound 1 derivatives and to pharmaceutically acceptable salts and prodrugs thereof.<br class="style-scope patent-text">    The Compounds of the invention may be characterized as chemically modified Compound 1 by: O and N acylation and alkylation, farnesyl side chain hydrogenolysis, epoxidation, and dihydroxylation. Compounds 2 to 12, 17, 18 and 46 may be characterized by any one of their physicochemical and spectral properties, such as mass and NMR, detailed in Examples 4 through 8.<br class="style-scope patent-text">     In another aspect, the invention relates to derivatives of Compound 1, represented by Formula I:<br class="style-scope patent-text">     Formula I <br class="style-scope patent-text"> <br class="style-scope patent-text"> wherein, W', W2 and W3 are each independently selected from H I _ _I _ _H I__ I ( ~~ . ~ H~C~ ' ~~ ~ ~C ~ ' Or R5 Rs ~ 0 the ctoain from the tricycle terminates at W3, W2 or W' with W3, W2 or W' respectively being either -CH=O or -CH20H;<br class="style-scope patent-text"> R' is selected from H, C~_~oalkyl, C2.~oalkenyl, C2_,oalkynyl, Cs.~oaryl, C5_ ~oheteroaryl, C3.iocycloalkyl, C3.~oheterocycloalkyl, C(O)Cl.~oalkyl, C(O)C2.~oalkenyl, C(O)C2_,oalkynyl, C(O)C6_~oaryl, C(O)C5_,oheteroaryl, C(O)C3_,ocycloalkyl; <br class="style-scope patent-text">C(O)C3_ ,oheterocycloalkyl or a C-coupled amino acid;<br class="style-scope patent-text">R2, R3, and R4 are each independently selected from H, C1_,oalkyl, C2_,oalkenyl, C2_,oalkynyl, C6.,oaryl, C5_ioheteroaryl, Cs_locycloalkyl, C3.ioheterocycloalkyl, C(O)H, C(O)C,_,oalkyl, C(O)C2_ioalkenyl, C(O)C2_ioalkynyl, C(O)C6_,oaryl, C(O)CS.ioheteroaryl, C(O)C3_locycloalkyl; C(O)C3_,oheterocycloalkyl or a C-coupled amino acid;<br class="style-scope patent-text">     R5 and R6 are each independently selected from H, OH and OC,_salkyl;<br class="style-scope patent-text">wherein, when any of R', R2, R3, R4, R5 and R6 comprises an alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group, then the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group is optionally substituted with substituents selected from acyl, amino, acylamino, acyloxy, carboalkoxy, carboxy, carboxyamido, cyano, halo, hydroxyl, nitro, thin, C,_salkyl, C2_,alkenyl, Cz_~alkynyl, C3.<br class="style-scope patent-text">iocycloalkyl, C3.loheterocycloalkyl, Cg.loaryl, C5_loheteroaryl, alkoxy, aryloxy, sulfinyl, sulfonyl, oxo, guanidino and formyl; and with the proviso that when W', W2 and W3 are all -CH=C(CH3)-, and R2, R3 and R4 are all H, then R' is not H;<br class="style-scope patent-text">or a pharmaceutically acceptable salt or prodrug thereof.<br class="style-scope patent-text">In one embodiment, R' is H, and all other groups are as previously disclosed. <br class="style-scope patent-text">In another embodiment, R' is -CHs, and all other groups are as previously disclosed. In another embodiment, R' is C,_loalkyl, and all other groups are as previously disclosed.<br class="style-scope patent-text">In a subclass of this embodiment, the alkyl group is optionally substituted with a substituent selected from halo, fluoro, Cs.~oaryl, and C5_,oheteroaryl. In another embodiment, R' is -C(O)C1_,oalkyl, and all other groups are as previously disclosed. In another embodiment, R2 is H, and all other groups are as previously disclosed. <br class="style-scope patent-text">In another embodiment, R3 is H, and all other groups are as previously disclosed. <br class="style-scope patent-text">In another embodiment, R4 is H, and all other groups are as previously disclosed. <br class="style-scope patent-text">In another embodiment, R2, R3 and R4 are each H, and all other groups are as previously disclosed. In another embodiment, one of R2, R3 and R4 is CH3, the others being each H, and all other.groups are as previously disclosed. In another embodiment, two of R2, R3 and R4 are CH3, the other being H, and all other groups are as previously disclosed.<br class="style-scope patent-text">In another embodiment, R2, R3 and R4 are each CH3, and all other groups are as previously disclosed. In another embodiment, R2, R3 and R4 are each H, and W' is -CH=C(CH3)-, and all other groups are as previously disclosed. In another embodiment, R2, R3 and R4 are each H, and W2 is -CH=C(CH3)-, and all other groups are as previously disclosed. In another embodiment, R2, R3 and R4 are each H, and W3 is -CH=C(CH3)-, and all other groups are as previously disclosed. In another embodiment, R' is H and R2, R3 and R are each H, and all other groups are as previously disclosed.<br class="style-scope patent-text">In another embodiment, R' is H, each of W', W2, and W3 is -CH=C(CH3)-, and all other groups are as previously disclosed. In another embodiment, R' is H, each of W', W2, and W3 is -CH2CH(CH3)-, and all other groups are as previously disclosed. In another embodiment, if each of W', W2 and W3 are -CH=C(CH3)-, and each of R2, R3, and R<br class="style-scope patent-text">are H, then R' is not H. in further embodiment, if each of W', W2 and W3 are -CH=C(CH3)-, and each of R2, R3, and R4 are H, then R' is not CH3. In further embodiment, if each of W', W2 and W3 are -CH=C(CH3)-, and each of R2, R3, and are H, then R' is neither H nor CH3. The invention encompasses all pharmaceutically acceptable salts and prodrugs of the foregoing compounds.<br class="style-scope patent-text">     The following are exemplary compounds of the invention, such named compounds are not intended to limit the scope of the invention in any way: <br class="style-scope patent-text"> <br class="style-scope patent-text"> Compound 1; Compound 2;<br class="style-scope patent-text">     Compound 3; Compound 4;<br class="style-scope patent-text">     Compound 5; Compound 6;<br class="style-scope patent-text">i i I i i Compound 7; Compound 8; <br class="style-scope patent-text"> <br class="style-scope patent-text"> Compound 9; Compound 10;<br class="style-scope patent-text">     Compound 11; Compound 12;<br class="style-scope patent-text">     Compound 13; Compound 14;<br class="style-scope patent-text">i i i i Compound 15; Compound 16;<br class="style-scope patent-text">i i Compound 17; Compound 18;<br class="style-scope patent-text">i , i Compound 19; Compound 20;<br class="style-scope patent-text"> <br class="style-scope patent-text">     Compound 21; Compound 22;<br class="style-scope patent-text">     Compound 23; Compound 24;<br class="style-scope patent-text">     Compound 25; Compound 26;<br class="style-scope patent-text">     Compound 27; Compound 28; <br class="style-scope patent-text"> <br class="style-scope patent-text"> Compound 29; Compound 30;<br class="style-scope patent-text">i Compound 31; Compound 32;<br class="style-scope patent-text"> <br class="style-scope patent-text">     Compound 33; Compound 34;<br class="style-scope patent-text">     Compound 35; Compound 36;<br class="style-scope patent-text">     Compound 37; Compound 38; <br class="style-scope patent-text"> <br class="style-scope patent-text"> Compound 39; Compound 40;<br class="style-scope patent-text">     Compound 41; Compound 42;<br class="style-scope patent-text">     Compound 43; Compound 44;<br class="style-scope patent-text">     Compound 45; Compound 46;<br class="style-scope patent-text">     Compound 47; Compound 48; <br class="style-scope patent-text"> <br class="style-scope patent-text"> Compound 49; Compound 50;<br class="style-scope patent-text">Compound 51; Compound 52;<br class="style-scope patent-text">     Compound 53; Compound 54;<br class="style-scope patent-text">     Compound 55; Compound 56;<br class="style-scope patent-text">     Compound 57; Compound 58; <br class="style-scope patent-text"> <br class="style-scope patent-text"> Compound 59; Compound 60;<br class="style-scope patent-text"> <br class="style-scope patent-text">i i i OH<br class="style-scope patent-text">     N &gt;-=Y<br class="style-scope patent-text">     OH<br class="style-scope patent-text">HO<br class="style-scope patent-text">     Compound 61; Compound 62;<br class="style-scope patent-text">     Compound 63; Compound 64;<br class="style-scope patent-text">     Compound 65; Compound 66;<br class="style-scope patent-text">     Compound 67; Compound 68; <br class="style-scope patent-text"> <br class="style-scope patent-text"> Compound 69; Compound 70;<br class="style-scope patent-text">     Compound 71; Compound 72;<br class="style-scope patent-text">i i i i Compound 73; Compound 74;<br class="style-scope patent-text">     Compound 75; and Compound 76;<br class="style-scope patent-text">or a pharmaceutically acceptable salt of prodrug of any one of Compounds 1 to 76.<br class="style-scope patent-text">Certain embodiments expressly exclude one or more of the compounds of Formula I. In one embodiment, Compound 1 is excluded. In another embodiment, Compound 2 is excluded. In a further embodiment, both Compound 1 and Compound are excluded.<br class="style-scope patent-text">     The compounds of this invention may be formulated into pharmaceutical compositions comprised of compounds of Formula I in combination with a pharmaceutically acceptable carrier, as discussed in Section IV below.<br class="style-scope patent-text">ill. Method of Making a Farnesyl Dibenzodiazepinone A. Fermentation In one embodiment, ECO-4601 is obtained by cultivating a novel strain of Micromonospora, namely Micromonospora sp. strain 046-EC011. Strain 046-EC011 was deposited on March 7, 2003, with the International Depositary Authority of Canada (IDAC), Bureau of Microbiology, Health Canada, 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3R2, under Accession No. 070303-01. The deposit of the strain was made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for Purposes of Patent Procedure. <br class="style-scope patent-text">The deposited strains will be irrevocably and without restriction or condition released to the public upon the issuance of a patent. The deposited strains are provided merely as convenience to those skilled in the art and are not an admission that a deposit is required for enablement.<br class="style-scope patent-text">It is to be understood that the present invention is not limited to use of the particular strain 046-EC011. Rather, the present invention contemplates the use of other ECO-4601 producing organisms, such as mutants or variants of 046-EC011 that can be derived from this organism by known means such as X-ray irradiation, ultraviolet irradiation, treatment with nitrogen mustard, phage exposure, antibiotic selection and the like; or through the use of recombinant genetic engineering techniques, as described in Section IV below.<br class="style-scope patent-text">     The farnesyl dibenzodiazepinone compounds of the present invention may be biosynthesized by various microorganisms. Microorganisms that may synthesize the compounds of the present invention include but are not limited to bacteria of the order Actinomycetales, also referred to as actinomycetes. Non-limiting examples of members belonging to the genera of Actinomycetes include Nocardia, Geodermatophilus, Actinopianes, Micromonospora, Nocardioides, Saccharothrix, Amycolatopsis, Kutzneria, Saccharomonospora, Saccharopolyspora, Kitasatospora, Streptomyces, Microbispora, Streptosporangium, and Actinomadura. The taxonomy of actinomycetes is complex and reference is made to Goodfellow, Suprageneric Classification of Actinomycetes (1989); Bergey's Manual of Systematic Bacteriology, Vol. 4 (Williams and Wilkins, Baltimore, pp. 2322-2339); and to Embley and Stackebrandt, "The molecular phylogeny and systematics of the actinomycetes," Annu. Rev. Microbiol. (1994) 48:257-289, for genera that may synthesize the compounds of the invention.<br class="style-scope patent-text">Farnesyl dibenzodiazepinone-producing microorganisms are cultivated in culture medium containing known nutritional sources for actinomycetes. Such media having assimilable sources of carbon, nitrogen, plus optional inorganic salts and other known growth factors at a pH of about 6 to about 9. Suitable media include, without limitation, the growth media provided in Table 1. Microorganisms are cultivated at incubation temperatures of about 18 C to about 40 C for about 3 to about 40 days.<br class="style-scope patent-text">     TABLE 1: PREFERRED MEDIA COMPOSITION FOR PRODUCTION OF ECO-4601 Com~~onent  pg  MA KH  RM  JA  FA <br class="style-scope patent-text"> <br class="style-scope patent-text"> pH*5        7.2 7.57   6.857.3 7.0 Glucose     12     10  10    10 Sucrose                100 Lactose Cane molasses                   15 Corn starch 30 Soluble starch10  25 Potato dextrin       20       40 Corn steep  5 solid Corn steep  5              15 liquor Dried yeast     2 Yeast extract       5 Malt extract               35 PharmamediaT""10             15 Glycerol NZ-Amine           5           10 Soybean powder    15 Component   pB. MA KH  RM  JA  FA <br class="style-scope patent-text"> <br class="style-scope patent-text"> Soybean flour Meat extract Bacto-peptone MgS04.7H20                     1 MgCl2. 6H20 CaC03           4  1       2   2 NaCI            5 (NHa)z SOa      2 KZ S04                 0.25 MnC12.4H20 MgC12.6H20             10 FeC12.4H20 ZnCl2 Na2HP04                        3 Thiamine Casamino               0.1 acid Proflo oil  4 Trace element           2 solution *3 ml/L             <br class="style-scope patent-text"> <br class="style-scope patent-text"> Unless otherwise indicated all the ingredients are in gm/L.<br class="style-scope patent-text">*3Trace elements solution contains: ZnCl2 40 mg; Fe CI36H20 (200 mg); CuCl2 2H20 (10 mg);<br class="style-scope patent-text">     MnC12.4H20; Na2B40,.10Hz0 (l0mg); (NH4) 6 MO~OZ4.4H20 (10 mg) per litre.<br class="style-scope patent-text">*5 The pH is to adjusted as marked prior to the addition of CaC03.<br class="style-scope patent-text">   The culture media inoculated with the farnesyl dibenzodiazepinone-producing microorganisms may be aerated by incubating the inoculated culture media with agitation, for example, shaking on a rotary shaker, or a shaking water bath. <br class="style-scope patent-text">Aeration may also be achieved by the injection of air, oxygen or an appropriate gaseous mixture to the inoculated culture media during incubation. Following cultivation, the farnesyl dibenzodiazepinone compounds can be extracted and isolated from the cultivated culture media by techniques known to a skilled person in the art and/or disclosed herein, including for example centrifugation, chromatography, adsorption, filtration. For example, the cultivated culture media can be mixed with a suitable organic solvent such as n-butanol, n-butyl acetate or 4-methyl-2-pentanone, the organic layer can be separated for example, by centrifugation followed by the removal of the solvent, by evaporation to dryness or by evaporation to dryness under vacuum. The resulting residue can optionally be reconstituted with for example water, ethanol, ethyl acetate, methanol or a mixture thereof, and re-extracted with a suitable organic solvent such as hexane, carbon tetrachloride, methylene chloride or a mixture thereof. <br class="style-scope patent-text">Following removal of the solvent, the compounds may be further purified by the use of standard techniques, such as chromatography.<br class="style-scope patent-text">8. Chemical Modifications:<br class="style-scope patent-text">     The farnesyl dibenzodiapezinones biosynthesized by microorganisms are subjected to random and/or directed chemical modifications to form compounds that are derivatives or structural analogs. Such derivatives or structural analogs having similar functional activities are within the scope of the present invention. <br class="style-scope patent-text">Farnesyl dibenzodiapezinone compounds may be modified using methods known in the art and described herein. Examples of chemical modifications are shown in Examples 4 to 8 and Example 15.<br class="style-scope patent-text">Derivatives of the ECO-4601 molecule, for example those identified herein as the compounds of Formula I and Compounds 2 to 76, are generated by standard organic chemistry approaches. General principles of organic chemistry required for making and manipulating the compounds described herein, including functional moieties, reactivity and common protocols are described, for example, in "Advanced Organic Chemistry,"<br class="style-scope patent-text">4t" Edition by Jerry March (1992), Wiley-Interscience, USA. In addition, it will be appreciated by one of ordinary skill in the art that the synthetic methods described herein may use a variety of protecting groups, whether or not they are explicitly described. A "protecting group" as used herein means a moiety used to block one or more functional moieties such as reactive groups including oxygen, sulfur or nitrogen, so that a reaction can be carried out selectively at another reactive site in a polyfunctional compound. General principles for the use of protective groups, their applicability to specific functional groups and their uses are described for example in T.<br class="style-scope patent-text">H. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3'~ <br class="style-scope patent-text">Edition, John Wiley &amp; Sons, New York (1999).<br class="style-scope patent-text">     Alcohols and phenols are protected with, for example: silyl ethers (TMS:<br class="style-scope patent-text">trimethylsilyl, TIPS: triisopropylsilyl), acetals (MOM: methyloxymethyl, BOM:<br class="style-scope patent-text">benzyloxymethyl), esters (acetate, benzoyl) and ethers (Bn: benzyl). Alcohols are deprotected by conditions such as: TBAF (tetrabutylammonium fluoride) for silyl ethers, aqueous acid catalysis for acetals and esters, saponification for esters, and hydrogenolysis for Bn and BOM. Amine is protected using standard amino acid protecting groups, for example, carbamates (such as t-butyl (BOC) and benzyl (CBZ)), fluorene derivatives (such as FMOC: N (9-fluorenylmethoxycarbonyl)-), etc. <br class="style-scope patent-text">Amine is deprotected by conditions such as: acid hydrolysis for BOC, hydrogenolysis for CBZ, or base treatment for FMOC. All protection and deprotection conditions are demonstrated in the Greene et al reference above.<br class="style-scope patent-text"> Those skilled in the art will readily appreciate that many synthetic chemical processes may be used to produce derivatives of Compound 1. The following schemes are exemplary of the routine chemical modifications that may be used to produce compounds of Formula I. Any chemical synthetic process known to a person skilled in the art providing the structures described herein may be used and are therefore comprised in the present invention.<br class="style-scope patent-text">     Scheme 1: Phenolic alcohol(s) modifications OH Rs_X ~z~<br class="style-scope patent-text">s Rs~~O~X ~ O R<br class="style-scope patent-text">     O<br class="style-scope patent-text">wherein, R5 and Rs are each selected from alkyl, alkalene, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and X is a suitable leaving group.<br class="style-scope patent-text">In Scheme 1, Phenols are independently alkylated or esterified. Allkylation is accomplished with an alkylating agent such as RX is a diazoalkane, or with a RX<br class="style-scope patent-text">reagent, wherein X is a suitable leaving group such as Br, I and trifluoromethane sulfonate in the presence of a base, preferably, a diazoalkane is used. A <br class="style-scope patent-text">phenolic alcohol is converted to ester when reacted with an activated carboxylic acid such as acid halides, anhydrides and N-hydroxysuccinimide esters or with carboxylic acids and coupling agents in the presence of a base like diisopropylethylamine. Scheme 1 is used to obtain Compounds 4 to 12 and 35 to 39 from Compound 1, and Compound 15 from Compound 13.<br class="style-scope patent-text">     Scheme 2: Amine modifications ~R<br class="style-scope patent-text">     R_x ~N<br class="style-scope patent-text">~NH<br class="style-scope patent-text">  RC(O)X ~<br class="style-scope patent-text">~N R<br class="style-scope patent-text">wherein, R is selected from alkyl, alkene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; and X is a suitable leaving group.<br class="style-scope patent-text">In Scheme 2, amine group is optionally alkylated or acylated. Amine is alkylated using an RX alkylating agent such as dialkyl sulfates and alkyl halide, preferably RX is an alkyl halide and a base is used. An amine is also acylated when reacted with an activated carboxylic acid such as acid halides, anhydrides and N-hydroxysuccinimide esters or with carboxylic acids and coupling agents in the presence of a base like diisopropylethylamine. Scheme 2 is used to obtain Compounds 2, 3, 13, 14 and 60 to 76 from Compound 1.<br class="style-scope patent-text">     Scheme 3: Double bonds) modifications H<br class="style-scope patent-text">~w / 1ol..i ~ H+<br class="style-scope patent-text">     O OH<br class="style-scope patent-text">     H Oa H H OH<br class="style-scope patent-text">     O H~ ~ ~ OH<br class="style-scope patent-text">     H<br class="style-scope patent-text">     H H<br class="style-scope patent-text">In Scheme 3, double bond is modified by hydrogenation, epoxidation and ozonolysis.<br class="style-scope patent-text">Hydrogenation is carried out using a hydrogen source in the presence of a catalyst (such as rhodium, platinum, palladium, etc). Epoxide is obtained from the reaction of a double bond with an oxidizing agent such as a peracid. The epoxide obtained is opened in aqueous conditions, preferably acidic, to produce a diol. An aldehyde is obtained form the reaction of the double bond with a controlled quantity of ozone. The aldehyde obtained is reduced to alcohol by a reducing agent [H] such as sodium borohydride (NaBH4), sodium cyanoborohydride (NaBH3CN) or LAH. Scheme 3 is used to obtain Compounds 16 to 22 and 40 to 46 from Compound 1, Compounds 53 to 59 respectively from Compounds 16 to 22, Compounds 23, 24 and 26 from Compound 42, Compounds 25, 27 and 29 from Compound 41, Compounds 28, 30 and 31 from Compound 40, Compounds 32, 33 and 34 respectively from Compounds 45, 44 and 43, Compounds 47, 49 and 51 from Compound 1, and Compounds 48, 50 and 52 respectively from Compounds 47, 49 and 49.<br class="style-scope patent-text">     IV. Pharmaceutical compositions comhrisinp the compounds of the invention In another embodiment, the invention relates to a pharmaceutical composition comprising a farnesyl dibenzodiazepinone, as described in the preceding section, and a pharmaceutically acceptable carrier, as described below. The pharmaceutical composition comprising the farnesyl dibenzodiazepinone is useful for treating a variety of diseases and disorders, including cancer, inflammation, autoimmune diseases, infections, neurodegenerative diseases and stress.<br class="style-scope patent-text">  The compounds of the present invention, or pharmaceutically acceptable salts thereof, can be formulated for oral, intravenous, intramuscular, subcutaneous, topical or parenteral administration for the therapeutic or prophylactic treatment of diseases, particularly acute and chronic inflammation, cancer, autoimmune diseases, infections, neurodegenerative diseases and stress. For oral or parenteral administration, compounds of the present invention can be mixed with conventional pharmaceutical carriers and excipients and used in the form of tablets, capsules, elixirs, suspensions, syrups, wafers and the like. The compositions comprising a compound of this present invention will contain from about 0.1 % to about 99.9%, about 1 % to about 98%, about 5% to about 95%, about 10% to about 80% or about 15% to about 60% by weight of the active compound.<br class="style-scope patent-text">   The pharmaceutical preparations disclosed herein are prepared in accordance with standard procedures and are administered at dosages that are selected to reduce, prevent, or eliminate cancer or inflammation, autoimmune diseases, infections, neurodegenerative diseases or stress. (See, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA; and Goodman and Gilman, Pharmaceutical Basis of Therapeutics, Pergamon Press, New York, NY, for a general description of the methods for administering various antimicrobial agents for human therapy). The compositions of the present invention can be delivered using controlled (e.g., capsules) or sustained release delivery systems (e.g., bioerodable matrices).<br class="style-scope patent-text">Exemplary delayed release delivery systems for drug delivery that are suitable for administration of the compositions of the invention (preferably of Formula I) are described in U.S. Patent Nos 4,452,775 (issued to Kent), 5,039,660 (issued to Leonard), 3,854,480 (issued to Zaffaroni).<br class="style-scope patent-text">The pharmaceutically acceptable compositions of the present invention comprise one or more compounds of the present invention in association with one or more non-toxic, pharmaceutically acceptable carriers and/or diluents and/or adjuvants and/or excipients, collectively referred to herein as "carrier" materials, and if desired other active ingredients. The compositions may contain common carriers and excipients, such as corn starch or gelatin, lactose, sucrose, microcrystailine cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride and alginic acid. The compositions may contain crosarmellose sodium, microcrystalline cellulose, sodium starch glycolate and alginic acid.<br class="style-scope patent-text">     Tablet binders that can be included are acacia, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone (Providone), hydroxypropyl methylcellulose, sucrose, starch and ethylcellulose.<br class="style-scope patent-text">     Lubricants that can be used include magnesium stearate or other metallic stearates, stearic acid, silicon fluid, talc, waxes, oils and colloidal silica.<br class="style-scope patent-text">Flavouring agents such as peppermint, oil of wintergreen, cherry flavouring or the like can also be used. It may also be desirable to add a coloring agent to make the dosage form more aesthetic in appearance or to help identify the product comprising a compound of the present invention.<br class="style-scope patent-text">For oral use, solid formulations such as tablets and capsules are particularly useful. Sustained released or enterically coated preparations may also be devised. For pediatric and geriatric applications, suspension, syrups and chewable tablets are especially suitable. For oral administration, the pharmaceutical compositions are in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a therapeutically-effective amount of the active ingredient. Examples of such dosage units are tablets and capsules. For therapeutic purposes, the tablets and capsules which can contain, in addition to the active ingredient, conventional carriers such as binding agents, for example, acacia gum, gelatin, polyvinylpyrrolidone, sorbitol, or tragacanth; fillers, for example, calcium phosphate, glycine, lactose, maize-starch, sorbitol, or sucrose; lubricants, for example, magnesium stearate, polyethylene glycol, silica or talc: disintegrants, for example, potato starch, flavoring or coloring agents, or acceptable wetting agents. Oral liquid preparations generally are in the form of aqueous or oily solutions, suspensions, emulsions, syrups or elixirs and may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous agents, preservatives, coloring agents and flavoring agents. Examples of additives for liquid preparations include acacia, almond oil, ethyl alcohol, fractionated coconut oil, gelatin, glucose syrup, glycerin, hydrogenated edible fats, lecithin, methyl cellulose, methyl or propyl para-hydroxybenzoate, propylene glycol, sorbitol, or sorbic acid.<br class="style-scope patent-text">For intravenous (iv) use, compounds of the present invention can be dissolved or suspended in any of the commonly used intravenous fluids and administered by infusion. Intravenous fluids include, without limitation, physiological saline or Ringer's solution.<br class="style-scope patent-text">Formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions or suspensions can be prepared from sterile powders or granules having one or more of the carriers mentioned for use in the formulations for oral administration. <br class="style-scope patent-text">The compounds can be dissolved in polyethylene glycol, propylene glycol, ethanol, corn oil, benzyl alcohol, sodium chloride, and/or various buffers.<br class="style-scope patent-text">     For intramuscular preparations, a sterile formulation of compounds of the present invention or suitable soluble salts forming the compound, can be dissolved and administered in a pharmaceutical diluent such as Water-for-Injection (WFI), physiological saline or 5% glucose. A suitable insoluble form of the compound may be prepared and administered as a suspension in an aqueous base or a pharmaceutically acceptable oil base, e.g. an ester of a long chain fatty acid such as ethyl oleate.<br class="style-scope patent-text">    For topical use the compounds of present invention can also be prepared in suitable forms to be applied to the skin, or mucus membranes of the nose and throat, and can take the form of creams, ointments, liquid sprays or inhalants, lozenges, or throat paints. Such topical formulations further can include chemical compounds such as dimethylsulfoxide (DMSO) to facilitate surface penetration of the active ingredient.<br class="style-scope patent-text">For application to the eyes or ears, the compounds of the present invention can be presented in liquid or semi-liquid form formulated in hydrophobic or hydrophilic bases as ointments, creams, lotions, paints or powders. <br class="style-scope patent-text"> <br class="style-scope patent-text"> For rectal administration the compounds of the present invention can be administered in the form of suppositories admixed with conventional carriers such as cocoa butter, wax or other glyceride.<br class="style-scope patent-text">Alternatively, the compound of the present invention can be in powder form for reconstitution in the appropriate pharmaceutically acceptable carrier at the time of delivery. In another embodiment, the unit dosage form of the compound can be a solution of the compound or a salt thereof in a suitable diluent in sterile, hermetically sealed ampoules.<br class="style-scope patent-text">     The amount of the compound of the present invention in a unit dosage comprises a therapeutically-effective amount of at least one active compound of the present invention which may vary depending on the recipient subject, route and frequency of administration. A recipient subject refers to a plant, a cell culture or an animal such as an ovine or a mammal including a human.<br class="style-scope patent-text">     According to this aspect of the present invention, the novel compositions disclosed herein are placed in a pharmaceutically acceptable carrier and are delivered to a recipient subject (including a human subject) in accordance with known methods of drug delivery. In general, the methods of the invention for delivering the compositions of the invention in vivo utilize art-recognized protocols for delivering the agent with the only substantial procedural modification being the substitution of the compounds of the present invention for the drugs in the art-recognized protocols.<br class="style-scope patent-text">     The compounds of the present invention provide a method for treating pre-cancerous or cancerous conditions, and acute or chronic inflammatory disease. <br class="style-scope patent-text">As used herein, the term "unit dosage" refers to a quantity of a therapeutically effective amount of a compound of the present invention that elicits a desired therapeutic response. As used herein, the phrase "therapeutically effective amount" means an amount of a compound of the present invention that prevents the onset, alleviates the symptoms, or stops the progression of pre-cancerous or cancerous condition. <br class="style-scope patent-text">The term "treating" is defined as administering, to a subject, a therapeutically effective amount of at least one compound of the present invention, both to prevent the occurrence of inflammation or pre-cancer or cancer condition, or to control or eliminate inflammation or pre-cancer or cancer condition. The term "desired therapeutic response refers to treating a recipient subject with a compound of the present invention such that a pre-cancer or cancer condition is reversed, arrested or prevented in a recipient subject.<br class="style-scope patent-text">  The compounds of the present invention can be administered as a single daily dose or in multiple doses per day. The treatment regime may require administration over extended periods of time, e.g., for several days or for from two to four weeks. The amount per administered dose or the total amount administered will depend on such factors as the nature and severity of the disease condition, the age and general health of the recipient subject, the tolerance of the recipient subject to the compound and the type of the inflammatory disorder, or type of cancer.<br class="style-scope patent-text">A compound according to this invention may also be administered in the diet or feed of a patient or animal. The diet for animals can be normal foodstuffs to which the compound can be added or it can be added to a premix.<br class="style-scope patent-text">  The compounds of the present invention may be taken in combination, together or separately with any known clinically approved antibiotic, inflammation or anti-cancer agent to treat a recipient subject in need of such treatment.<br class="style-scope patent-text">     V. Method of Inhibiting Tumor Growth In another embodiment, the present invention relates to a method of inhibiting tumor growth. Compounds as described herein can possess anti-tumor activity. <br class="style-scope patent-text">The compounds are effective against mammalian tumor cells such as leukemia cells, melanoma cells, breast carcinoma cells, lung carcinoma cells, pancreatic carcinoma cells, ovarian carcinoma cells, renal carcinoma cells, colon carcinoma cells and glioma cells. The antitumor method of the invention results in inhibition of tumor cells. The term "inhibition", when used in conjunction with the antitumor method refers to suppression, killing, stasis, or destruction of tumor cells. The antitumor method preferably results in prevention, reduction or elimination of invasive activity and related metastasis of tumor cells. The term "effective amount" when used in conjunction with the antitumor cell method refers to the amount of the compound sufficient to result in the inhibition of mammalian tumor cells.<br class="style-scope patent-text">     The inhibition of mammalian tumor growth according to this method can be monitored in several ways. First, tumor cells grown in vitro can be treated with the compound and monitored for growth or death relative to the same cells cultured in the absence of the compound. A cessation of growth or a slowing of the growth rate (i.e., the doubling rate), e.g., by 10% or more, is indicative of tumor cell inhibition.<br class="style-scope patent-text">Alternatively, tumor cell inhibition can be monitored by administering the compound to an animal model of the tumor of interest. Examples of experimental animal tumor models are known in the art and described in the examples herein. A cessation of tumor growth (i.e., no further increase in size) or a reduction in tumor size (i.e., tumor volume) or cell number (e.g., at least a 10% decrease in either) in animals treated with a compound as described herein relative to tumors in control animals not treated with the compound is indicative of tumor growth inhibition.<br class="style-scope patent-text">To monitor the efficacy of tumor treatment in a human, tumor size or tumor cell titer is measured before and after initiation of the treatment, and treatment is considered effective if either the tumor size or titer ceases further growth, or if the tumor is reduced in size or titer, e.g., by at least 10% or more (e.g., 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or even 100%, that is, the absence of the tumor). Methods of determining the size or cell titer of a tumor in vivo vary with the type of tumor, and include, for example, various imaging techniques well known to those in the medical imaging or oncology fields (MRI, CAT, PET, etc.), as well as histological techniques and flow cytometry.<br class="style-scope patent-text">   For the anti-tumor method of the invention, a typical effective dose of the compounds given orally or parenterally would be from about 5 to about 100 mg/kg of body weight of the subject with a daily dose ranging from about 15 to about 300 mg/kg of body weight of the subject.<br class="style-scope patent-text">     VI. Method of Treating Cancer In another embodiment, the present invention relates to a method of treating a precancerous or cancerous condition in a mammal, comprising the steps of administrating a pharmaceutical composition, containing a dibenzodiazepinone compound of the present invention in combination with a physiologically acceptable carrier. In one embodiment, the compound is represented by Formula i. As described elsewhere in the application, the compounds of the present invention can have antitumor activity. Specifically, the compounds are effective against mammalian tumor cells such as leukemia cells, melanoma cells, breast carcinoma cells, lung carcinoma cells, pancreatic carcinoma cells, ovarian carcinoma cells, renal carcinoma cells, colon carcinoma cells, prostate carcinoma cells and glioma cells.<br class="style-scope patent-text">     In addition, the compound of Formula I is bioavailable via the oral, intraperitoneal, subcutaneous and intravenous administration. Furthermore, as is described within the Examples section, the compounds of the present invention penetrate into brain tissues, and therefore can be useful in the treatment of numerous pre-cancerous and cancerous conditions of the brain.<br class="style-scope patent-text">    The cancer treatment method preferably results in prevention, reduction or elimination of invasive activity and related metastasis of tumor cells. The term "therapeutically effective amount" when used in conjunction with the cancer treatment method refers to the amount of the compound sufficient to result in the prevention, reduction or elimination tumors or cancer in a mammal.<br class="style-scope patent-text">  The treatment of cancer according to this method can be monitored in several ways. To monitor the efficacy of tumor treatment in a human, tumor size or tumor cell titer is measured before and after initiation of the treatment, and treatment is considered effective if either the tumor size or titer ceases further growth, or if the tumor is reduced in size or titer, e.g., by at least 10% or more (e.g., 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or even 100%, that is, the absence of the tumor). Methods of determining the size or cell titer of a tumor in vivo vary with the type of tumor, and include, for example, various imaging techniques well known to those in the medical imaging or oncology fields (MRI, CAT, PET, etc.), as well as histological techniques and flow cytometry.<br class="style-scope patent-text">For the cancer treatment method of the invention, a typical effective dose of the compounds given orally or parenterally would be from about 5 to about 100 mg/kg of body weight of the subject with a daily dose ranging from about 15 to about 300 mg/kg of body weight of the subject. Alternatively, compounds can be given intravenously, intraperitoneally or subcutaneously at a range from about 5 to about 300 mg/kg.<br class="style-scope patent-text">   In addition to the compounds of this invention, pharmaceutically acceptable derivatives or prodrugs of the compounds of this invention may also be employed in compositions to treat or prevent the above-identified disorders.<br class="style-scope patent-text">     A "pharmaceutically acceptable derivative or prodrug" means any pharmaceutically acceptable salt, ester, salt of an ester or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof. Particularly favored derivatives or prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species.<br class="style-scope patent-text">     Pharmaceutically acceptable prodrugs of the compounds of this invention include, without limitation, esters, amino acid esters, phosphate esters, metal salts and sulfonate esters.<br class="style-scope patent-text">     VII. Method of Inhibiting Lipoxygenase In another embodiment, the present invention also provides for a method of treating diseased states, in particular inflammation, caused by the 5-lipoxygenase system and/or by the synthesis of the Leukotrienes C4, D4, E4 and F4 as well as Leukotriene B4 in mammals, especially in human subjects. This method comprises administering to a subject an effective amount of a compound of Formula I. The compound of Formula I may be used alone or in combination with other anti-inflammatory compounds to treat or prevent disease states related to inflammation including pulmonary conditions, inflammation, cardiovascular conditions, central nervous system conditions or skin conditions. More specific diseases include gastritis;<br class="style-scope patent-text">erosive esophagitis; inflammatory bowel disease; ethanol-induced hemorrhagic erosions; hepatic ischemia; ischemic neuronal injury; noxious agent induced damage or necrosis of hepatic, pancreatic, renal, neuronal or myocardial tissue; liver parenchyma) damage caused by hepatoxic agents such as CC14 and D-galactosamine; ischemic renal failure; disease-induced hepatic damage; trauma- or stress-induced cell damage;<br class="style-scope patent-text">asthma, multiple sclerosis, ischemic reperfusion, edema, rheumatoid arthritis, viral encephalitis; bacterial pneumonia, neurodegeneration, Alzheimer's disease and glycerol-induced renal failure.<br class="style-scope patent-text">For the method of the invention related to the 5-lipoxygenase system and/or the biosynthesis of Leukotrienes, a typical effective unit dose of a compound of Formula I, or an analog given orally or parenterally would be from about 5 to about 100 mg/kg of body weight of the subject with a daily dose ranging from about 15 to about 300 mg/kg of body weight of the subject.<br class="style-scope patent-text">  The inhibition of lipoxygenase enzymes is monitored using methods well known in the art and as described in the examples herein. A decrease in enzyme activity by at least 10%, relative to the activity in the absence of a compound as described herein is indicative of effective inhibition of lipoxygenase activity.<br class="style-scope patent-text">   Farnesyl dibenzodiazepinone compounds useful according to the invention can be used to reduce or prevent inflammation. Among the hallmarks of local acute inflammation are heat, redness, swelling, pain and loss of function. These changes are induced largely by changes in vascular flow and caliber, changes in vascular permeability and leukocyte exudation (Robbins et al., "Pathologic Basis of Disease", 6tn Ed., W.B. Saunders Co., Philadelphia, PA). Anti-inflammatory therapy performed using compounds useful according to the invention can be monitored for success by tracking any of these changes. For example, a decrease in swelling (e.g., at least 10%<br class="style-scope patent-text">decrease following treatment) or reported pain (e.g., a sustained decrease of 1 point or more on a 1-10 scale reported by the patient, with 10 being the worst pain experienced in association with this disorder prior to treatment, and 0 being no pain) can be used to indicate successful treatment.<br class="style-scope patent-text"> Other measurable hallmarks of inflammation include leukocyte infiltration and inflammatory cytokine levels. These hallmarks can be monitored by biopsy of the affected tissue. A decrease of 10% or more in leukocyte infiltration in fixed, stained tissue relative to infiltration in similar tissue prior to treatment can be used to indicate successful treatment, as can a decrease of 10% or more in the level of any given inflammatory cytokine, relative to the level before treatment. Those skilled in the art can readily assay for inflammatory cytokine levels in tissue, blood, or other fluid samples. Alternatively, the level of systemic indicators of inflammation such as C<br class="style-scope patent-text">reactive protein levels and erythrocyte sedimentation rate can be monitored. <br class="style-scope patent-text">Each of these has established normal ranges in medicine, and treatment is considered successful if one or more of such indicators goes from outside the normal range to inside the normal range after the initiation of treatment.<br class="style-scope patent-text">     VIII. Method of Bindin tq o Peripheral-type Benzodiazepine Receptor PBR) PBR receptor is a mitochondria) protein, involved in the regulation of cholesterol transport for the outer to the inner mitochondria) membrane, the rate-determining step in steroid biosynthesis. PBR is a critical component of the mitochondria) permeabilitytransition pore (MPTP), which is intimately involved in the initiation and regulation of apoptosis. PBR overexpression is also found to be a prognostic indicator of the aggressive phenotype at least in breast, colorectal and prostate cancer. PBR<br class="style-scope patent-text">expression is also correlated with the quality of kidney preservation. <br class="style-scope patent-text">Overexpression is also found to have correlation with, inflammation and autoimmune diseases, viral infections, Alzheimer's disease and other neurodegenerative diseases.<br class="style-scope patent-text">     The method of treatment of a subject with a condition which needs administration of a PBR binding agent is accomplished using methods known to the art (for example see: cancer treatment: Starosta-Rubinstein et al (1987), Proc. <br class="style-scope patent-text">Nat). Acad.<br class="style-scope patent-text">Sci. USA, vol 84, no 3, 891; Junck et al (1989), Ann. Neurol.,vol 26, 752; <br class="style-scope patent-text">Maaser et al (2002), Clin. Cancer Res., vol 8, 3205; Alzheimer's disease : Owen ef al (1983), Br. <br class="style-scope patent-text"> <br class="style-scope patent-text"> Res., vol 273, 373; Diorio et al (1991 ), Neurobiology of Aging, vol 12, 255; <br class="style-scope patent-text">Huntington's disease : Messmer et al (1998), Neuroscience Letters, vol 241, 53; Multiple sclerosis Debruyne et al (2002), Acta Neul. 8e1., vol 102, no 3, 127) . The method comprises administering to a subject an effective amount of a compound of Formula I. The compound may be used alone or in combination with other compounds to treat or prevent disease states related to cancer, inflammation/auto-immune diseases (such as rheumatoid arthritis, lupus, skin or pulmonary inflammation), infections (antiparasitic), neurodegenerative diseases (Alzeihmer's disease, Huntington's disease and multiple sclerosis) and stress.<br class="style-scope patent-text">For the method of the invention related to the binding of PBR, a typical effective unit dose of the compound of the invention given orally or parenterally would be from about 5 to about 100 mg/kg of body weight of the subject with a daily dose ranging from about 15 to about 300 mg/kg of body weight of the subject.<br class="style-scope patent-text">    The binding of PBR is monitored using methods well known in the art and as described in the examples herein. For example, cancer treatment is monitored by correlation with tumor grade and patient survival. Imaging is used to monitor efficacy of the compounds in neurodegenerative diseases. Farnesyl dibenzodiazepinone compounds useful according to the invention can be used to reduce or prevent inflammation. Inflammation treatment is monitored as in Section VII above.<br class="style-scope patent-text">   In addition to the compounds of this invention, pharmaceutically acceptable derivatives or prodrugs of the compounds of this invention may also be employed in compositions to treat or prevent the above-identified disorders.<br class="style-scope patent-text">     A "pharmaceutically acceptable derivative or prodrug" means any pharmaceutically acceptable salt, ester, salt of an ester or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof. Particularly favored derivatives or prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species.<br class="style-scope patent-text">     Pharmaceutically acceptable prodrugs of the compounds of this invention include, without limitation, esters, amino acid esters, phosphate esters, metal salts and sulfonate esters.<br class="style-scope patent-text">Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.<br class="style-scope patent-text">     EXAMPLES<br class="style-scope patent-text">   Unless otherwise noted, all reagents were purchased from Sigma Chemical Co.<br class="style-scope patent-text">(St. Louis, MO), Aldrich.<br class="style-scope patent-text">     All NMR spectra were collected in deuterated solvent on a Varian 500T""<br class="style-scope patent-text"> Spectrometer ('H NMR at 500 MHz,'3C NMR at 125 MHz). UV and mass spectra were collected by Waters 2690T"~ HPLC using a photodiode array detector (PDA, 210-400nm) coupled to a Waters MicromassT"" ZQTM mass detector.<br class="style-scope patent-text">     EXAMPLE 1: PREPARATION OF PRODUCTION CULTURE<br class="style-scope patent-text">     Micromonospora spp. (deposit accession number IDAC 070303-01 ) was maintained on agar plates of ISP2 agar (Difco Laboratories, Detroit, MI). An inoculum for the production phase was prepared by transferring the surface growth of the Micromonospora spp. from the agar plates to 125-mL flasks containing 25 mL of sterile medium comprised of 24 g potato dextrin, 3 g beef extract, 5 g Bacto-casitone, 5 g glucose, 5 g yeast extract, and 4 g CaCOs made up to one liter with distilled water (pH<br class="style-scope patent-text">7.0). The culture was incubated at about 28C for approximately 60 hours on a rotary shaker set at 250 rpm. Following incubation, 10 mL of culture was transferred to a 2L<br class="style-scope patent-text">baffled flask containing 500 mL of sterile production medium containing 20 g/L <br class="style-scope patent-text">potato dextrin, 20 g/L glycerol, 10 g/L Fish meal, 5 g/L Bacto-peptone, 2 g/L CaC03, and 2 g/L<br class="style-scope patent-text">(NH4)2S04, pH 7 Fermentation broth was prepared by incubating the production culture at 28C in a rotary shaker set at 250 rpm for one week.<br class="style-scope patent-text">     Alternate procedure:<br class="style-scope patent-text"> The fermentation was accomplished as a 1 x 10L batch in a 14.5 L fermentor (BioFlo 110T"~ Fermentor, New Brunswick Scientific, Edison, NJ, USA) using an improved procedure described in CA patent application 2,466,340, filed January 21, 2004.<br class="style-scope patent-text">     Micromonospora sp. (deposit accession number IDAC 070303-01) was maintained on agar plates of ISP2 agar (Difco Laboratories, Detroit, MI). An inoculum for the production phase was prepared by transferring the surface growth of the Micromonospora sp. from the agar plates to 2-L flasks containing 500 mL of sterile medium comprised of 10 g glucose, 20 g potato dextrin, 5 g yeast extract, 5 g NZ-Amine A, and 1 g CaC03 made up to one liter with tap water (pH 7.0). The culture was incubated at about 28C for approximately 70 hours on a rotary shaker set at 250 rpm.<br class="style-scope patent-text"> Following incubation, 300 mL of culture was transferred to a 14.5 L fermentor containing 10 L of sterile production medium. Each liter of production medium was composed of 20 g potato dextrin, 30 g glycerol, 2.5 g Bacto-peptone, 8.34 g yeast extract, 0.3 mL Silicone defoamer oil CChem Service), 0.05 ml Proflo oilT"" <br class="style-scope patent-text">(Traders protein) and 3 g CaC03 made to one liter with distilled water and adjusted to pH 7<br class="style-scope patent-text">The culture was incubated at 28 C, with dissolved oxygen (d02) controlled at 25% in a cascade loop with agitation varied between 150-450 RPM and aeration set at a fixed rate of 0.5 V/V/M.<br class="style-scope patent-text">Other preferred media for the production of Compound 1 by fermentation are provided in Table 1. <br class="style-scope patent-text"> <br class="style-scope patent-text"> EXAMPLE 2: ISOLATION OF COMPOUND 1 500 mL ethyl acetate was added to 500 mL of fermentation broth prepared as described in Example 1 above. The mixture was agitated for 30 minutes on an orbital shaker at 200 rpm to create an emulsion. The phases were separated by centrifugation and decantation. Between 4 and 5 g of anhydrous MgS04 was added to the organic phase, which was then filtered and the solvents removed in vacuo.<br class="style-scope patent-text">An ethyl acetate extract from 2 L fermentation was mixed with HP-20 resin (100 mL; Mitsubishi Casei Corp., Tokyo, Japan) in water (300 mL). Ethyl acetate was removed in vacuo, the resin was filtered on a Buchner funnel and the filtrate was discarded. The adsorbed HP-20 resin was then washed successively with 2 x 125 mL<br class="style-scope patent-text">of 50% acetonitrile in water, 2x125 mL of 75% acetonitrile in water and 2 x 125 mL of acetonitrile.<br class="style-scope patent-text">     Fractions containing Compound 1 were evaporated to dryness and 100 mg was digested in the 5 mL of the upper phase of a mixture prepared from chloroform, cyclohexane, methanol, and water in the ratios, by volume, of 5:2:10:5. The sample was subjected to centrifugal partition chromatography using a High Speed Countercurrent (HSCC) system (Kromaton Technologies, Angers, France) fitted with a 200 mL cartridge and prepacked with the upper phase of this two-phase system. <br class="style-scope patent-text">The HSCC was run with the lower phase mobile and Compound 1 was eluted at approximately one-half column volume. Fractions were collected and Compound 1 was detected by TLC of aliquots of the fractions on commercial Kieselgel 60F2sa plates.<br class="style-scope patent-text">Compound could be visualized by inspection of dried plates under UV light or by spraying the plates with a spray containing vanillin (0.75%) and concentrated sulfuric acid (1.5%, v/v) in ethanol and subsequently heating the plate. Fractions contained substantially pure Compound 1, although highly colored. A buff-colored sample could be obtained by chromatography on HPLC as follows. </div>
      <div class="description-paragraph style-scope patent-text">6 mg of sample was dissolved in acetonitrile and injected onto a preparative HPLC column (XTerra ODS (l0pm), 19x150mm, Waters Co., Milford, MA), with a 9 mUmin flow rate and UV peak detection at 300 nm. The column was eluted with acetonitrile/buffer (5 mM of NH4HC03) according to the following gradient shown in Table 2.<br class="style-scope patent-text">     Table 2 Time min         Water %         Acetonitrile 0                50              _ 0               _ Fractions containing the Compound 1 were combined, concentrated and lyophilized to give a yield of 3.8 mg compound.<br class="style-scope patent-text">     Alternative Protocol 1 Compound 1 was also isolated using the following alternative protocol. At the end of the incubation period, the fermentation broth from the baffled flasks of Example 1 was centrifuged and the supernatant decanted from the pellet containing the bacterial mycelia. 100 mL of 100% MeOH was added to the mycelial pellet and the sample was stirred for 10 minutes and centrifuged for 15 minutes. The methanolic supernatant was decanted and saved. 100 mL of acetone was then added to the mycelial pellet and stirred for 10 minutes then centrifuged for 15 minutes. The acetonic supernatant was decanted and combined with the methanolic supernatant. Finally, 100 mL of 20%<br class="style-scope patent-text">MeOH/H20 was added to the mycelial pellet, stirred for 10 minutes and centrifuged for 15 minutes. The supernatant was combined with the acetonic and methanolic supernatants.<br class="style-scope patent-text">     The combined supernatant was added to 400 ml of HP-20 resin in 1000 mL of water and the organics were removed in vacuo. The resulting slurry was filtered on a Buchner funnel and the filtrate was discarded. Adsorbed HP-20 resin was washed successively with 2x500mL of 50% MeOH/H20, 2x500mL of 75% MeOH/H20 and 2x500mL of MeOH.<br class="style-scope patent-text">     The individual washes were collected separately and analyzed by TLC as described above. Those fractions containing Compound 1 were evaporated to near dryness and lyophilized. The lyophilizate was dissolved in methanol and injected onto a preparative HPLC column (Xterra ODS (10~,m), 19x150mm, Waters Co., Milford, MA) with a flow rate of 9 mUmin and peak detection at 300 nm.<br class="style-scope patent-text"> The column was eluted with acetonitrile/buffer (5 mM of NH4HC03) according to gradient shown in Table 3.<br class="style-scope patent-text">Teble 3 Time min        Buffer %        Acetonitrile Fractions containing Compound 1 were combined, concentrated and lyophilized to yield about 33.7 mg of compound.<br class="style-scope patent-text">     Alternative Protocol 2 liters of the whole broth from Example 1 are extracted twice with equal volumes of ethyl acetate and the two extracts are combined and concentrated to dryness. The dried extract is weighed, and for every gram of dry extract, 100 mL of MeOH-H20 (2:1 v/v) and 100 mL of hexane is added. The mixture is swirled gently but well to achieve dissolution. The two layers are separated and the aqueous layer is washed with 100 mL of hexane. The two hexane layers are combined and the combined hexane solution is washed with 100 mL methanol:water (2:1, v/v). The two methanol:water layers are combined and treated with 200 mL of EtOAc and 400 mL <br class="style-scope patent-text">of water. The layers are separated and the aqueous layer is extracted twice more with 200 mL portions of EtOAc. The EtOAc layers are combined and concentrated. The residue obtained will be suitable for final purification, either by HSCC or by HPLC as described above. This extraction process achieves a ten-fold purification when compared with the extraction protocol used above. <br class="style-scope patent-text"> <br class="style-scope patent-text"> EXAMPLE 3: ELUCIDATION OF THE STRUCTURE OF COMPOUND 1 1" 2" 3"<br class="style-scope patent-text">     O<br class="style-scope patent-text">1' 2 ~1 a 11 1N 2~3, 4. 5, g~~, g~ 9, 1 ~ ~<br class="style-scope patent-text">~4a 4 5N C28H34N2~4 Mol. Wt.: 462.58 H<br class="style-scope patent-text">  The structure of Compound 1 (ECO-4601 ) was derived from spectroscopic data, including mass, UV, and NMR spectroscopy. Mass was determined by electrospray mass spectrometry to be 462.6, UVmax 230nm with a shoulder at 290 nm. Mass data confirmed a calculated molecular weight of 462.58 and a molecular formula of C28H34N2O4. NMR data were collected dissolved in MeOH-d4 including proton (Figure 1 ), and multidimensional pulse sequences gDQCOSY, gHSQC, gHMBC, and NOESY.<br class="style-scope patent-text">A number of cross peaks in the 2D spectra of ECO-4601 are key in the structural determination. For example, the farnesyl chain is placed on the amide nitrogen by a strong cross peak between the proton signal of the terminal methylene of that chain at 4.52 ppm and the amide carbonyl carbon at 170 ppm in the gHMBC experiment. <br class="style-scope patent-text">This conclusion is confirmed by a cross peak in the NOESY spectrum between the same methylene signals at 4.52 ppm and the aromatic proton signal at 6.25 ppm from one of the two protons of the tetra substituted benzenoid ring. Assignement of proton and carbon signals are shown in Table 4.<br class="style-scope patent-text">     Based on the mass, UV and NMR spectroscopy data, the structure of the compound was determined to be the structure of Compound 1 shown above.<br class="style-scope patent-text">     Table 4 'H and'3C   NMR (8H, ppm) Data of Compound 1 in MeOH-D4 Assignment 'H '3C Group 1           7.15 122.3 CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 1 a         - 125.0 C <br class="style-scope patent-text"> <br class="style-scope patent-text"> 2           6.74 121.0 CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> Table 4 'H and'3C                           <br class="style-scope patent-text">     NMR (8H, ppm) Data of Compound 1 in MeOH-D4 Assignment'H           '3C          Group 3         6.83         116.9        CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 4         -            146.0        C-OH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 4a        -            142.0        C <br class="style-scope patent-text"> <br class="style-scope patent-text"> 6         -            153.0  C-OH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 6a        -            126.0        C </div>
      <div class="description-paragraph style-scope patent-text">7         6.20         100.0     CH </div>
      <div class="description-paragraph style-scope patent-text">8         -            148.2        C-OH </div>
      <div class="description-paragraph style-scope patent-text">9         6.25         100.1        CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 9a        -            135.0        C <br class="style-scope patent-text"> <br class="style-scope patent-text"> 11        -            170.0        C(O) 1'        4.52         48.7         CH2 2'        5.35  i 21.1       CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 3'        -            138.5        C <br class="style-scope patent-text"> <br class="style-scope patent-text"> 4'        1.95   39.6         CH2 5'        2.02         26.7         CHz 6'        5.09       124.1        CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> T         -            135.0        C <br class="style-scope patent-text"> <br class="style-scope patent-text"> 8'        2.03         39.5         CH2 9'        2.08         26.3         CH2 10'    5.06         124.4        CH </div>
      <div class="description-paragraph style-scope patent-text">11'       -            130.9        C </div>
      <div class="description-paragraph style-scope patent-text">12'     1.55         16.5         CH3 1"        1.72         15.5         CH3 2"        1.59         14.9         CH3 3"        1.64         24.8         CH3 EXAMPLE 4: SYNTHESIS AND ELUCIDATION OF COMPOUND 2 Compound 2, namely 10-Farnesyl-4,6,8-trihydroxy-5-methyl-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one, was prepared and identified as follows:<br class="style-scope patent-text"> <br class="style-scope patent-text">.~ ,2~ <br class="style-scope patent-text"> <br class="style-scope patent-text"> Preparation:<br class="style-scope patent-text">     Compound 1 (61.3 mg) was stirred overnight with NaHCOs (60.9 mg, Aldrich) and dimethyl sulfate (360 NI, Sigma) in MeOH (3.0 mL). The resulting mixture was filter through a 0.45 Nm 13 mm Acrodisc GHP syringe filter and subjected to HPLC<br class="style-scope patent-text">separation. Purification by multiple injection on a Waters RCM Nova-Pak HR C18 6Nm 60A 25 x 200 mm column (20 mUmin H20/CH3CN 80:30-70:75, 0-8 min; 30:70-0:100, 8-18 min) gave Compound 2 (37.5 mg) with retention time of 13.5 min.<br class="style-scope patent-text">     Compounds 60 to 76 are also prepared via this procedure, by reaction of Compound 1 with the appropriate dialkyl sulfate.<br class="style-scope patent-text">     Structure elucidation:<br class="style-scope patent-text">     The calculated molecular weight (476.61 ) and formula (C29HssN20a) of Compound 2 was confirmed by mass spectral analysis: negative ionization gave an (M-H)~ molecular ion of 475.55 and positive ionization gave an (M+Na)+ molecular ion of 499.35. Proton NMR spectral analysis is shown in Table 5. Signals were easily assigned based on Compound 1 structure knowledge.<br class="style-scope patent-text">     Table 5 'H NMR (8H, ppm) Data of Compound 2 in MeOH-D4 Assignment     Compound 2     Group 1              7.21           CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 2              7.12           CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 3              7.01           CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 2.92        N-CH3 7              6.22           CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 9              6.34 CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 1'             4.82, 4.58     CH2 2'             5.44           C H <br class="style-scope patent-text"> <br class="style-scope patent-text"> 4' a           1.94           CHz 5' a           2.06           CHZ <br class="style-scope patent-text"> <br class="style-scope patent-text"> 6'     5.07           CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 8' a           2.03           CH2 9' a           2.11           CHZ <br class="style-scope patent-text"> <br class="style-scope patent-text"> 10'            5.07           CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> Table 5 'H NMR (8H, ppm) Data of Compound 2 in MeOH-D4 Assignment Compound 2 Group 12' 1.54 CH3 1" 1.76 CH3 2" 1.59 CH3 3" 1.64 CH3 a. Signals at 4', 5', 8' and 9' are very close; assignement was based on Compound 1 EXAMPLE 5: SYNTHESIS AND ELUCIDATION OF COMPOUND 3 1.<br class="style-scope patent-text">11 10 2~3, 4~ 5. 6~~, g' 9 1 ~ ~, 12' \a ~N<br class="style-scope patent-text">9a 9 ~4a ~ ~ B OH<br class="style-scope patent-text">4 5 N 6a C3sHaoN2~a off J1~' ~ Mol. Wt.: 552.70 2~'~<br class="style-scope patent-text">3"' Compound 3, namely 5-Benzyl-10-farnesyl-4,6,8-trihydroxy-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one was prepared and identified as follows:<br class="style-scope patent-text">     Preparation:<br class="style-scope patent-text">Compound 1 (60.5 mg) was stirred 84 hrs with benzyl chloride (1.8 mL, Sigma) in presence of two drops of pyridine (Aldrich). The resulting mixture was directly subjected to HPLC separation. Purification by multiple injection on a Waters RCM Nova-Pak HR<br class="style-scope patent-text">     C18 6Nm 60A 25 x 200 mm column (20 mL/min H20/CH3CN 80:30-70:75, 0-8 min;<br class="style-scope patent-text">30:70-0:100, 8-18 min) gave Compound 3 (46.0 mg) with retention time of 17.5 min.<br class="style-scope patent-text">     Compounds 60 to 76 are also prepared via this procedure, by reaction of Compound 1 with the appropriate alkyl halide.<br class="style-scope patent-text">     Structure elucidation:<br class="style-scope patent-text">     The calculated molecular weight (552.70) and formula (C~H~N204) of Compound 3 was confirmed by mass spectral analysis: negative ionization gave an (M-H)- molecular ion of 551.65 and positive ionization gave an (M+Na)+ molecular ion of 575.45. Proton NMR spectral analysis is shown in Table 6. Signals were easily assigned based on Compound 1 structure knowledge.<br class="style-scope patent-text">     Table 6 'H NMR (8H, ppm) Data of Compound 3 in MeOH-D4 Assignment     Compound 3    Group 1              7.19           CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 2              7.09           CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 3              6.96           CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 7              6.16           CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 9       6.31           CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 1'             4.55, 4.48     CH2 2'             5.44           CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 4' a           1.94           CH2 5' a           2.08    CH2 6'             5.10           CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 8' a           2.01           CHZ <br class="style-scope patent-text"> <br class="style-scope patent-text"> 9' a           2.13           CH2 10'            5.04           CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 12'       1.52           CH3 1 "            1.79           CH3 2"             1.56           CH3 3"             1.64           CH3 1 "'           4.34, 4.25     CH2 3"'            7.20           CH (2H) 4"'            7.23  CH (2H) 5"'            7.23           CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> a. Signals at 4', 5', 8' and 9' are very close; assignement was based on Compound 1 EXAMPLE 6: SYNTHESIS AND ELUCIDATION OF COMPOUNDS 4. 5L6. 7 AND 8 1" ~ 2..<br class="style-scope patent-text"> <br class="style-scope patent-text">2~3' 4' S' ~ T 8' 9. 1 X11' 12' g                           4-OMe6-OH8-OH<br class="style-scope patent-text">~       <br class="style-scope patent-text">~                                    <br class="style-scope patent-text">~   <br class="style-scope patent-text">\                                    <br class="style-scope patent-text"> <br class="style-scope patent-text">x Compound 4:                                    <br class="style-scope patent-text"> <br class="style-scope patent-text"> a N Compound 5:          4-OH 6-OMe8-OH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 4-OH,6-OMe8-OMe a Compound 6:                      <br class="style-scope patent-text"> <br class="style-scope patent-text"> x  6 7 Compound 7:     4-OMe6-OMe8-OH <br class="style-scope patent-text"> <br class="style-scope patent-text"> Compound                         4-OMe6-OMe8-OMe 8:                                  <br class="style-scope patent-text"> <br class="style-scope patent-text"> x Monomethylated: Compounds 4 and 5: 10-Farnesyl-6,8-dihydroxy-4-methoxy-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one and 10-Farnesyl-4,8-dihydroxy-6-methoxy-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one, have a calculated molecular weight of 476.61 g/mol and a formula of C2sHssN204.<br class="style-scope patent-text">    Dimethylated: Compounds 6 and 7: 10-Farnesyl-4-hydroxy-6,8-dimethoxy-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one and 10-Farnesyl-8-hydroxy-4,6-dimethoxy-5,10-dihydro-dibenzo(b,e][1,4]diazepin-11-one, have a calculated molecular weight of 490.63 g/mol and a formula of C3oH38N204.<br class="style-scope patent-text">     Trimethylated: Compound 8: 10-Farnesyl-4,6,8-trimethoxy-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one, has a calculated molecular weight of 504.66 g/mol and a formula of C3, H4oN204.<br class="style-scope patent-text"> All 0-methylated compounds (4 to 8) were prepared and identified according to the following procedure:<br class="style-scope patent-text">     Preparation:<br class="style-scope patent-text">     Compound 1 (20.0 mg) in MeOH (2.0 mL) was treated with excess of CH2N2 in diethyl ether and the mixture stirred overnight. The resulting mixture was separated by preparative TLC (Merck Silica gel 60 F254), using 2.5% MeOH in CHC13 as eluent. A<br class="style-scope patent-text">mixture of Compounds 4 and 5 (1.0 mg), Compound 6 (0.5 mg), Compound 7 (5.5 mg) and Compound 8 (3.0 mg) were isolated with Rf value of 0.09, 0.35, 0.39 and 0.92 respectively.<br class="style-scope patent-text">     Structure elucidation The calculated molecular weights (mono: 476.61, di: 490.63 and tri: 504.66) and formulae (mono: C29H36N2O4, di: C~oH~N204 and tri: C3lH~oN2O4) respectively of mono methylated (Compounds 4 and 5), dimethylated (Compounds 6 and 7) and trimetylated (Compound 8) were confirmed by mass spectral (MS) analysis. Compounds 4 and 5 MS gave a (M-H)- molecular ion of 475.45 by negative ionization and a (M+Na)+<br class="style-scope patent-text">molecular ion of 499.35 by positive ionization. Compound 6 MS gave a (M-H)-molecular ion of 489.45 by negative ionization and a (M+Na)+ molecular ion of 513.35 by positive ionization. Compound 7 MS gave a (M-H)- molecular ion of 489.45 by negative ionization and a (M+Na)+ molecular ion of 513.35 by positive ionization.<br class="style-scope patent-text"> Compound 8 gave a (M-H)- molecular ion of 503.55 by negative ionization and a (M+Na)+ molecular ion of 527.35 by positive ionization. Proton NMR spectral analysis for Compounds 4 to 8 is shown in Table 7. Signals were easily assigned based on Compound 1 structure knowledge.<br class="style-scope patent-text">     Table 7 'H NMR (SH, ppm) Data of Compounds 4, 5, 6, 7 and 8 in MeOH-D4 Assignment 4       5     6        7        8       Group 1          7.28    7.17     7.19     7.28     7.29    CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 2          6.91    6.78     6.86     6.92     6.92    CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 3        7.03    6.86     6.79     7.03     7.03    CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 4          3.94    N/D    N/D      3.93     3.94    C-X a N/D     N/D      N/D      N/D      6.95    NH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 6          N/D     3.87     3.91     3.87     3.89    C-X b 7    6.28    6.23     6.46     6.33     6.45    CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 8          N/D     N/D      3.75     N/D      3.74    C-X <br class="style-scope patent-text"> <br class="style-scope patent-text"> 9          6.38    6.34     6.52     6.38     6.57    CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 1'         4.56    4.56     4.61     4.57     4.60    CH2 2'  5.36    5.36     5.38     5.34     5.31    CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 4' d       1.96    1.96     1.95     1.95     1.93    CH2 5' d       2.05    2.05     2.05     2.05     2.04    CHZ <br class="style-scope patent-text"> <br class="style-scope patent-text"> 6'         5.09    5.09     5.07     5.08     5.06    CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 8' d       2.04    2.04     2.04     2.04     2.03    CH2 9' d       2.10    2.10     2.09     2.09     2.08    CHZ <br class="style-scope patent-text"> <br class="style-scope patent-text"> 10'        5.09    5.09     5.07     5.08     5.06   CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 12'        1.57    1.57     1.55     1.57     1.55    CH3 1 "        1.74    1.74     1.75     1.73     1.73    CH3 2"         1.60    1.60     1.60     1.59     1.59    CH3 3"         1.66    1.66     1.65     1.66     1.65  CH3 N/D: Not determined - not observed a. X is OCH3 in Compounds 4, 7 and 8; X is OH in Compounds 5 and 6 b. X is OCH3 in Compounds 5, 6, 7 and 8; X is OH in Compound 4 c. X is OCH3 in Compounds 6 and 8; X is OH in Compounds 4, 5 and 7 d. Signals at 4', 5', 8' and 9' are very close; assignement was based on Compound 1 EXAMPLE 7: SYNTHESIS AND ELUCIDATION OF COMPOUNDS 9. 10. 11 AND 12 2~ 3' a~ 5~~~9'~ 1~~ 2~<br class="style-scope patent-text"> <br class="style-scope patent-text"> P<br class="style-scope patent-text">x ~aa ~ ~ ~ x Compound 9: 4-OH 6-OAc 8-OAc a 5N sa~ Compound 10: 4-OAc 6-OAc 8-OH<br class="style-scope patent-text">x ~~g-=--'~ Compound 11: 4-OAc 6-OH 8-OAc Com ound 12: 4-OAc 6-OAc 8-OAc Diacetylated: Compounds 9, 10 and 11: 6,8-Diacetoxy-10-farnesyl-4-hydroxy-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one; 4,6-Diacetoxy-10-farnesyl-8-hydroxy-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one and 4,8-Diacetoxy-10-farnesyl-6-hydroxy-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one, have a  calculated molecular weight of 546.65 g/mol and a formula of Cs2H38N20s.<br class="style-scope patent-text">Triacetylated: Compound 12: 4,6,8-Triacetoxy-10-farnesyl-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one, has a calculated molecular weight of 588.69 g/mol and a formula of C34HaoN2~~.<br class="style-scope patent-text"> All acetylated compounds (9 to 12), were prepared and identified according to the following procedure:<br class="style-scope patent-text">     Preparation:<br class="style-scope patent-text">    Compound 1 (120.5 mg) was stirred overnight with acetic anhydride (720 NL, Aldrich) in presence of 6 drops of pyridine (Aldrich). The reaction mixtures submitted to HPLC separation. Purification by multiple injection on a Waters RCM Nova-Pak HRT""<br class="style-scope patent-text">    C18, 6Nm, 60A 25 x 200 mm column (20 mUmin H20/CH3CN 80:30-70:75, 0-8 min;<br class="style-scope patent-text">30:70-0:100, 8-18 min and HPLC run for 20 min) gave Compound 11 (11.4 mg), Compound 10 (9.2 mg), Compound 9 (11.4 mg), Compound 12 (91.2 mg) with retention time of 16.2, 17.6, 18.0 and 18.5 min, respectively.<br class="style-scope patent-text">     Structure elucidation:<br class="style-scope patent-text">The calculated molecular weights (di: 546.65 and tri: 588.69) and formulae (di:<br class="style-scope patent-text">C32H38N206 and tri: C34H40N2O7) respectively of diacetylated (Compounds 9, 10 and 11 ) and triacetylated (Compound 12) were confirmed by mass spectral (MS) analysis. <br class="style-scope patent-text"> <br class="style-scope patent-text"> Compound 9 MS gave a (M-H)- molecular ion of 545.55 by negative ionization and a (M+Na)+ molecular ion of 569.35 by positive ionization. Compound 10 MS gave a (M-H)-molecular ion of 545.55 by negative ionization and a (M+Na)+ molecular ion of 569.45 by positive ionization. Compound 11 MS gave a (M-H)- molecular ion of 545.45 by negative ionization and a (M+Na)+ molecular ion of 569.35 by positive ionization.<br class="style-scope patent-text">Compound 12 gave a (M-H)- molecular ion of 587.55 by negative ionization and a (M+Na)+ molecular ion of 611.45 by positive ionization. Proton NMR spectral analysis for Compounds 9 to 12 is shown in Table 8. Signals were easily assigned based on Compound 1 structure knowledge.<br class="style-scope patent-text">     Table 8 'H NMR (8H, ppm) Data of Compounds 9, 10, 11 and 12 in CDCI3 Assignment  9        10        11         12        Group 1           7.27     7.72      7.75       7.75      CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 2      6.67     6.99      7.02       7.10      CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 3           6.67     7.15  7.15       7.16      CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 4           N/D      2.42      2.42       2.41      C-X a 6.45     5.90      6.29       6.15      NH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 6           2.36     2.41    N/D        2.40      C-X b 7           6.82     6.52      6.15       6.96     CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 8           2.28     N/D       2.25       2.27      C-X <br class="style-scope patent-text"> <br class="style-scope patent-text"> 9           6.95     6.67      6.55       6.84      CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 1'          4.60     4.57      4.57       4.58      CH2 2'          5.43     5.38      5.41       5.42      CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 4' d        1.98     1.97      1.98       1.98      CH2 5' d        2.08     2.06      2.05       2.06      CHZ <br class="style-scope patent-text"> <br class="style-scope patent-text"> 6'          5.10     5.09      5.09       5.10      CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 8' d        2.08     2.06      2.05       2.06      CH2 9' d   2.09     2.08      2.09       2.09      CH2 10'         5.10     5.09      5.09       5.10      CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 12'         1.60     1.60      1.60       1.60      CH3 1 "         1.72     1.70      1.71       1.72      CH3 2"          1.61   1.60      1.60       1.61      CH3 3"          1.69     1.69      1.69  1.68      CH3 N/D: Not determined - not observed a. X is OAc in Compounds 10, 11 and 12; X is OH in Compound 9 b. X is OAc in Compounds 9, 10 and 12; X is OH in Compound 11 c. X is OAc in Compounds 9, 11 and 12; X is OH in Compound 10 d. Signals at 4', 5', 8' and 9' are very close; assignement was based on Compound 1 EXAMPLE 8: FARNESYL SIDE CHAIN MODIFICATIONS<br class="style-scope patent-text">8.1 S~inthesis and elucidation of Compound 46 i1" i 1' 2' 3, 4. 5, g' ~, g' g, 10' 11 N<br class="style-scope patent-text">9a g ----- C28H40N2~4 ~h H ~ Mol. Wt.: 468.63 Compound 46: 10-(3,7,11-trimethyldodecanyl)-4,6,8-trihydroxy-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one.<br class="style-scope patent-text"> Hexahydro Compound 46, was prepared and identified according to the following procedure:<br class="style-scope patent-text">     Preparation:<br class="style-scope patent-text">     A solution of Compound 1 (51.1 mg in 3.0 mL MeOH) was stirred under hydrogen gas overnight in presence of platinum oxide (Pt02,10 mg) as a catalyst. The reaction mixture was filtered and purified by direct preparative HPLC using Phenomenex MAX PR 21.2 x 200 mm column (20 mUmin, H20/CH3CN gradient 30:70-30:70, 0-2 min; 30:70-0:100, 2-20 min). Fractions having a retention time of 12.8 min were combined to give 45.2 mg of Compound 46.<br class="style-scope patent-text">     Structure elucidation:<br class="style-scope patent-text"> Calculated molecular weight (468.63) and formulae (C2sH4oN2O4) were confirmed by mass spectral analysis. Compound 46 mass spectra gave a (M-H)- molecular ion of 467.35 by negative ionization and a (M+H)+ molecular ion of 469.43 by positive ionization. Proton NMR spectral analysis of Compound 46 is shown in Table 9. <br class="style-scope patent-text">Signals were easily assigned based on Compound 1 structure knowledge. As expected, aliphatic proton signals at positions 1'-11' all have very close chemical shifts ranging from about 1 to 1.75 ppm (integrating for 19 protons), methyl protons at positions 12' and 1 "-3" are all very close as well (shifts 0.8-0.95 ppm, integrating for 12 protons).<br class="style-scope patent-text">These signals are also complex from the fact that 4 diastereomers of positions 3', 7 and 11' are present in the mixture, and in different proportions. Labile protons were not observed since NMR was done in deuterated methanol.<br class="style-scope patent-text">     Table 9 'H NMR (8H, ppm) Data of Compound 46 in CD30D      <br class="style-scope patent-text"> <br class="style-scope patent-text"> Assignment    8H, ppm    Group 1             7.15       CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 2          6.76       CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 3             6.84       CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 7             6.24 CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 9             6.26       CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 1'-11' a      - 1.00-1.753CH, 8CH2 (19H) 12' and 1"-3" -- 0.8-0.954CH3 (12H) a a. Signals are very close 8.2 Synthesis and elucidation of Com,nounds 17 and 18 1" 2" 3"<br class="style-scope patent-text">1' 2~ 4' S' 6' $' g' 1 ~ 12' -~~OH<br class="style-scope patent-text">     C28H34N2~5 Mol. Wt.: 478.58 I' Ho Compound 17 1" 2" 3"<br class="style-scope patent-text">1' 2~ 4' S' 6~ 8' 9. 10' 12' -~~OH<br class="style-scope patent-text">     C28H34N2~5 Mol. Wt.: 478.58 Compound 18 Compound 17: 10-(3,7,11-trimethyl-6,7-epoxydodeca-2,10-dienyl)-4,6,8-trihydroxy-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one.<br class="style-scope patent-text">     Compound 18: 10-(3,7,11-trimethyl-10,11-epoxydodeca-2,10-dienyl)-4,6,8-trihydroxy-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one.<br class="style-scope patent-text">    Monoepoxide Compounds 17 and 18, were prepared and identified according to the following procedure:<br class="style-scope patent-text">     Preparation:<br class="style-scope patent-text">     A mixture of Compound 1 (24.0 mg) and 3-chloroperbenzoic acid (mCPBA, 7.8 mg) in THF (1.0 mL) were stirred overnight at room temperature. The reaction mixture was diluted with MeOH (1.0 mL) and subjected to purification on Waters HPLC <br class="style-scope patent-text">using a Photodiode Array detector. The mixture was purified by multiple injections on a Nova PackT"" C-18 25 x 200 mm column (20 mUmin, H20/CH3CN gradient 80:20-30:70, 0-8 min; 30:70-0:100, 8-20 min). Pure Compound 17 (2.11 mg) and Compound 18 (1.68 mg) were obtained by concentration in vacuo of the combined fractions respectively having retention time 11.2 min and 10.6 min.<br class="style-scope patent-text">     Structure elucidation:<br class="style-scope patent-text">     Calculated molecular weights (478.58) and formulae (C2sH~N205) were confirmed by mass spectral analysis. Compound 17 mass spectra gave a (M-H)-molecular ion of 477.34 by negative ionization and a (M+H)+ molecular ion of 479.44 by positive ionization. Compound 18 mass spectra gave a (M-H)- molecular ion of 477.34 by negative ionization and a (M+H)+ molecular ion of 479.40 by positive ionization.<br class="style-scope patent-text">Proton NMR spectral analysis of Compounds 17 and 18 is shown in Table 10. <br class="style-scope patent-text">Signals were easily assigned based on Compound 1 structure knowledge. As expected, epoxide protons signals were shifted upfield, compared to the alkene protons of Compound 1 (from 5.09 to 2.75 ppm for Compound 17, and from 5.06 to 2.73 ppm for Compound 18). Labile protons were not observed since NMR was done in deuterated methanol.<br class="style-scope patent-text">    Table 10 'H NMR (8H, ppm) Data of Compounds 17 and 18 in CD30D                             <br class="style-scope patent-text"> <br class="style-scope patent-text"> Assignment Compound 17  Compound 18    Group 1          7.17         7.18           CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 2    6.77         6.77           CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 3          6.85         6.86           CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 7          6.22         6.23           CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 9          6.27         6.27    CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 1'         4.61, 4.54   4.55           CHz 2'         5.42         5.37           CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 4'         2.17         2.08 a         CH2 5'         1.62, 1.42   2.13 a         CH2 6'         2.75         5.16           CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 8'   1.62, 1.42   2.08 a         CH2 9'         2.09         1.60           CH2 10'        5.09         2.73           CH <br class="style-scope patent-text"> <br class="style-scope patent-text"> 12'        1.60         1.20     CH3 1 "        1.77         1.74           CH3 2"         1.26         1.64           CH3 3"         1.67         1.26           CH3 a. Signals are very close, and are interchangeable EXAMPLE 9: PHARMACOLOGICAL ACTIVITY PROFILE<br class="style-scope patent-text">     Compound 1 and analogs of Compounds 1 referred to herein as Compounds 2 to 12 and Compound 46 were tested for binding against a variety of enzymes and/or receptors. These enzymes or receptor used for these assays were known to be involved in anticancer activity of known compounds, as well as other diseases. <br class="style-scope patent-text">Data were also compared to inhibition of GABAA Central Benzodiazepine Receptor, to show selectivity.<br class="style-scope patent-text">     A. Enzymes and Receptors:<br class="style-scope patent-text">5-Lipoxygenase (5-LO) catalyzes the oxidative metabolism of arachidonic acid to 5-hydroxyeicosatetraenoic acid (5-HETE), the initial reaction leading to formation of leukotrienes. Eicosanoids derived from arachidonic acid by the action of lipoxygenases or cycloxygenases have been found to be involved in acute and chronic inflammatory diseases (i.e. asthma, multiple sclerosis, rheumatoid arthritis, ischemia, edema) as well in neurodegeneration (Alzheimer disease), aging and various steps of carcinogenesis, including tumor promotion, progression and metastasis. The aim of this study was to determine whether ECO-4601, is able to block the formation of leukotrienes by inhibiting the enzymatic activity of human 5-LO.<br class="style-scope patent-text">AcyICoA-Cholesterol Acyltransferase, Hepatic (AcoA-AT) converts cholesterol to colesteryl esters and is involved in the development of artherioscerosis.<br class="style-scope patent-text">Cyclooxygenase (COX-2) enzyme is made only in response to injury or infection.<br class="style-scope patent-text">  It produces prostaglandins involved in inflammation and the immune response.<br class="style-scope patent-text">     Elevated levels of COX-2 in the body have been linked to cancer.<br class="style-scope patent-text">     The peripheral benzodiazepine receptor (PBR or PBenzR) is a well-characterized receptor known to be directly involved in diseases states. PBR <br class="style-scope patent-text">is involved in the regulation of immune responses. These diseases states include tumors, inflammatory diseases (such as rheumatoid arthritis and lupus), parasitic infections and neurodegenerative diseases (such as Alzheimer, Huntington and Multiple Sclerosis).<br class="style-scope patent-text">Leukotriene, Cysteinyl (CysLT~) is involved in inflammation and CysLTi-selective antagonists are used as treatment for bronchial asthma. CysLT, and 5-LO were found to be upregulated in colon cancer.<br class="style-scope patent-text">     GABAA Central Benzodiazepine Receptor (CBenzR or CBR) binding is involved in anxiolitic activities.<br class="style-scope patent-text">     B. General Procedures:<br class="style-scope patent-text">     The procedures used were based on known assays: AcoA-AT (from rat; Ref:<br class="style-scope patent-text">Largis et al (1989), J. Lipid. Res., vol 30, 681-689), COX-2 (human; Ref: <br class="style-scope patent-text">Riendeau et al (1997), Can. J. Physiol. Pharmacol., vol 75, 1088-1095 and Warner ef al (1999), Pro.<br class="style-scope patent-text">Natl. Acad Sci. USA, vol 96, 7563-7568), 5-LO (human; Ref: Carter et al (1991 ), J.<br class="style-scope patent-text">Pharmacol. Exp. Ther., vol 256, no 3, 929-937, and Safayhi et al (2000), Planta Medica, vol 66, 110-113), PBenzR (from rat; Le Fur et al (1983), Life Sci. USA, vol 33, 449-457), CvsLT, (human; Martin et al (2001 ), Biochem. Pharmacol., vol 62, no 9, 1193-1200) and CBenR (from rat; Damm et al (1978), Res. Comm. Chem. Pathol. Pharmacol., vol 22, 597-600 and Speth et al (1979), Life Sci., vol 24, 351-357).<br class="style-scope patent-text">     C. Binding assay of Compound 1 on 5-LO:<br class="style-scope patent-text">    Human peripheral blood mononuclear cells (PMNs) were isolated through a Ficoll-Paque density gradient. PMNs were stimulated by addition A23187 (30 NM <br class="style-scope patent-text">final concentration). Stimulated PMNs were adjusted to a density of 5 x106 cells/mL <br class="style-scope patent-text">in HBBS<br class="style-scope patent-text">medium and incubated with the vehicle control (DMSO), ECO-4601 (at final concentrations of 0.1, 0.5, 1, 2.5, 5 and 10 NM) and NDGA as positive control (at final concentrations of 3, 1, 0.3, 0.1 and 0.03 NM) for 15 minutes at 37C. <br class="style-scope patent-text">Following incubation, samples were neutralized with NaOH and centrifuged. Leukotriene B4 content was measured in the supernatant using an Enzyme Immunosorbant Assay (EIA) assay. The experiment was performed in triplicate.<br class="style-scope patent-text">Results shown in Figure 2 demonstrated that ECO-4601 inhibited the activity of human 5-LO with an apparent IC~o = 0.93 NM (versus 0.1 NM for the positive control NDGA) and therefore displays anti-inflammatory properties.<br class="style-scope patent-text">     D. Percentage inhibition or binding of Compound 1-12 and 46:<br class="style-scope patent-text">     Binding assays were done for each of Compounds 1-12 and 46 using AcoA-AT, COX-2, 5-LO, PBenzR and CysLTi enzymes. The procedures used are based on the respective references mentioned above and the conditions are summarized in Tables 11 (enzyme assays) and 12 (radioligand receptor assays).<br class="style-scope patent-text">     Table 11 Enzyme Assays Conditions Source Substrate Pre-I a I<br class="style-scope patent-text"> ACoA AT  Wistar rat hepatic 12.7 NM ['4C)palmitoyl CoA <br class="style-scope patent-text">l5min/37C l0min/37C<br class="style-scope patent-text">microsomes COX-2 d Human recombinant 0.3 uM arachidonic acid l5miN37C <br class="style-scope patent-text">5miN37C <br class="style-scope patent-text"> <br class="style-scope patent-text"> Table 11 Enzyme Assays Conditions Source Substrate Pre-I a I b insect Sf21 cells 5-LO a Human PBML cells Arachidonic acid l5miN37C l5miN37C<br class="style-scope patent-text">a. Pre-Incubation TimelTemperature b. Incubation Time/Temperature c. Incubation buffer: 0.2 M phosphate buffer (pH 7.4 at 25C); Method: <br class="style-scope patent-text">Quantitation of ['4C]cholesterol ester by column chromatography.<br class="style-scope patent-text">d. Incubation buffer: 100mM Tris-HCI, pH 7.7, 1mM glutathione, 1NM hematin, 500NM phenol;<br class="style-scope patent-text">     Method: EIA quantitation of PGE2.<br class="style-scope patent-text">e. Incubation buffer: HBSS (Hank's balanced salt solution); Method: EIA <br class="style-scope patent-text">quantitation of LTB4.<br class="style-scope patent-text">     Table 12 Radioligand Binding Assays Conditions a Source Ligand I b Non-spec ligand PBenzR  Wistar rat heart 0.3 nM [3H]PK-11195 l5min/25C <br class="style-scope patent-text">Dipyridamole f CysLT, d Human recombinant 0,3 nM [3H]leukotriene D4 30miN25C <br class="style-scope patent-text">Leukotriene D4 9 CHO-K1 cells CBenzR a Wistar rat brain 1 nM [3H]flunitrazepam 60min/25C <br class="style-scope patent-text">Diazepam "<br class="style-scope patent-text">a. Quantitation Method: Radioligand binding b. Incubation Time/Temperature c. Incubation buffer: 50mM Tris-HCI, pH 7.5, lOmM MgCl2 at 25C.<br class="style-scope patent-text">d. Incubation buffer: 50mM Tris-HCI, pH 7.4, 5mM CaCl2, 5mM MgCl2, 100NglmL <br class="style-scope patent-text">bacitracin, 1mM<br class="style-scope patent-text">bezamidine, 0.1 mM PMSF.<br class="style-scope patent-text">e. Incubation buffer: 50mM Na-K phosphate, pH 7.4 at 25C.<br class="style-scope patent-text">f. Non specific ligand: 100NM, Kp: 2.3nM, 8",a,~: 0.17 pmoUmg protein, Specific binding: 90%<br class="style-scope patent-text">g. Non specific ligand: 0.3NM, Kp: 0.21 nM, Bm~: 3 pmol/mg protein, Specific binding: 93%<br class="style-scope patent-text">h. Non specific ligand: 10NM, Kp: 4.4nM, Bmax~ 1.2 pmol/mg protein, Specific binding: 91 Binding Assays were done at constant concentration of the compound, in 1 DMSO as vehicle, and are specified below each enzyme/receptor type in Table 13. The results are expressed in Table 13 as percentage inhibition. Significance was obtained when a result was ?50% binding or inhibition (underlined).<br class="style-scope patent-text">     Table 13 Percentage of inhibition or binding activity Compound ACoA-AT COX-2 5-LO PBenzR CysLT, CbenzR<br class="style-scope patent-text">(10 NM) (4 NM) (4 NM) (1 NM) (4 NM) (10 NM) 1 90 9~ 99 80 92 39 Table 13 Percentage of inhibition or binding activity ACoA-AT   COX-2    5-LO     PBenzR    CysLT,   CbenzR <br class="style-scope patent-text"> <br class="style-scope patent-text"> Compound  (10 NM)   (4 NM)   (4 NM)   (1 NM)    (4 NM)   (10 NM) All of the exemplified Compounds 1-12 and 46 possessed inhibition and/or binding activity. None of them significantly binded the central benzodiazepine receptor (CBenzR), which showed selectivity was present.<br class="style-scope patent-text">     Cytotoxic activity (Gl5o) of these compounds are shown in Example 10.<br class="style-scope patent-text">     EXAMPLE 10. IN VITRO CYTOTOXIC ACTIVITY OF COMPOUNDS 1-12 AND 46 Cytotoxic activities were determined in vitro for exemplified Compounds 1-12 and 46 to determine the concentration of each compound needed to obtain a 50% <br class="style-scope patent-text">inhibition of cell proliferation (GlSO). The GlSO value emphasizes the correction for the cell count at time zero and, using the seven absorbance measurements [time zero, (Tz), control growth, (C), and test growth in the presence of drug at the five concentration levels (Ti)], Gl5o is calculated as [(Ti-Tz)/(C-Tz)] x 100 = -50, which is the drug concentration resulting in a 50% reduction in the net DNA increase in control cells during the drug incubation.<br class="style-scope patent-text"> Compounds were tested in four cell lines: HT-29 (colorectal carcinoma), SF268 (CNS), MDA (mammary gland adenocarcinoma) and PC-3 (prostate adenocarcinoma).<br class="style-scope patent-text">Compounds were dissolved at 10 mM in DMSO. Dilution in vehicle to concentrations of 30, 10, 3, 1 and 0.3 NM were prepared immediately before assays.<br class="style-scope patent-text">Depending on the cell lines growth characteristics, 4000-i 0000 cells were plated in two 96-wells pates (day 0) and incubated for i 6 hours. The following day, propidium iodide ws added to one of the two plates and fluorescence measured (Tz). Test compounds were added to the second plate, as well as vehicle control, and cells further incubated for 96 hours. Each compound was tested at each concentration and in triplicates. The equivalent cell number was determined after adding propidium iodide by measuring the signal by fluorescence (C for control). GlSO results were calculated using the formula above and are shown in Table 14.<br class="style-scope patent-text">     Table 14 Cytotoxic Activities of Compounds 1-12 and 46 (G1~ NM) Compound HT-29       SF268      PC-3       MDA-231 1        9.538       2.134      2.223      2.143 2        0.457/0.821*&lt;0.3/0.014*&lt;0.3/0.046*&lt;0.3/0.3* <br class="style-scope patent-text"> <br class="style-scope patent-text"> 3        5.945       5.419      5.701      5.745 4        14.934      7.4        6.671      16.545 19.420      14.615     17.984     18.003 6        &gt; 30        21.775     24.231    &gt; 30 7        12.765      19.283     17.945     24.463 8        &gt; 30    &gt; 30       &gt; 30       &gt; 30 9        11.699      2.417      1.605      9.115 12,606      2.602      1.944      2.007 11       15.565      6.656      5.868      7.349 12       7.533       2.252      0.935      1.442 46       2.633       0.808      0.937      0.711 *Result of a second test, using lower concentrations.<br class="style-scope patent-text">Compound 8 was not active at 30 pM against these four cell lines, but showed a 55% binding to the peripheral benzodiazepine receptor in Example 9. It is expected that this compound is active at higher concentration levels or on different strains than the four strains used.<br class="style-scope patent-text">     Compound 2 has an unexpected increase in cytotoxic activity compared to parent Compound 1. A fifty fold increase of activity was observed against HT-29 cell line. Cytotoxic activity (GlSO) of Compound 2 for the other three strains was outside the expected range of concentrations used in the first tests. The second test showed nanomolar activities for Compound 2, a 100-fold increase in potency.<br class="style-scope patent-text">     EXAMPLE 11. IN VITRO ANTICANCER ACTIVITY OF COMPOUND 1 AGAINST<br class="style-scope patent-text">     HUMAN AND ANIMAL TUMOR CELL LINES FROM VARIOUS TISSUES<br class="style-scope patent-text">Culture conditions: The cell lines listed in Table 15 were used to characterize the cytotoxicity of ECO-4601 against human and animal tumor cell lines. These cell lines were shown to be free of mycoplasma infection and were maintained in the appropriate media (Table 15) supplemented with 10% heat-inactivated fetal bovine serum and penicillin-streptomycin, under 5% C02 at 37C. Cells were passaged two to three times per week. Viability was examined by staining with 0.25% trypan blue and only flasks where cell viability was &gt;95% were used for this study.<br class="style-scope patent-text">Cell lines amplification and platinq: Tumor cells were seeded (1-3 x 103 cells per 100 ~L) in 96-well flat bottom microtiter plates and incubated at 37C and 5% C02 for 16 hrs before treatment in drug-free medium supplemented with 10% serum.<br class="style-scope patent-text">Evaluation of inhibitory activity on cell proliferation: Cells were incubated for 96 hrs with 6 logo-fold concentrations of the test substance starting at lONg/ml (20 NM). <br class="style-scope patent-text">The test substance stock solution (5 mg/mL) was initially diluted at 1/70 fold in medium supplemented with serum. Other concentrations were then obtained from 1/10 fold successive dilutions in the same supplemented medium. Cell survival was evaluated 96 h later by replacing the culture media with 150 pL fresh medium containing 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer, pH 7.4. Next, 50 NL of 2.5 mg/mL<br class="style-scope patent-text">of 3-(4,5-dimethylthiazo-2-yl)-2,5-diphenyltetrazolium bromide (MTT) in phosphate buffer solution, pH 7.4, was added. After 3-4h of incubation at 37C, the medium and soluble MTT was removed, and 200 NL of dimethyisulfoxide was added to dissolve the precipitate of reduced MTT followed by addition of 25 pL glycine buffer (0.1 M <br class="style-scope patent-text">glycine plus 0.1 M NaCI, pH 10.5). The absorbance was determined at 570 nm with a microplate reader. Results were expressed as the concentration of drug which inhibits 50% of the cell growth (IC5o). The low micromolar levels of ICSO values shown in Table 15 demonstrated a pharmacologically relevant cytotoxic activity of ECO-4601 against a variety of tumor types such as leukemias, melanomas, pancreatic and breast carcinomas.<br class="style-scope patent-text">    Table 15 ICso Cell linesType            Origin  Source Culture medium (NgImL) K562      Leukemia        Human   ATCC   RPM11640       8.6 myelogeneous P388      Leukemia        Mouse   ATCC   RPM11640          10.9 183       Leukemia  Human   ATCC   RPM11640          2.7 B16 (F10) Melanoma        Mouse   ATCC   RPMI 1640         11.4 SK-II~EL  Melanoma        Human   ATCC   RPMI 1640         14.0 SK-MEL    Melanoma        Human   ATCC   RPMI 1640         14.3 28~                                                    <br class="style-scope patent-text"> <br class="style-scope patent-text"> (expressing VEGF) SK-MEL-1  Melanoma        Human   ATCC   EMEM 1 % non-essential14.1 amino acid 1% Sodium puryvate Panc 96 Pancreatic      Human   ATCC   RPMI 1% Sodium    12.5 carcinoma        puryvate _         Pancreatic      Human   ATCC   RPMI 1% Sodium    14.2 Panc 10.05 carcinoma                      puryvate Insulin MCF-7     Breast   Human   ATCC   RPMI1640          9.7 adenocarcinoma EXAMPLE 12. IN VITRO ANTICANCER ACTIVITY OF COMPOUND 1 AGAINST<br class="style-scope patent-text">     VARIOUS HUMAN TUMOR CELL LINES FROM THE U.S. NCI PANEL<br class="style-scope patent-text">A study measuring the in vitro antitumor activity of ECO-4601 was performed by the National Cancer Institute (National Institutes of Health, Bethesda, Maryland, USA) against panel of human cancer cell lines in order to determine the ECO-4601 concentrations needed to obtain a 50% inhibition of cell proliferation (GlSO). <br class="style-scope patent-text">The operation of this unique screen utilizes 50 different human tumor cell lines, representing leukemia, melanoma and cancers of the lung, colon, brain, ovary, breast, prostate, and kidney.<br class="style-scope patent-text">Culture conditions and platina: The human tumor cell lines of the cancer-screening panel were grown in RPMI 1640 medium containing 5% fetal bovine serum and 2 mM<br class="style-scope patent-text">L-glutamine. For a typical screening experiment, cells were inoculated into 96 well microtiter plates in 100 NL at plating densities ranging from 5,000 to 40,000 cells/well depending on the doubling time of individual cell lines (Table 16). After cell inoculation, the microtiter plates were incubated at 37C, 5% COz, 95% air and 100% <br class="style-scope patent-text">relative humidity for 24 h prior to addition of experimental drugs. After 24 h, two plates of each cell line were fixed in situ with TCA, to represent a measurement of the cell population for each cell line at the time of drug addition (Tz).<br class="style-scope patent-text">Evaluation of inhibitory activity on cell proliferation: ECO-4601 was provided as a lyophilized powder with an estimated purity of 90+%. The compound was stored at -20C until day of use. ECO-4601 was solubilized in dimethyl sulfoxide at 400-fold the desired final maximum test concentration. At the time of drug addition, an aliquot of frozen concentrate was thawed and diluted to twice the desired final maximum test concentration with complete medium containing 50Ng/mL gentamicin. Additional four, 10-fold or ~h log serial dilutions were made to provide a total of five drug concentrations plus control. Aliquots of 100 NI of these different drug dilutions were added to the appropriate microtiter wells already containing 100 NI of medium, resulting in the required final drug concentrations (8.0 x 10-5 M to 8.0 x 10-9 M).<br class="style-scope patent-text">Following drug addition, the plates were incubated for an additional 48 h at 37C, 5% C02, 95% air, and 100% relative humidity. For adherent cells, the assay was terminated by the addition of cold TCA. Cells were fixed in situ by the gentle addition of 50 NI of cold 50% (w/v) TCA (final concentration, 10% TCA) and incubated for minutes at 4C. Supernatants were discarded, and the plates were washed five times with tap water and air-dried. Sulforhodamine B (SRB) solution (100 NI) at 0.4% <br class="style-scope patent-text">(w/v) in 1 % acetic acid was added to each well, and plates were incubated for 10 minutes at room temperature. After staining, unbound dye was removed by washing five times with 1 % acetic acid and the plates were air-dried. Bound stain was subsequently solubilized with 10 mM trizmaT"~ base, and the absorbance was read on an automated plate reader at a wavelength of 515 nm. For suspension cells, the methodology was the same except that the assay was terminated by fixing settled cells at the bottom of the wells by gently adding 50 NI of 80% TCA (final concentration, 16% TCA).<br class="style-scope patent-text">  The growth inhibitory activity of ECO-4601 was measured by NCI utilizing the GlSO value, rather than the classical ICSO value. The GlSO value emphasizes the correction for the cell count at time zero and, using the seven absorbance measurements [time zero, (Tz), control growth, (C), and test growth in the presence of drug at the five concentration levels (Ti)j, Gl5o is calculated as [(Ti-Tz)/(C-Tz)j x 100 = -50, which is the drug concentration resulting in a 50% reduction in the net protein increase (as measured by SRB staining) in control cells during the drug incubation.<br class="style-scope patent-text">Result: ECO-4601 shows a significant antitumor activity against several types of tumor as revealed by the NCI screening. Results of the screen are shown in Table 16, and more detailed results of activity against gliomas are shown in Example 13 (Table 17).<br class="style-scope patent-text">     Table 16 Inoculation Density Cell Line NameType             Origin     Glso (NM) (cells/well) CCRF-CEM      Leukemia         Human   40,000    1.08 K-562         Leukemia         Human   5,000            1.43 RPMI-8226     Leukemia         Human   20,000           3.15 A549/ATCC     Non-Small Cell   Human   7,500            9.10 Lung EKVX          Non-Small Cell   Human   20,000    0.23 Lung HOP-62        Non-Small Cell   Human   10,000           8.29 Lung NCI-H226      Non-Small Cell   Human   20,000           2.00 Lung NCI-H23       Non-Small Cell   Human   20,000           2.02 Lung NCI-H460      Non-Small Cell   Human   7,500            13.60 Lung NCI-H522      Non-Small Cell   Human   20,000           3.44 Lung COLO 205      Colon            Human   15,000           12.70 HCT-116       Colon            Human   5,000            2.92 HCT-15        Colon            Human   10,000           9.73 HT29          Colon Human   5,000            20.70 SW-620        Colon            Human   10,000           2.72 SF-268        CNS              Human   15,000   4.94 SF-295        CNS              Human   10,000           12.70 SF-539        CNS              Human   15,000           0.0075 Table 16 Inoculation Density Cell Line NameType          Origin                      Gl~o (IrM) (cells/well) SNB-7 9       CNS           Human      15,000           2.90 SNB-75        CNS           Human      20,000           7.71 U251        CNS           Human      7,500            2.19 LOX IMVI      Melanoma      Human      7,500            4.53 M14           Melanoma      Human      15,000           4.57 SK-MEL-2      Melanoma      Human      20,000           25.0 SK-MEL-28     Melanoma      Human      10,000  11.6 SK-MEL-5      Melanoma      Human      10,000           7.80 UACC-257      Melanoma      Human      20,000           2.31 UACC-62    Melanoma      Human      10,000           1.55 IGR-OV1       Ovarian      Human      10,000           3.11 OVCAR-3       Ovarian       Human     10,000           13.50 OVCAR-4       Ovarian       Human      15,000           9.67 OVCAR-5       Ovarian       Human      20,000           2.81 OVCAR-8       Ovarian       Human      10,000           2.65 SK-OV-3       Ovarian       Human      20,000           4.00 786-0         Renal         Human      10,000           6.99 A498          Renal         Human      25,000           22.30 ACHN          Renal         Human      10,000           3.10 CAKI-1        Renal         Human      10,000   15.20 RXF 393       Renai         Human      15,000           7.71 SN12C         Renal         Human      15,000           3.85 UO-31      Renal         Human      15,000           19.70 DU-145        Prostate      Human      10,000           3.56 MCF7          Breast        Human      10,000           10.10 NCI/ADR-RES   Breast        Human      15,000           18.30 MDA-MB-231/ATCCBreast        Human      20,000    2.72 HS 578T       Breast        Human      20,000           2.76 MDA-MB-435    Breast        Human      15,000           15.30 BT-549       Breast        Human      20,000           0.11 T-47D         Breast        Human      20,000           0.77 The results indicate that ECO-4601 was effective against most of the human tumor cell lines that have been assayed in the NCI screening panel suggesting a broad anticancer activity against several types of human cancer.<br class="style-scope patent-text">     EXAMPLE 13: IN VITRO ANTIPROLIFERATIVE STUDY AGAINST A PANEL OF<br class="style-scope patent-text">     GLIOMA CELL LINES<br class="style-scope patent-text">     The anticancer activity of ECO-4601 was evaluated using a panel of glioma cancer cell lines shown in Table 17, and the 50% inhibition of cell proliferation (ICSO) was determined.<br class="style-scope patent-text">Culture conditions: The cell lines listed in Table 17 were shown to be free of mycoplasma infection and were maintained on DMEM medium supplemented with 10%<br class="style-scope patent-text">heat-inactivated fetal bovine serum and 1 % penicillin-streptomycin, under 5% <br class="style-scope patent-text">C02 at 37C. Cells were passaged once a week. Prior to use the cells were detached from the culture flask by treating with trypsin for five to ten minutes. The cells were counted with a Neubauer glass slide and viability assessed by 0.25% trypan blue exclusion. <br class="style-scope patent-text">Only flasks with &gt;95% cell viability, were used in the study.<br class="style-scope patent-text">Cell lines amplification and plating: Cells, 5 x 103 cells per well in 100 NL <br class="style-scope patent-text">drug-free medium supplemented with 10% serum, were plated in 96-well flat bottom microtiter plates and incubated at 37C for 48 hrs before treatment.<br class="style-scope patent-text">Evaluation of inhibitor~r activity on cell proliferation: Cells (in triplicate wells) were incubated 96 hrs with medium containing different concentrations of ECO-4601, starting at 5.0 Ng/ml (10 NM). The compound was used in a solution of 1 % DMSO in D-MEM <br class="style-scope patent-text">or RPMI media (or other equivalent media). The concentrations of ECO-4601 were as follows: 10 NM (5.0 Ng/ml), 1 NM (0.50 Ng/ml), 0.5 NM (0.25 Ng/ml), 0.1 NM <br class="style-scope patent-text">(0.050 Ng/ml), 0.5 NM (0.025 Ng/ml), 0.01 NM (0.0050 Ng/ml), 0.001 NM (0.00050 Ng/ml).<br class="style-scope patent-text">Negative controls were cells treated with vehicle alone (1 % DMSO in culture medium).<br class="style-scope patent-text">Positive controls were cells treated with 4 to 6 increasing concentrations of cisplatin (CDDP) (data not shown). The optical density was measured before incubation (time 0) and following 96 hrs of incubation with test compound in order to measure the growth rate of each cell line.<br class="style-scope patent-text">At the end of the cell treatment, cell culture media was replaced with 150 NI <br class="style-scope patent-text">of fresh medium containing 10 mM of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer, pH 7.4. Then 50 NI of 2.5 mg/ml of 3-(4,5-dimethylthiazo-2-yl)-2,5-diphenyltetrazolium bromide in PBS pH 7.4, were added to each well and the culture plates incubated for 4 hrs at 37C. The resulting supernatant was removed and formazan crystals were dissolved with 200 NI of DMSO followed by 25 NI of glycine buffer (0.1 M glycine plus 0.1 M NaCI, pH 10.5). The optical density was read in each well using a single wavelength spectrophotometer plate reader at 570 nm. <br class="style-scope patent-text">Results were expressed as the concentration of drug, which inhibits 50% of the cell growth (ICSO). Each of the cell lines was tested in at least 3 independent experiments.<br class="style-scope patent-text">Results shown in Table 17 confirmed the activity of ECO-4601 against different brain cancer cell lines including gliosarcoma, which is the most malignant form of type IV glioblastoma multiform. Gliosarcomas are a mixture of glial and endothelial cells and are resistant to any chemotherapy.<br class="style-scope patent-text">     Table 17 Cell linesType           Origin  Source  IC5o (x 10'~<br class="style-scope patent-text">    M) 9L       Gliosarcoma    Rat     ATCC    6.82 t 2.90 GHD      Astrocytoma    Human   ATCC    6.29 t 2.98 U 373    Astrocytoma    Human   ATCC    3.83 t 1.37 GL26     Glioblastoma   Human   ATCC    8.93 t 1.10 C6       Glioblastoma   Rat     ATCC    4.28 t 2.82 DN       OligodendrogliomaHuman   ATCC    3.26 t 0.93 GHA      OligodendrogliomaHuman   ATCC    1.78 t 0.84 EXAMPLE 14: IN VIVO EFFICACY IN A GLIOMA MODEL<br class="style-scope patent-text"> The aim of this study was to test whether ECO-4601 administered by i.p. route prevents or delays tumor growth in C6 glioblastoma cell-bearing mice, and to determine an effective dosage regimen.<br class="style-scope patent-text">Animals: A total of 60 six-week-old female mice (Mus musculus nude mice), ranging between 18 to 25 g in weight, were observed for 7 days before treatment. <br class="style-scope patent-text">Animal experiments were performed according to ethical guidelines of animal experimentation (Charte du comite d'ethique du CNRS, juillet 2003) and the English guidelines for the welfare of animals in experimental neoplasia ( UVORKMAN, P., 71NENT'YMAN, P., BALKI~VILL, F., et al. ()998). United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Guidelines for the welfare of animals in experimental neoplasia (Second Edition, July )997; British Journal of Cancer 77: )-)0). Any dead or apparently sick mice were promptly removed and replaced with healthy mice. Sick mice were euthanized upon removal from the cage. Animals were maintained in rooms under controlled conditions of temperature (2312C), humidity (4515%), photoperiodicity (12 hrs light / 12 hrs dark) and air exchange. Animals were housed in polycarbonate cages (5/single cage) that were equipped to provide food and water. Animal bedding consisted of sterile wood shavings that were replaced every other day. Food was provided ad libitum, being placed in the metal lid on the top of the cage. Autoclaved tap water was provided ad libitum. Water bottles were equipped with rubber stoppers and sipper tubes. Water bottles were cleaned, sterilized and replaced once a week. Two different numbers engraved on two earrings identified the animals. Each cage was labelled with a specific code.<br class="style-scope patent-text">Tumor Cell Line: The C6 cell line was cloned from a rat glial tumor induced by N-nitrosomethyurea (NMU) by Premont et al. (Premont J, Benda P, Jard S., ~3H]<br class="style-scope patent-text">norepinephrine binding by rat glial cells in culture. Lack of correlation between binding and adenylate cyclase activation. Biochim Biophys Acta. )975 Feb )3;38)(2):368-76.) after series of alternate culture and animal passages.<br class="style-scope patent-text">Cells were grown as adherent monolayers at 37C in a humidified atmosphere (5%<br class="style-scope patent-text"> C02, 95% air). The culture medium was DMEM supplemented with 2 mM L-glutamine and 10% fetal bovine serum. For experimental use, tumor cells were detached from the culture flask by a 10 min treatment with trypsin-versen. The cells were counted in a hemocytometer and their viability assessed by 0.25% trypan blue exclusion.<br class="style-scope patent-text">Preparation of the Test Article: For the test article, the following procedure was followed for reconstitution (performed immediately preceding injection). The vehicle consisted of a mixture of benzyl alcohol (1.5%), ethanol (8.5%), propylene glycol (27%), (27%), dimethylacetamide (6%) and water (30%). The vehicle solution was first vortexed in order to obtain a homogeneous liquid. 0.6 mL of the vortexed vehicle solution was added to each vial containing the test article (ECO-4601 ). Vials were mixed thoroughly by vortexing for 1 minute and inverted and shaken vigorously. <br class="style-scope patent-text">Vials were mixed again prior to injection into each animal.<br class="style-scope patent-text">Animal Inoculation with tumor cells: Experiment started at day 0 (Do). On Do, mice received a superficial intramuscular injection of C6 tumor cells (5 x 105 cells) in 0.1 mL<br class="style-scope patent-text">of DMEM complete medium into the upper right posterior leg.<br class="style-scope patent-text">Treatment regimen and Results In a first series of experiments, treatment started 24 hrs following inoculation of C6 cells. On the day of the treatment, each mouse was slowly injected with 100 NL of test or control articles by i.p. route. For all groups, treatment was performed until the tumor volume of the saline-treated mice (group 1 ) reached approximately 3 cm3 (around day 16). Mice of group 1 were treated daily with a saline isosmotic solution for 16 days.<br class="style-scope patent-text">Mice of group 2 were treated daily with the vehicle solution for 16 days. Mice of group 3 were treated daily with 10 mg/kg of ECO-4601 for 16 days. Mice of group 4 were treated every two days with 30 mg/kg of ECO-4601 and received 8 treatments. <br class="style-scope patent-text">Mice of group 5 were treated every three days with 30 mg/kg of ECO-4601 and received 6 treatments. Measurement of tumor volume started as soon as tumors became palpable (&gt;100 mm3; day 11 post-inoculation) and was evaluated every second day until the end of the treatment using callipers. As shown in Table 18 and Figure 3, the mean value of the tumor volume of all ECO-4601 treated groups (6 mice/group) was significantly reduced as demonstrated by the one-way analysis of variance (Anova) test followed by the non-parametric Dunnett's multiple comparison test comparing treated groups to the saline group. An asterisk in the P value column of Table 18 indicates a statistically significant value, while "ns" signifies not significant.<br class="style-scope patent-text">     Table 18 Treatment        Treatment Tumor volume (mm) % InhibitionP value regimen   (mean t SEM) Saline           Q1 x 16   3,004.1 t 249.64  -         -Vehicle solution Q1 x 16   2,162.0 t 350.0   28.0%  &gt;0.05 ns ECO-4601 (10 mg/kg)Q1 x 16   1,220.4 t 283.46  59.4%     &lt;0.01 ECO-4601 (30 mg/kg)Q2 x 8    1,236.9 t 233.99  58.8%     &lt;0.01 ECO-4601 (30 mg/kg)Q3 x 6    1,184.1 t 221.45  60.6%     &lt;0.01 In a second series of experiments, treatment started at day 10 following inoculation of C6 cells when tumors became palpable (around 100 to 200 mm3).<br class="style-scope patent-text">Treatment was repeated daily for 5 consecutive days. On the day of the treatment, each mouse was slowly injected with 100 pL of ECO-4601 by i.p. route. Mice of group 1 were treated daily with saline isosmotic solution. Mice of group 2 were treated daily with the vehicle solution. Mice of group 3 were treated daily with 20 mg/kg of ECO-4601.<br class="style-scope patent-text">Mice of group 4 were treated daily with 30 mg/kg of ECO-4601. Mice were treated until the tumor volume of the saline-treated control mice (group 1 ) reached around 4 cm3.<br class="style-scope patent-text">Tumor volume was measured every second day until the end of the treatment using callipers. As shown in Table 19 and Figure 4, the mean value of the tumor volume of all ECO-4601 treated groups (6 mice/group) was significantly reduced as demonstrated by the one-way analysis of variance (Anova) test followed by the non-parametric Dunnett's multiple comparison test comparing treated groups to the saline group. An asterisk in the P value column of Table 19 indicates a statistically significant value, while "ns"<br class="style-scope patent-text">signifies not significant.<br class="style-scope patent-text">     Histological analysis of tumor sections showed pronounced morphological changes between ECO-4601-treated tumors and control groups. In tumors treated with ECO-4601 (20 - 30 mg/kg), cell density was decreased and the nuclei of remaining tumor cells appeared larger and pycnotic while no such changes were observed for vehicle-treated mice (Figure 5).<br class="style-scope patent-text">     Table 19 Treatment         Treatment Tumor volume (mm % InhibitionP value ) regimen   (mean t SEM) Saline            Q1 x 5    4,363.1 t 614.31 -          -Vehicle solution  Q1 x 5    3,205.0  632.37  26.5%      &gt;0.05 ns ECO-4601 (20 mg/kg)Q1 x 5    1,721.5 t 374.79 60.5%      &lt;0.01 ECO-4601 (30 mg/kg)Q1 x 5    1,131.6 t 525.21 74.1 %     &lt;0.01 EXAMPLE 15: COMPOUND 1 DERIVATIVES GENERAL PROCEDURES<br class="style-scope patent-text">15.1: Eeoxidation The epoxide compounds of the present invention (e.g., compounds according to exemplary Compounds 16-22 are made from Compound 1 (ECO-4601 ) by treatment with any of a number of epoxidizing reagents such as perbenzoic acid, monoperphthalic acid or more preferably by m-chloroperbenzoic acid in an inert solvent such as dichloromethane or 1,2-dichloroethane. It will be appreciated by one of ordinary skill in the art that slightly greater than one molecule equivalent of epoxidizing agent will result in the maximal yield of mono-epoxides, and that the reagent, solvent, concentration and temperature of the reaction will dictate the ratio of specific mono-epoxides formed. It will also be appreciated that the mono-epoxides will be enantiomeric mixtures, and that the di-epoxides and the tri-epoxide can be prepared as diastereomers and that the conditions of the reaction will determine the ratios of the products. One skilled in the art will appreciate that under most conditions of reactions the product will be a mixture of all possible epoxides and that these may be separated by standard methods of chromatography. Exemplary approaches to the generation of mono-, di-, and tri-epoxides are provided below.<br class="style-scope patent-text">     A) Mono-epoxides Compounds 16, 17 and 18 prepared by epoxidation of Compound 1: <br class="style-scope patent-text"> <br class="style-scope patent-text"> O<br class="style-scope patent-text">i i \ / N O \ / N O<br class="style-scope patent-text">/ N / \<br class="style-scope patent-text">     Ho H _ \ off Compound 16 Ho H _ off Compound 17 HO<br class="style-scope patent-text">i i \ / N O<br class="style-scope patent-text">     HO<br class="style-scope patent-text">\ pH Compound 18 H<br class="style-scope patent-text">   To a solution of Compound 1 dissolved in tetrahydrofuran (THF) is added 1.1 equivalents of meta-chloroperbenzoic acid. The reaction is cooled in an ice bath and stirred at 0 C for 1-2 hours. The reaction mixture is then evaporated to dryness, re-dissolved in methanol and subjected to liquid chromatography on a column of SephadexT"" LH-20 to isolate a mixture of predominantly Compounds 16, 17 and 18, contaminated with some unchanged starting material and some di- and tri-epoxides.<br class="style-scope patent-text">   Compounds 16, 17 and 18 are separated and purified by HPLC using the system described in Example 2 for the purification of Compound 1. In a typical experiment yields of 15% to 25% are obtained for each of Compounds 16, 17 and 18.<br class="style-scope patent-text">     B) Synthesis of Compounds 19, 20 and 21 by di-epoxidation of Compound 1:<br class="style-scope patent-text">\ / N O O / \ / N / O<br class="style-scope patent-text">/ /<br class="style-scope patent-text">     HO HO _ \ OH Compound 19 Ho H - \ off Compound 20 \ / N / O O<br class="style-scope patent-text">     HO H /_ \ off Compound 21 HO<br class="style-scope patent-text">   To a solution of Compound 1 dissolved in tetrahydrofuran (THF) is added 2.3 equivalents of meta-chloroperbenzoic acid. The reaction is cooled in an ice bath and stirred at 0 C for 1-2 hours. The reaction mixture is then evaporated to dryness, re-dissolved in methanol and subjected to liquid chromatography on a column of SephadexT"" LH-20 to isolate a mixture of predominantly Compounds 19, 20 and 21, contaminated with traces of unchanged starting material and some mono- and tri-epoxides. Compounds 19, 20 and 21 are separated and purified by HPLC using the system described in Example 2 for the purification of Compound 1. In a typical experiment, yields of 15% to 20% are obtained for each of Compounds 19, 20 and 21.<br class="style-scope patent-text">C) Synthesis of Compound 22 by tri-epoxidation of Compound 1:<br class="style-scope patent-text">\ / N o Compound 22 To a solution of Compound 1, dissolved in tetrahydrofuran (THF), is added 3.5 equivalents of meta-chloroperbenzoic acid. The reaction is cooled in an ice bath and stirred at 0 C for 1-2 hours. The reaction mixture is then evaporated to dryness, re-dissolved in methanol and subjected to liquid chromatography on a column of SephadexT"" LH-20 to isolate Compound 22 in an essentially pure form in a yield of 80+%.<br class="style-scope patent-text">     D) Syntheses of Compounds 23 and 24 by epoxidation of Compound 42.<br class="style-scope patent-text">\ / 'N O \ /<br class="style-scope patent-text">     OH Compound 23 HO H / ~ OH Compound 24 HO<br class="style-scope patent-text">  To a solution of Compound 42 dissolved in tetrahydrofuran (THF) is added 1.1 equivalents of meta-chloroperbenzoic acid. The reaction is cooled in an ice bath and stirred at 0 C for 1-2 hours. The reaction mixture is then evaporated to dryness, re-dissolved in methanol and subjected to liquid chromatography on a column of SephadexT"" LH-20 to isolate a mixture of predominantly Compounds 23 and 24, contaminated with some unchanged starting material and some diepoxide. <br class="style-scope patent-text"> <br class="style-scope patent-text"> Compounds 23 and 24 are separated and purified by HPLC or HSCC using one of the systems described in Example 2 for the purification of Compound 1. In a typical experiment yields of 35% to 40% are obtained for each of Compounds 23 and 24.<br class="style-scope patent-text">     E) Synthesis of Compound 28 by epoxidation of Compound 40.<br class="style-scope patent-text">~ 'N<br class="style-scope patent-text">     H N ~ \ H Compound 28 H<br class="style-scope patent-text">     H<br class="style-scope patent-text">     To a solution of Compound 40 dissolved in tetrahydrofuran (THF) is added 2.2 equivalents of meta-chloroperbenzoic acid. The reaction is cooled in an ice bath and stirred at 0 C for 1-2 hours. The reaction mixture is then evaporated to dryness, re-dissolved in methanol and subjected to liquid chromatography on a column of SephadexT"" LH-20 to isolate essentially pure Compound 28 in good yield.<br class="style-scope patent-text">15.2: N-Aceylation Synthesis of Compound 13 by N-acetylation of Compound 1.<br class="style-scope patent-text">     N i i i HO N / \ OH Compound 13 Ac --HO<br class="style-scope patent-text">   To a solution of Compound 1 dissolved in tetrahydrofuran (THF) is added 1.2 equivalents of acetic anhydride and a few drops of triethylamine. The reaction mixture allowed to stand at room temperature for 1-2 hours and then evaporated to dryness under reduced pressure to obtain Compound 13 in an essentially pure form in an almost quantitative yield 15.3: N-alk !ay tion Syntheses of Compounds 2, 3 and 14 by N-alkylation of Compound 1. <br class="style-scope patent-text"> <br class="style-scope patent-text"> i ~ i Compound 2 R = methyl Compound 3 R = benzyl Ho Compound 14 R = ethyl To a solution of Compound 1 dissolved in terachloroethylene is added 1.2 equivalents of the appropriate alkyl bromide (iodomethane for Compound 2, benzyi bromide for Compound 3 or ethyl bromide for Compound 14). The reaction mixture the reaction mixture is heated under reflux for 1-2 hours and then evaporated to dryness under reduced pressure to obtain Compound 2, 3 or 14 respectively, in an essentially pure form in an almost quantitative yield.<br class="style-scope patent-text">     Compounds 60 to 76 are also prepared via this procedure, by reaction of Compound 1 with the appropriate alkyl halide or dialkyl sulfate.<br class="style-scope patent-text">15.4: H~roqenolysis A) Syntheses of Compounds 40, 41 and 42 by hydrogenolysis of Compound 1.<br class="style-scope patent-text">     Compound 40 Ho ~N--~ ~~, , Compound 41 Compound 42 H<br class="style-scope patent-text"> A solution Compound 1 (462 mg) in ethanol (200 ml) with palladium on charcoal (25 mg of 5%) is shaken in an hydrogenation apparatus in an atmosphere of hydrogen.<br class="style-scope patent-text">The uptake of hydrogen by the reaction is measured carefully and at the point where one millimole of hydrogen has been consumed, shaking is stopped, the vessel is rapidly evacuated and the atmosphere is replaced with nitrogen. The catalyst is removed by filtration and the filtrate is concentrated to obtain a crude mixture of Compounds 40, 41 and 42 contaminated by unreacted starting material and minor amounts of over reduced products. The desired products may be separated and purified by HPLC <br class="style-scope patent-text">or HSCC chromatography using the systems as described in Example 2 above, to obtain approximately 100 mg of each of Compounds 40, 41 and 42.<br class="style-scope patent-text">     B) Syntheses of Compounds 43, 44 and 45 by hydrogenolysis of Compound 1.<br class="style-scope patent-text">     Compound 43 Ho ~N--~~ ~~~ Compound 44 H<br class="style-scope patent-text">     Compound 45 H<br class="style-scope patent-text">     A solution of Compound 1 (462 mg) in ethanol (200 ml) with palladium on charcoal (25 mg of 5%) is shaken in an hydrogenation apparatus in an atmosphere of hydrogen. The uptake of hydrogen by the reaction is measured carefully and at the point where two millimoles of hydrogen has been consumed, shaking is stopped, the vessel is rapidly evacuated and the atmosphere is replaced with nitrogen. The catalyst is removed by filtration and the filtrate is concentrated to obtain a crude mixture of Compounds 43, 44 and 45 contaminated by trace amounts unreacted starting material and minor amounts of under and over reduced products. The desired products may be separated and purified by HPLC or HSCC chromatography using the systems as described in Example 2 above, to obtain approximately 100 mg of each of Compounds 43, 44 and 45.<br class="style-scope patent-text">     C) Syntheses of Compound 46 by hydrogenolysis of Compound 1 (alternate procedure). <br class="style-scope patent-text"> <br class="style-scope patent-text"> Compound 46 A solution of Compound 1 (462 mg) in ethanol (200 ml) with palladium on charcoal (25 mg of 5%) is shaken in an hydrogenation apparatus in an atmosphere of hydrogen. The uptake of hydrogen by the reaction is measured carefully and at the point where three millimoles of hydrogen has been consumed, shaking is stopped, the vessel is rapidly evacuated and the atmosphere is replaced with nitrogen. The catalyst is removed by filtration and the filtrate is concentrated to obtain an essentially pure sample of Compound 46.<br class="style-scope patent-text">15.5: Peracet~rlation Syntheses of Compound 15 by peracetylation of Compound 1.<br class="style-scope patent-text">     N ~<br class="style-scope patent-text">     A N / \ OAc Compound 15 Act Ac0 A solution of Compound 1 (100 mg) in acetic anhydride (5 ml) is treated with pyridine (250 u1). The reaction mixture is allowed to stand overnight at room temperature and is then diluted with toluene (100 ml). The toluene solution is washed well with aqueous 5% sodium bicarbonate solutions, then with water and is finally concentrated under reduced pressure to give an essentially pure sample of Compound 15 in almost quantitative yield.<br class="style-scope patent-text">15.6: Eiooxide opening Syntheses of Compound 53 by opening the epoxide of Compound 16. <br class="style-scope patent-text"> <br class="style-scope patent-text"> i i \ I N f..pH<br class="style-scope patent-text">     HO N ~ \ Compound 53 H , OH<br class="style-scope patent-text">     H<br class="style-scope patent-text">A solution of Compound 16 (100 mg) in tetrahydrofuran (50 ml) is treated with aqueous hydrochloric acid (5 ml). The reaction mixture is stirred overnight at room temperature and is then diluted with toluene (100 ml) and water (200 ml). The toluene layer is separated and the aqueous layer is extracted with a further 100 ml of toluene.<br class="style-scope patent-text">   The combined toluene layers are washed once more with water (50 ml) and the separated and dried under vacuum to give the vicinal glycol Compound 53.<br class="style-scope patent-text">15. 7: Ozonolvsis Syntheses of Compounds 47, 49 and 51 by ozonolysis of Compound 1.<br class="style-scope patent-text">     O<br class="style-scope patent-text">   N i i ~O ' N i ~O<br class="style-scope patent-text">\ I \ I<br class="style-scope patent-text">     Compound 47 N ~ \ Compound 49 HO H ._ OH HO H , OH<br class="style-scope patent-text">     HO H<br class="style-scope patent-text">     I NCO<br class="style-scope patent-text">\ N / ~ Compound 51 HO H OH<br class="style-scope patent-text">     HO<br class="style-scope patent-text">A solution of Compound 1 (462 mg) in dry ethyl acetate (200 ml) in an ozonolysis apparatus is cooled to below -20C. A stream of ozone containing oxygen is passed into the solution from an ozone generator, which has been precalibrated such that the rate of ozone generation is known. To obtain predominantly Compound 47 the passage of ozone is halted after 0.9 millimole have been generated. To obtain predominantly Compound 49 the ozone passage is halted after 2 millimoles have been generated and to obtain Compound 51 as the predominant product 3.3 millimoles of ozone are generated.<br class="style-scope patent-text">At the completion of the ozonolysis, the reaction mixture is transferred to an hydrogenation apparatus, 5/a palladium on calcium carbonate catalyst (0.2 g) is added to the reaction mixture which is maintained at less than -20C and is hydrogenated.<br class="style-scope patent-text">When hydrogen uptake is complete the hydrogen atmosphere is replaced with nitrogen and the reaction mixture is allowed to come to room temperature, filtered to remove catalyst and the filtrate is concentrated. The crude product may be purified by chromatography using either HPLC or HSCC with the systems as described in Example 2 to give, dependent on the amount of ozone used, Compounds 47, 49 and 51.<br class="style-scope patent-text">15.8: Reduction Synthesis of Compound 48 by reduction of the aldehyde of Compound 47.<br class="style-scope patent-text">/ N i i OH<br class="style-scope patent-text">     Ho N / \ Compound 48 H , OH<br class="style-scope patent-text">     H<br class="style-scope patent-text">A solution of Compound 47 (50 mg) in isopropanol (5 ml) is cooled in an ice-salt bath and sodium borohydride (10 mg) is added and the mixture is stirred for 20 minutes. It is then diluted with water (20 ml) and extracted twice with toluene (10 ml portions) at ambient temperature. The combined toluene extracts are filtered and the filtrate is concentrated to give Compound 48.<br class="style-scope patent-text">15.8: Esterification Syntheses of Compounds 35, 36 and 37 by esterification of Compound 1.<br class="style-scope patent-text">i i i \ / N i i i Ac0 N ~ \ Compound 35 HD N / \ Compound 36 OH H , OH<br class="style-scope patent-text">     HO Ac0 N i i HO H / \ oAc Compound 37 H<br class="style-scope patent-text"> To a solution of Compound 1 dissolved in toluene (9 parts) tetrahydrofuran (1 part), cooled in an ice-bath is added 1.1 equivalents of acetic anhydride and two drops of boron trifluoride etherate. The reaction is maintained cool in an ice bath and stirred at 0 C for 1-2 hours. The reaction mixture is then poured into aqueous 5% <br class="style-scope patent-text">sodium bicarbonate solution shaken and the toluene layer is removed. The aqueous laer is re-extracted with toluene and the combined toluene layers are concentrated to a mixture of predominantly Compounds 35, 36 and 37, contaminated with some unchanged starting material and some diacetates. Compounds 35, 36 and 37 are separated and purified by HPLC or HSCC using one of the systems described in Example 2 for the purification of Compound 1. In a typical experiment yields of 25% to 30% are obtained for each of Compounds 35, 36 and 37.<br class="style-scope patent-text">15.9: Alk~rlation Syntheses of Compounds 6, 7 and 38 by methylation of Compound 1.<br class="style-scope patent-text">     O<br class="style-scope patent-text">   N i i i \ / N i i i Me0 N ~ \ Compound 6 Hp N ~ \ off Compound 7 OH<br class="style-scope patent-text">     HO Me0 N i i i HO N ~ \ Compound 38 H , OMe H<br class="style-scope patent-text">A solution of Compound 1 (1 g) in tetrahydrofuran 50 (ml) is titrated with exactly one equivalent of sodium methoxide, allowed to stand for 30 minutes at room temperature and then treated with 1.2 equivalents of dimethylsulphate. Heat the mixture under reflux for one hour, cool to room temperature and pour into a mixture of toluene (200 ml) and water (200 ml). The layers are separated and the aqueous layer is extracted once more with an equal portion of toluene. The combined toluene layers are washed once with 1 N aqueous acetic acid and then concentrated to s crude product, which is predominantly a mixture of Compounds 6, 7 and 38 with some unchanged starting material and traces of over-methylated derivatives. The desired products may be separated and purified by HPLC or HSCC chromatography using the systems as described in Example 2 above, to obtain approximately 200 mg of each of Compounds 6, 7 and 38.<br class="style-scope patent-text">While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims. </div>
    </disclosure>
  </div>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
            <div class="flex flex-width style-scope patent-result">
              <section id="claims" class="style-scope patent-result">
                <h3 class="style-scope patent-result">
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Claims <span class="style-scope patent-result">(34)</span></div>
                    <div class="collapse style-scope patent-result">
                      Hide Dependent <iron-icon style="height: 15px; width: 15px;" icon="expand-less" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 8l-6 6 1.41 1.41L12 10.83l4.59 4.58L18 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </div>
                  </div>
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result"></div>
                    <div class="righthead style-scope patent-result" hidden="">translated from </div>
                  </div>
                </h3>
                <patent-text name="claims" enable-text-selection="" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><div mxw-id="PCLM55437372" lang="EN" load-source="patent-office" class="claims style-scope patent-text">
    <div class="claim style-scope patent-text"> <div num="1" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">1. A compound of Formula I:<br class="style-scope patent-text"> <br class="style-scope patent-text"> <span class="patent-image-not-available style-scope patent-text"></span> wherein, W1, W2 and W3 are each independently selected from <span class="patent-image-not-available style-scope patent-text"></span> the chain from the tricycle terminates at W3, W2 or W1 with W3, W2 or W1 respectively being either -CH=O or -CH2OH;<br class="style-scope patent-text"> R1 is selected from H, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C6-10aryl, C5-10heteroaryl, C3-10cycloalkyl, C3-10heterocycloalkyl, C(O)C1-10alkyl, C(O)C2-10alkenyl, C(O)C2-10alkynyl, C(O)C6-10aryl, C(O)C5-10heteroaryl, C(O)C3-10cycloalkyl; <br class="style-scope patent-text">C(O)C3-10heterocycloalkyl or a C-coupled amino acid;<br class="style-scope patent-text">R2, R3, and R4 are each independently selected from H, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C6-10aryl, C5-10heteroaryl, C3-10cycloalkyl, C3-10heterocycloalkyl, C(O)H, C(O)C3-10alkyl, C(O)C2-10alkenyl, C(O)C2-10alkynyl, C(O)C6-10aryl, C(O)C5-10heteroaryl, C(O)C3-10cycloalkyl; C(O)C3-10heterocycloalkyl or a C-coupled amino acid;<br class="style-scope patent-text">     R5 and R6 are each independently selected from H, OH and OC1-6alkyl;<br class="style-scope patent-text">wherein, when any of R1, R2, R3, R4, R5 and R6 comprises an alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group, then the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group is optionally substituted with substituents selected from acyl, amino, acylamino, acyloxy, carboalkoxy, carboxy, carboxyamido, cyano, halo, hydroxyl, nitro, thio, C1-6alkyl, C2-7alkenyl, C2-7alkynyl, C3-10cycloalkyl, C3-10heterocycloalkyl, C6-10aryl, C5-10heteroaryl, alkoxy, aryloxy, sulfinyl, sulfonyl, oxo, guanidino and formyl; and with the proviso that when W1, W2 and W3 are all -CH=C(CH3)-, and R2, R3 and R4 are all H, then R1 is not H;<br class="style-scope patent-text">or a pharmaceutically acceptable salt or prodrug thereof. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="2" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">2. The compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein said R1 is H. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="3" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">3. The compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein said R1 is CH3. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="4" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">4. The compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein said R1 is C1-10alkyl. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="5" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">5. The compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein said R1 is C1-10 alkenyl. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="6" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">6. The compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein said R2 is H. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="7" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">7. The compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein said R3 is H. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="8" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">8. The compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein said R4 is H. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="9" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">9. The compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein said R2, R3 and R4 are each H. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="10" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">10. The compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein two of R2, R3 and R4 are CH3. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="11" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">11. The compound of claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein each of W1, W2, and W3 is -CH2CH(CH3)-. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="12" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">12. The compound of claim 1, wherein said compound is selected from:<br class="style-scope patent-text"> <br class="style-scope patent-text"> <span class="patent-image-not-available style-scope patent-text"></span> <span class="patent-image-not-available style-scope patent-text"></span> <span class="patent-image-not-available style-scope patent-text"></span> <span class="patent-image-not-available style-scope patent-text"></span> <span class="patent-image-not-available style-scope patent-text"></span> <span class="patent-image-not-available style-scope patent-text"></span> <span class="patent-image-not-available style-scope patent-text"></span> <span class="patent-image-not-available style-scope patent-text"></span> <span class="patent-image-not-available style-scope patent-text"></span> or a pharmaceutically acceptable salt or prodrug thereof. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="13" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">13. The compound of claim 12, wherein said compound is Compound 2, or a pharmaceutically acceptable salt or prodrug thereof. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="14" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">14. The compound of claim 12, wherein said compound is selected from Compounds 17 and 18, or a pharmaceutically acceptable salt or prodrug thereof. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="15" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">15. The compound of claim 12, wherein said compound is selected from Compounds 3 to 7, 9 to 12 and 46, or a pharmaceutically acceptable salt or prodrug thereof. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="16" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">16. The compound of claim 12, wherein said compound is a selected from Compounds 4 to 7, 10 and 46, or a pharmaceutically acceptable salt or prodrug thereof. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="17" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">17. The compound of claim 12, wherein said compound is a compound selected from Compounds 3 and 60 to 76, or a pharmaceutically acceptable salt or prodrug thereof. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="18" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">18. The compound of claim 12, wherein said compound is Compound 8, or a pharmaceutically acceptable salt or prodrug thereof. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="19" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">19. A process for making a compound of any one of claims 1-18, comprising cultivation of a Micromonospora sp. strain, in a nutrient medium comprising at least one source of carbon atoms and at least one source of nitrogen atoms, isolation and purification of the compound, and chemical modification of the isolated compound. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="20" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">20. A pharmaceutical composition comprising a compound of any one of claims 1 to 11, together with a pharmaceutically acceptable carrier. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="21" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">21. A pharmaceutical composition comprising a compound of claim 12, together with a pharmaceutically acceptable carrier. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="22" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">22. A pharmaceutical composition comprising a compound of claim 13, together with a pharmaceutically acceptable carrier. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="23" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">23. A pharmaceutical composition comprising a compound of any one of claims 14-18, together with a pharmaceutically acceptable carrier. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="24" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">24. Use of a compound of any one of claims 1-12 as an antitumor agent. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="25" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">25. Use of a compound of claim 13 as an antitumor agent. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="26" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">26. Use of a compound of any one of claims 14-17 as an antitumor agent. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="27" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">27. Use of a compound of any one of claims 1-12 for the treatment of precancerous or cancerous conditions. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="28" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">28. Use of a compound of claim 13 for the treatment of precancerous or cancerous conditions. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="29" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">29. Use of a compound of any one of claims 14-17 for the treatment of precancerous or cancerous conditions. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="30" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">30. Use of a compound of any one of claims 1-12, in the manufacture of a medicament for the treatment of precancerous or cancerous conditions. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="31" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">31. Use of a compound of claim 13, in the manufacture of a medicament for the treatment of precancerous or cancerous conditions. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="32" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">32. Use of a compound of any one of claims 14-17, in the manufacture of a medicament for the treatment of precancerous or cancerous conditions. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="33" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">33. Use of a compound of any one of claims 1-18 as a peripheral benzodiazepine receptor (PBR) binding agent for the treatment of a condition involving PBR. </div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div num="34" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">34. Use of a compound of any one of claims 1-17 as a 5-Lipooxygenase (5-LO) inhibitor for the treatment of a condition involving the 5-LO enzyme. </div>
    </div>
  </div> </div>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
          </div>

          <div class="footer style-scope patent-result">

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="similarDocuments" class="scroll-target style-scope patent-result">
              Similar Documents
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication</span>
                    <span class="th style-scope patent-result">Publication Date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7304054B2/en"><a id="link" href="#" class="style-scope state-modifier">US7304054B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-12-04</span>
                    <span class="td style-scope patent-result">Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20090170837A1/en"><a id="link" href="#" class="style-scope state-modifier">US20090170837A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-07-02</span>
                    <span class="td style-scope patent-result">Methods for treating ras driven cancer in a subject 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR101522625B1/en"><a id="link" href="#" class="style-scope state-modifier">KR101522625B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-05-22</span>
                    <span class="td style-scope patent-result">Novel cyclic peptide compound, a use thereof, and a preparing method thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7186713B2/en"><a id="link" href="#" class="style-scope state-modifier">US7186713B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-03-06</span>
                    <span class="td style-scope patent-result">Farnesyl dibenzodiazepinones and methods of treating cancer using same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR101119561B1/en"><a id="link" href="#" class="style-scope state-modifier">KR101119561B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-03-07</span>
                    <span class="td style-scope patent-result">Microorganism of Fusarium genus producing cyclic pentadepsipeptides 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2497031A1/en"><a id="link" href="#" class="style-scope state-modifier">CA2497031A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-05-08</span>
                    <span class="td style-scope patent-result">Farnesyl dibenzodiazepinones, processes for their production and their use as pharmaceuticals 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20090062255A1/en"><a id="link" href="#" class="style-scope state-modifier">US20090062255A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-03-05</span>
                    <span class="td style-scope patent-result">Tumor-targeting evaluation methodology and compounds related thereto 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR101120565B1/en"><a id="link" href="#" class="style-scope state-modifier">KR101120565B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-03-09</span>
                    <span class="td style-scope patent-result">Novel cyclic pentadepsipeptide(I) and its use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2017182828A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2017182828A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-10-26</span>
                    <span class="td style-scope patent-result">Antimicrobial agents 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2511750C/en"><a id="link" href="#" class="style-scope state-modifier">CA2511750C</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-11-21</span>
                    <span class="td style-scope patent-result">Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7655646B2/en"><a id="link" href="#" class="style-scope state-modifier">US7655646B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-02-02</span>
                    <span class="td style-scope patent-result">Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2467249C/en"><a id="link" href="#" class="style-scope state-modifier">CA2467249C</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-03-22</span>
                    <span class="td style-scope patent-result">Polyene polyketides, processes for their production and their use as pharmaceuticals 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2006034574A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2006034574A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-04-06</span>
                    <span class="td style-scope patent-result">Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6025466A/en"><a id="link" href="#" class="style-scope state-modifier">US6025466A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-02-15</span>
                    <span class="td style-scope patent-result">Cyclic hepta-peptide derivative from colonial ascidians, Lissoclinum sp. 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JPWO2004078764A1/en"><a id="link" href="#" class="style-scope state-modifier">JPWO2004078764A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-06-08</span>
                    <span class="td style-scope patent-result">
  Antitumor effect potentiator comprising GM-95 substance, antitumor combination preparation and antitumor agent
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2340251A1/en"><a id="link" href="#" class="style-scope state-modifier">EP2340251A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-07-06</span>
                    <span class="td style-scope patent-result">Pyrrolo[4,3,2-de]quinolin-8-amine compounds and methods of their preparation and use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2003251730B2/en"><a id="link" href="#" class="style-scope state-modifier">AU2003251730B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-04-30</span>
                    <span class="td style-scope patent-result">Bafilomycin-like metabolite from a novel Micromonospora species 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/DE102004010219B4/en"><a id="link" href="#" class="style-scope state-modifier">DE102004010219B4</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-02-01</span>
                    <span class="td style-scope patent-result">
  HKI10311129, new antibiotic, process for its preparation and pharmaceutical compositions containing HKI10311129
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20060106028A1/en"><a id="link" href="#" class="style-scope state-modifier">US20060106028A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-05-18</span>
                    <span class="td style-scope patent-result">Polycyclic aromatics and derivatives thereof and processes for their preparation 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP1633352A1/en"><a id="link" href="#" class="style-scope state-modifier">EP1633352A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-03-15</span>
                    <span class="td style-scope patent-result">Polyene oxazoles with antitumour activity and processes for their preparation using a streptomyces strain 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR101182589B1/en"><a id="link" href="#" class="style-scope state-modifier">KR101182589B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-09-18</span>
                    <span class="td style-scope patent-result">Novel cyclic pentadepsipeptideII and its use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20040033940A1/en"><a id="link" href="#" class="style-scope state-modifier">US20040033940A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-02-19</span>
                    <span class="td style-scope patent-result">Cyclic hepta-peptide derivative from colonial ascidians, lissoclinum SP 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20090029972A1/en"><a id="link" href="#" class="style-scope state-modifier">US20090029972A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-01-29</span>
                    <span class="td style-scope patent-result">Dibenzodiazepinone Analogues, Processes for Their Production and Their Use as Pharmaceuticals 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/MXPA03002343A/en"><a id="link" href="#" class="style-scope state-modifier">MXPA03002343A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-06-30</span>
                    <span class="td style-scope patent-result">Citrullimycines, a process for their production and their use as pharmaceuticals. 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004012756A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2004012756A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-02-12</span>
                    <span class="td style-scope patent-result">New cytotoxic cyclopeptide and its use for the treatment of cancer 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="relatedApplications" class="scroll-target style-scope patent-result">Priority And Related Applications</h3>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="applicationPriorityApps" class="scroll-target style-scope patent-result">
              Priority Applications (11)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2511750C/en"><a id="link" href="#" class="style-scope state-modifier">CA002511750A</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2004-11-08</span>
                    <span class="td nowrap style-scope patent-result">2005-07-21</span>
                    <span class="td style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals 
     <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2005289317A1/en"><a id="link" href="#" class="style-scope state-modifier">AU2005289317A</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2004-09-27</span>
                    <span class="td nowrap style-scope patent-result">2005-09-26</span>
                    <span class="td style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals 
     <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2581658A1/en"><a id="link" href="#" class="style-scope state-modifier">CA002581658A</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2004-09-27</span>
                    <span class="td nowrap style-scope patent-result">2005-09-26</span>
                    <span class="td style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals 
       <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2008514551A/en"><a id="link" href="#" class="style-scope state-modifier">JP2007532739A</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2004-09-27</span>
                    <span class="td nowrap style-scope patent-result">2005-09-26</span>
                    <span class="td style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
  Dibenzodiazepinone analogues, their production and use as pharmaceuticals
 
       <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20090029972A1/en"><a id="link" href="#" class="style-scope state-modifier">US11/663,890</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2004-09-27</span>
                    <span class="td nowrap style-scope patent-result">2005-09-26</span>
                    <span class="td style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        Dibenzodiazepinone Analogues, Processes for Their Production and Their Use as Pharmaceuticals 
       <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP1809612A4/en"><a id="link" href="#" class="style-scope state-modifier">EP05791575A</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2004-09-27</span>
                    <span class="td nowrap style-scope patent-result">2005-09-26</span>
                    <span class="td style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals 
       <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2006034574A1/en"><a id="link" href="#" class="style-scope state-modifier">PCT/CA2005/001467</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2004-09-27</span>
                    <span class="td nowrap style-scope patent-result">2005-09-26</span>
                    <span class="td style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals 
       <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7304054B2/en"><a id="link" href="#" class="style-scope state-modifier">US11/235,398</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2003-01-21</span>
                    <span class="td nowrap style-scope patent-result">2005-09-27</span>
                    <span class="td style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals 
       <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20060079512A1/en"><a id="link" href="#" class="style-scope state-modifier">US11/253,658</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2003-01-21</span>
                    <span class="td nowrap style-scope patent-result">2005-10-20</span>
                    <span class="td style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals 
       <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/IL182214A0/en"><a id="link" href="#" class="style-scope state-modifier">IL182214A</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2004-09-27</span>
                    <span class="td nowrap style-scope patent-result">2007-03-26</span>
                    <span class="td style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        Dibenzodiaepinone analogues, processes for their production and their use as pharmaceuticals 
     <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7655646B2/en"><a id="link" href="#" class="style-scope state-modifier">US11/962,855</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2003-01-21</span>
                    <span class="td nowrap style-scope patent-result">2007-12-21</span>
                    <span class="td style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals 
       <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="appsClaimingPriority" class="scroll-target style-scope patent-result">
              Applications Claiming Priority (2)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US62565304P<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2004-11-08</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        USUSSN60/625,653<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2004-11-08</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="legalEvents" class="scroll-target style-scope patent-result">
              Legal Events
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Date</span>
                    <span class="th style-scope patent-result">Code</span>
                    <span class="th style-scope patent-result">Title</span>
                    <span class="th style-scope patent-result">Description</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2007-05-14</span>
                    <span class="td nowrap style-scope patent-result">FZDE</span>
                    <span class="td nowrap style-scope patent-result">Dead</span>
                    <span class="td style-scope patent-result">
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <div id="notices" class="vertical layout center style-scope patent-result">
              
                <span class="style-scope patent-result">Data provided by IFI CLAIMS Patent Services</span>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
          </div>
          <div class="bottombar style-scope patent-result">
            <bottom-bar class="style-scope patent-result"><template is="dom-if" class="style-scope bottom-bar"></template>
</bottom-bar>
          </div>
        </div>
      </div>
      <template is="dom-if" class="style-scope patent-result"></template>
    </div>
  </patent-result>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
  </result-container>
        </div>
      </div>
    
        </div>
      </div>
      <search-footer class="style-scope search-ui">
    
    

    <div id="footer" class="vertical layout center style-scope search-footer">
        <span class="links style-scope search-footer">
          <overlay-tooltip positioning-target="#footerAbout" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Learn more about data coverage, search syntax and other features.
    </div>
  </overlay-tooltip>
          <a id="footerAbout" data-proto="ABOUT" href="https://support.google.com/faqs/answer/6390996" target="_blank" class="style-scope search-footer">About</a>
          <overlay-tooltip positioning-target="#footerFeedback" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Send feedback about technical issues or feature requests for Google Patents.
    </div>
  </overlay-tooltip>
          <a id="footerFeedback" data-proto="SEND_FEEDBACK" href="#" onclick="sendFeedback();" class="style-scope search-footer">Send Feedback</a>
          <a data-proto="PUBLIC_DATASETS" href="https://console.cloud.google.com/marketplace/product/google_patents_public_datasets/google-patents-public-data" target="_blank" class="style-scope search-footer">Public Datasets</a>
          <a data-proto="TERMS" href="https://www.google.com/policies/terms/" target="_blank" class="style-scope search-footer">Terms</a>
          <a data-proto="PRIVACY_POLICY" href="https://www.google.com/privacy/privacy-policy.html" target="blank" class="style-scope search-footer">Privacy Policy</a>
          <a data-proto="SEARCH_HELP" href="https://support.google.com/websearch/" target="_blank" class="style-scope search-footer">Help</a>
        </span>
    </div>
  </search-footer>
    </div>

  </search-ui>
  </search-result>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <paper-toast id="toast" duration="3000" class="style-scope search-app x-scope paper-toast-0" aria-hidden="true" style="outline: none; display: none;">
    

    <span id="label" class="style-scope paper-toast"></span>
    
      <div id="noticeContent" class="style-scope search-app"></div>
    
  </paper-toast>
  </search-app>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  

<iframe id="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.1169822775" name="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.1169822775" style="width: 1px; height: 1px; position: absolute; top: -100px; display: none;" src="https://scone-pa.clients6.google.com/static/proxy.html?usegapi=1&amp;jsh=m%3B%2F_%2Fscs%2Fabc-static%2F_%2Fjs%2Fk%3Dgapi.lb.en.IKZeRvoAYNY.O%2Fam%3DAAAQ%2Fd%3D1%2Frs%3DAHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw%2Fm%3D__features__#parent=https%3A%2F%2Fpatents.google.com&amp;rpctoken=215608884" tabindex="-1" aria-hidden="true"></iframe><iron-a11y-announcer>
    
    <div class="style-scope iron-a11y-announcer" aria-live="polite"></div>
  </iron-a11y-announcer></body></html>